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Abstract 
Epstein-Barr virus (EBV) is strongly associated with rare but aggressive lymphoproliferative 
diseases of NK and T cell origin. The finding of clonal and episomal forms of the virus in tumour 
cells from these clinically diverse diseases indicates involvement of EBV at an early stage of 
lymphomagenesis. However, many fundamental questions about EBV‟s contribution to 
pathogenesis remain unanswered. In vivo analyses herein found that infection of tonsillar (but not 
peripheral blood) T cells occasionally occurred in primary and persistent infection, whilst infection 
of NK cells was a rare event. By contrast, a high EBV load was found in peripheral blood NK cells 
from 3 adult patients with EBV-associated haemophagocytic-lymphohistiocytosis, a disease 
previously associated with CD8
+ 
T cell infection in children.  
Complementary studies examined EBV latent gene expression in EBV
+ 
T/NK malignancies. 
Notwithstanding an apparent absence of latent membrane protein 2A and 2B (LMP2A/B), these 
tumour cells were recognised and killed by LMP2-specific cytotoxic T lymphocytes. This paradox 
was resolved by identifying a novel LMP2 mRNA, initiated from within the terminal repeat (TR) 
region of the viral genome and containing downstream epitope-encoding exons. Expression of 
LMP2-TR in T/NK cell lines and primary tissue implicates this truncated viral protein in T/NK 
lymphomagenesis. 
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Introduction 
Discovery of EBV 
In 1957 whilst working at Mulago Hospital, Kampala, Uganda, a British surgeon named Denis 
Burkitt became intrigued by the unusual clinical presentation of jaw tumours in children, often 
associated with intra-abdominal tumours
1
. The curiously high prevalence of such extranodal 
tumours in areas of holoendemic malaria prompted his initial hypothesis that this may be caused 
by transmission of an infectious agent by mosquitos
2-3
. Subsequent collaboration between Denis 
Burkitt and Anthony Epstein led to the first lymphoid cell line grown in suspension in vitro – 
established from disaggregated fresh tissue of a Burkitt lymphoma biopsy, flown to the UK from 
Kampala (and subsequently named EB1
4
). A pellet of cells from EB1 was examined by electron 
microscopy by Dr Anthony Epstein, unequivocally demonstrating virus particles whose 
morphology suggested membership of the herpes family
5
. Subsequent virological, immunological 
and biochemical analyses confirmed that this was indeed a newly identified herpes virus
6-9
, 
although no biological activity was initially demonstrable. 
Within BL cell lines, a minority of cells hosted viral replication allowing development of an 
immunofluorescent assay that reacted with the viral capsid antigen (VCA)
9
. The detection of high 
viral antibody titres in the serum of BL patients and subsequently in carcinomas of the post-nasal 
space (nasopharyngeal carcinoma, NPC)
10
 prompted seroepidemiological surveys of healthy 
adults. Unexpectedly, approximately 90% of the adult human population
11
 appeared to have been 
exposed to the virus, now termed Epstein-Barr virus (EBV). It was later established that EBV was 
able to persist in serologically immune hosts; latent virus was found in B lymphocytes and active 
lytic replication was observed in the oropharynx
12
. A seminal study of 42 children and young 
adults with the clinical syndrome of infectious mononucleosis (IM) showed that they developed 
VCA antibodies in the acute stages of this illness, whereas their baseline sera were negative
13
. 
This and other evidence directly implicated EBV as the causative agent of IM
13-14
. 
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Critically, it was also elucidated that EBV from irradiated BL cell lines or cell free virus could infect 
resting B lymphocytes in vitro resulting in transformed, continuously proliferating lymphoblastoid 
cell lines (LCLs). Together with its association with BL, this key demonstration of EBV‟s B-
lymphotrophic transforming ability implicated it as a ubiquitous and potentially oncogenic virus
15-
16
. 
Classification of EBV 
Epstein-Barr virus (EBV), or Human Herpes virus 4 (HHV4), is one of eight known human 
herpesviruses, genetically stable infectious agents with large double-stranded DNA genomes that 
have evolved over millions of years to co-exist with our species and its antecedents. 
This family is divided into Alpha (α), Beta () and Gamma () sub-groups based on genome 
homology. The -viruses are further separable into two genera, -1 and -2, with different sets of 
latent cycle genes and molecular strategies that have evolved to induce latent cell proliferation. 
Kaposi‟s sarcoma herpesvirus (KSHV) and its distant relative, mouse herpesvirus 68 (MHV68), 
are classical -2 viruses (or rhadinoviruses), that can establish latency in B cells but have no 
autonomous capacity to drive B cell growth
17
. This contrasts with the ability of -1 viruses (or 
lymphocryptoviruses, LCV), a more recently evolved genus whose members are found only in 
primates, that can independently actuate B cell growth transformation
18
. EBV is considered the 
prototype LCV and has been found exclusively in humans. Each primate species is infected by a 
closely related member of the LCV family, similar in both genome structure and gene organisation 
to EBV
19
. 
EBV structure 
EBV‟s nucleocapsid is composed of 162 capsomers, a protein tegument and an outer envelope 
with external glycoprotein spikes. The icosahedral viral capsid comprises 3 major tubular proteins 
and a number of minor virion proteins. The tegument comprises a mixture of cellular and virally 
encoded proteins, whereas the envelope is dominated by the virally encoded 350 or 220kDa 
glycoprotein (gp350/220)
20
.  
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The EBV genome comprises a linear double-stranded DNA, approximately 184kb long
21-22
, 
wrapped around a toroid-shaped protein core
23
. The genome is divided into long unique 
sequence domains by 3kbp internal direct reiterations
24
.The prototype B95-8 strain, the first virus 
to be fully cloned and sequenced
21
, is unusual as it has a 11.8kb deletion
22
. The complete 
sequences of two more strains of EBV have recently been determined: GD1
25
, derived from a 
NPC tumour in a Chinese patient; and AG876
26
, derived from a Ghanian BL patient. The ends of 
the genome are flanked by 4-12 tandem copies of the 538bp terminal repeats
27
 (TR) which 
mediate episomal circularisation. The precise number of TRs is determined during viral replication 
which serves as a invaluable marker of clonality, as the progeny of latently infected cells retain an 
identical number of TRs to the parental cell
28
. Since the prototype sequencing was achieved by a 
BamHI fragment cloned library, genes and genomic locations are often referred to by specific 
BamHI fragments - alphabetically in order of descending fragment size (Figure 1). EBV can 
potentially encode approximately 80 proteins, some of which remain uncharacterised
29
. 
There are 2 major strain subtypes of EBV, referred to as type 1 and type 2, which can be further 
subdivided into different EBV strains
30
. All EBV isolates are highly homologous and share a 
common genome organisation
31
. The predominant sequence differences between type 1 and 
type 2 viruses relates to genes encoding the Epstein-Barr nuclear antigen (EBNA) 2, 3A, 3B and 
3C
32
. EBV strains within a designated type can be distinguished on the basis of single nucleotide 
changes, sequence repeats and, notably, the presence or absence of a 30bp region within the 
latent membrane protein 1 (LMP1) gene
33-34
.  
Although it had been proposed that certain EBV gene polymorphisms are specifically associated 
with some malignancies and confer a more aggressive phenotype
35
, this has not borne out; no 
definitive evidence exists that a given strain is more „tumourogenic‟ than another. Rather, it 
appears that the majority of EBV gene polymorphisms discernible in healthy virus carriers occur 
at a similar frequency in EBV
+
 tumours from the same geographical region
33
.  
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Figure 1 Map of EBV genome 
Schematic map of the EBV genome divided into specific BamHI digest fragments, referred to 
alphabetically in order of descending fragment size. Arrows represent latent promoters, black filled 
segments represent genes encoding the latent proteins whilst the grey shaded region represents the 
terminal repeat region (TR).  
Latent infection in transformed primary B cells 
The Latency I, II and III nomenclature was originally established following key observations on the 
pattern of EBNA and LMP protein expression in BL and LCLs 
36
. Exclusive expression of EBNA1, 
the viral protein essential for replication and maintenance of its own episome, was considered the 
most restricted form of latency: i.e. Latency I observed in BL. However, in non-dividing cells such 
as memory B lymphocytes in healthy carriers
37
 EBNA1 appears not to be critical, thus the term 
Latency 0 is applied to such cells where no viral antigen expression is seen. These terms will be 
used for discussion of viral gene expression within this thesis, although caveats relating to such 
nomenclature, particular when applied to an in vivo context, do exist. For example, considerable 
variation is seen to exist in B cell lymphomas of the immunocompromised, both between 
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tumours
38
 and - at the single cell level
39
 - within a malignant population. Nonetheless, an accurate 
picture of latent gene expression within a tumour can usually be established by combining an 
assessment of viral proteins at the single cell level alongside quantitative RT-PCR to analyse the 
range of latent transcripts expressed. 
Following in vitro infection of primary B lymphocytes, circularised viral genomes are appreciable 
within the nuclei 12 to 16 hours after virus binding. At around the same time, the W promoter 
(Wp), present in the BamHI-W long internal repeat element, initiates rightward transcription
40-41
 . 
The B cell specificity of this promoter is facilitated by B cell lineage specific activator protein 
(BSAP, or Pax5) binding sites upstream of Wp
42-43
. Wp promotes the transcription of the initial 
viral RNAs, which are differentially spliced to generate mRNAs coding for the EBNA-LP and 
EBNA2 proteins. Transcription is undertaken by host cell RNA polymerase II.  
Twenty-four to 36 hours following B cell infection, levels of EBNA-LP and EBNA2 protein are 
approximately equivalent to those seen in established LCLs
41
. These early latent proteins 
cooperate to initiate transcription from the upstream BamHI C promoter (Cp)
44-45
. The mutual 
exclusivity of Wp and Cp activity within a single cell results in Cp replacing Wp as the dominant 
promoter for transcription of the EBNAs
46
. The switch from Wp to Cp results in expression of the 
remaining EBNA transcripts
47
. All EBNA mRNAs have exons in common from the BamHI W viral 
genomic fragment but alternative splicing into one of 4 alternative acceptor sites determines 
whether EBNA3A, 3B, 3C or EBNA1 is translated
48
, each of which encodes its own 
polyadenylation signal. Expression of these EBNAs occurs at approximately 24 hours following 
infection and reaches a plateau after 48-72 hours. A positive feedback loop enhancing Cp 
activity, initially mediated by EBNA2 and EBNA-LP and thereafter by EBNA1, is countered by the 
repressive action of the EBNA3 proteins
49. In LCLs, transcription of EBV‟s latent membrane 
proteins is activated by EBNA2. The expression and regulation of LMP1 and LMP2 is discussed 
later under the individual latent gene headings (pages 9-17).  The non-coding, non-
polyadenylated EBER1 and EBER2 transcripts are the last of the latent transcripts to be 
expressed, reaching substantial expression levels 3 days after infection. Transcription is 
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predominantly mediated by cellular RNA polymerase III and EBERs are the most abundantly 
expressed EBV RNAs in established LCLs
50
.  
More recently a relatively large number of EBV-encoded microRNAs (miRs) have been 
identified
51-52
, encoded within two primary transcripts: the BHRF1 transcript which also contains 
the BHRF1 open-reading frame (ORF); the miR-BARTS, processed from the introns of the long, 
alternatively spliced BARTS which contain two clusters of miRs, designated cluster 1 and cluster 
2; and an isolated mirBART2 at the 3′ end of the BARTs. The BARTs are transcribed across a 
region of the viral genome that is deleted in the prototype B95-8 and thus removes the coding 
sequence for part of BART Cluster 1 and all of the Cluster 2 miRs. The miR-BARTs are 
expressed in all forms of latency and in lytic cycle, differing to the more restricted expression of 
the BHRF1-derived miRs. BHRF1 transcripts in latent infection are almost exclusively initiated 
from the Cp/Wp promoters
51-52
. 
Alternate patterns of latent gene expression  
Figure 2 is adapted from reference
29
 and represents a schematic of the four alternate patterns of 
viral gene expression observed in latent EBV infection. 
Latency III 
Following infection of primary B lymphocytes in vitro, almost all nuclear genome-positive B cells 
promptly express EBNA2 which initiates and drives the virus‟ growth transforming programme, 
inducing cell cycle transit (usually within 48-72 hours); ultimately leading to an established LCL
53
. 
Latently infected B cells express 6 EBV nuclear antigens (EBNAs), EBNA 1, 2, 3A, 3B, 3C and 
LP and 3 latent membrane proteins (LMPs), 1, 2A and 2B
54
. More recently, a tenth latent antigen 
expressed from Wp-initiated transcripts - the BHRF1 protein (a Bcl-2 homologue with anti-
apoptotic function) - has also been associated with Latency III type infection
55
. In addition, small, 
non-polyadenylated EBER1 and EBER2 transcripts, the highly spliced BamHI-A rightward 
transcripts (BARTs) and a number of EBV-encoded microRNAs (miRs)
52
 are expressed. Such 
pattern of latent gene expression is referred to as Latency III
36, or the „growth programme‟56. 
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The latency III pattern of gene expression seen in LCLs is inextricably accompanied by an equally 
characteristic cellular phenotype; markers of B cell activation and adhesion, usually absent (or 
weakly expressed) on resting B cells, are readily identified
57
; LCLs resemble lymphocytes 
proliferating in response to antigen, mitogen, or stimulation with CD40 and IL4
58-62
. Such a 
transformative impact of Latency III gene products on B cell phenotype implicated these viral 
proteins as key effectors of cell „immortalisation‟ and, importantly, is analogous to EBV-driven B 
cell lymphoproliferations occurring in the context of impaired T cell immunity
39,63-64
 (see PTLD, 
pages 47-50). 
 
Figure 2 Patterns of latent gene expression  
This figure is adapted from reference
29
. Boxes represent open-reading frames for latent genes; shaded 
boxes indicating those that are translated into viral protein, whereas open boxes represent non-coding 
viral RNAs. A linear EBV genome is shown at the top of the schematic. 
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Latency I 
The characterisation of latent gene expression in EBV-associated tumours and cell lines 
established from BL biopsies highlighted two alternate patterns of Latency. EBNA-1 is the only 
protein consistently expressed in BL
57
, alongside the non-coding EBERs, BARTs
65
 and 
miRNAs
51
. This restricted pattern is referred to as Latency I and is characterised by activity of the 
Q promoter (Qp), for EBNA1 transcription, and silence of Cp, Wp, and the LMP promoters
66
. It 
should be noted, however, that isolated cells within a Burkitt tumour biopsy can express LMP1 
and EBNA2
67
 similar to the in vitro phenomenon of BL cell lines that are seen to „drift‟ towards a 
Latency III phenotype. 
Latency II 
An intermediate pattern of EBV gene expression was originally identified in undifferentiated 
nasopharyngeal carcinoma (NPC) 
68-70
, and thereafter in EBV-associated gastric carcinomas
71
, 
Hodgkin‟s lymphomas72, and extra-nodal NK/T cell lymphomas (ENKTL)73. 
Akin to latency I, EBNA1 is transcribed from a highly spliced Q-U-K transcript driven by Qp, a 
TATA-less promoter whose configuration resembles the promoters of housekeeping genes - 
suggesting that Qp may act as a default promoter for EBNA1 in the absence of a „growth 
program‟74. This Q-U-K-spliced structure of the EBNA-1 transcript has been demonstrated in 
HL
75
, NPC
70,76
 and ENKTL
73
. As in BL, EBNA 1 expression is accompanied by the EBER and 
BART transcripts, but in Latency II additional latent membrane proteins (LMP1, LMP2A and 
LMP2B) are expressed (Figure 2). Acknowledging that these tumours arise from different cell 
lineages, and that cellular factors regulating LMP1 and LMP2 expression are yet to be delineated, 
it should be noted that heterogeneity of viral gene expression within the Latency II pattern exists. 
For example, LMP2 expression in the malignant cells of gastric carcinoma is at a low level 
compared to very high levels of both LMP1 and LMP2A in the Reed-Sternberg cells of HL, whilst 
expression of the LMP2 proteins in ENKTL has not been elucidated
54
. 
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EBV Latent gene products 
LMP 1 
In LCLs, LMP1 is translated from an RNA transcribed from the BNLF1 gene at the right end of the 
virus genome
77-78
 , initiating from a site (ED-L1) within the BamHI N-EcoRI D fragment of the EBV 
genome
77,79
. The unprocessed transcript  - which lies entirely within the antisense strand of the 
first intron of LMP2A - is spliced to a 2.4kb mRNA, with an ORF of 1.3kb which crosses two 
introns
77
 (Figures 2 and 3). Later analyses of a nude mouse-passaged NPC detected two 3‟ co-
terminal LMP1 transcripts of 2.8kb and 3.5kb, at apparently equal levels as assessed by Northern 
blotting
68
. An alternative (TATA-less
80
) LMP1 promoter (pL1-TR) was subsequently mapped 
within 20 bp of the start of the first TR - approximately 600 bp upstream of ED-L1 - and gives rise 
to the larger mRNA. Both transcripts utilise the same ATG initiator, hence the encoded LMP1 
protein is identical. The 3.5kb mRNA was also found to be expressed in LCLs (IB4) and the BL 
Akata line, although levels of the 2.8kb mRNA were substantially higher in these B lymphoid 
cells
81
.   
By 36 hours following in vitro infection of primary B lymphocytes, LMP1 mRNA is measurable 
and, within the first few days, approaches a level similar to an established LCL
41,82
. The 
nucleotide sequence of the ORF predicted that LMP1 would comprise six hydrophobic 
transmembrane domains and a 200 amino acid acidic carboxy terminus. A monoclonal antibody, 
S12, confirmed that LMP 1 is distributed throughout the cytoplasmic and plasma membrane 
where it forms distinct aggregates
83-84
. 
Further characterisation of the structure confirmed that LMP1 is an integral membrane protein of 
63 kDa and delineated three distinct domains. The amino-terminal cytoplasmic tail (aa 1–23) 
functions to tether LMP1 to the plasma membrane and orientates the protein; six hydrophobic 
transmembrane loops (aa 24–186) are involved in homo-oligomerisation and self-aggregation; an 
elongated carboxyterminal cytoplasmic region (amino acids 187–386) mediates most of the 
signalling activity of the molecule
85
.  
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Interest in LMP1 as a crucial growth transforming protein of EBV was initially stimulated by a 
study demonstrating that LMP1 functions as a classic oncogene in a rodent fibroblast-
transformation assay
86
. Subsequent studies corroborated its transformative properties by 
showing a requirement for LMP1 in EBV-induced B cell transformation in vitro
87-88
. Mutational 
analyses indicated that LMP1‟s cytoplasmic C-terminus and transmembrane domain 1 (TM1) 
were essential for B cell transformation
89-90
. Deletion of the cytoplasmic N-terminus adversely 
impacted, but did not prevent transformation
91
. In vivo, transgenic mice expressing LMP1 under 
the Ig heavy chain promoter developed monoclonal/oligoclonal splenic B cell lymphomas 
expressing LMP1 – confirming the potent oncogenic potential of this viral protein92. 
LMP1 has pleiotropic effects on cellular phenotype, resulting in the induction of cell-surface 
adhesion molecules and activation antigens
93
, and upregulation of anti-apoptotic proteins (eg 
BCL2)
94
. LMP1 functions as a constitutively activated member of the tumour necrosis factor 
receptor (TNFR) superfamily and activates a range of signalling pathways in a ligand-
independent manner
95-97
. Functionally, LMP1 resembles CD40 – a bona fide member of the 
TNFR superfamily - and can partially substitute for CD40, as shown in LMP1 transgenic mice, 
providing both growth and differentiation signals to B cells
98
.  
The activation of several downstream signalling pathways contributes to the multiple phenotypic 
consequences of LMP1 expression. Two distinct functional domains referred to as C-terminal 
activation regions 1 and 2 (CTAR1 and CTAR2) were identified by virtue of their ability to activate 
the nuclear factor B (NF-κB) transcription-factor pathway99. The signalling abilities of LMP1 result 
from the ability of tumour necrosis factor receptor (TNFR)-associated factors (TRAFs) to engage 
either directly with CTAR1 or indirectly by interacting with the death-domain-containing protein 
TRADD, which binds to CTAR2 
85
. This results in the recruitment of a multiprotein catalytic 
complex containing the NF-κB-inducing kinase (NIK), the IκB kinases (IKKs) with consequent 
activation of both the classic IκB-dependent100 and independent101-102 NF-κB pathways.  Other 
kinases are also recruited to LMP1 through interactions with TRAF molecules, including mitogen-
activated protein kinase kinase kinases (MAPKKKs), which in turn contribute to the activation of 
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the NF-κB, MAPK and phosphatidylinositol 3-kinase (PI3K) pathways85. Taken together, it is clear 
that LMP1 effectively utilises its position within the plasma membrane to influence a large number 
of cellular genes and signalling pathways to promote the transformation of B cells and epithelial 
cells. 
Factors regulating LMP1 expression  
The dominant (2.8kb) LMP1 mRNA found in LCLs is expressed from the ED-L1 site upon 
transcriptional activation by the EBNA-2 protein, which interacts with cellular transcription factors 
such as the repressor RBP-J kappa (CBF1 - involved in the Notch signalling pathway) and PU-
1(Spi1). Both cellular proteins bind to distinct sites in the LMP-1 promoter 
103-107
. By contrast, 
regulation of expression of LMP1 from the alternate, EBNA2-independent, L1-TR promoter is less 
well understood. pL1-TR is transcriptionally active in NPC cell lines
68,81
, NPC tumour tissue
108
 
and Hodgkin lymphoma tissue
108
 and appears to be the dominant LMP1 promoter in these 
tumours, although the PCR methods in these studies were not quantitative
124,108
. Sadler et al 
found that transcription was initiated from within the first TR but not from within distal TR 
elements and suggested that unique sequences adjacent to the first TR may contribute to 
promoter activity
109
. 
Chen et al found that both LMP1 promoters responded to activation of the JAK/STAT pathway, 
with evidence of functional STAT-binding motifs at both sites
108,110
. This feature is in common 
with STAT-mediated positive regulation of Qp-driven transcription of EBNA1
111
 and, specifically, 
STAT3 is implicated as a biologically relevant candidate for activation of the Qp and L1-TR 
promoters
108
. Other cellular factors such as Sp1
112
 and the unfolded protein response (UPR) 
protein XBP-1
113
 are also thought to contribute to promoter activity.  
It seems likely that the EBNA2-independent pL1-TR promoter is transcriptionally dominant in 
LMP1-expressing cells of EBV
+ 
NK and T cell lymphoproliferations, but this remains to be formally 
shown. LMP1 expression in ENKTL cell lines can be regulated by cytokines such as IL10
114
 (a 
potent activator of STAT3), IL15 and IFN
115
, although such cytokines were not sufficient for their 
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proliferation in the absence of IL-2. Recent work on Latency I BL lines found that IL-21 could 
potently induce LMP1 expression (in the absence of EBNA2), with the majority of the LMP-1 
mRNA originating from the ED-L1 promoter
116
. 
Thus, it is feasible that rather than LMP-1 being a stable characteristic of a „Latency II‟ EBV-
infected cell, expression may be dynamic and influenced by extracellular signals. 
LMP1 expression and function in T cells 
Studies examining the role of LMP1 expression in T and NK cells are restricted to in vitro models 
expressing LMP1 in EBV-negative T cell lymphoma lines
117,118-121
, whereas NK cells have not 
been studied in this context. Following from an initial observation that in vitro infection of a T cell 
lymphoma line with EBV resulted in up-regulation of TNF-α expression120, it was subsequently 
shown that the candidate protein was LMP1
121
. Further work from the same group, investigating 
the pathogenesis of EBV-HLH, indicated that LMP-1-expressing T cells were relatively resistant 
to TNF-α-induced apoptosis likely due, in part, to downregulation of TNFR1.  Moreover, TRADD 
was constitutively recruited by LMP-1 in T cells with consequent suppression of activity of 
apoptotic caspases 3, 8, and 9. These data suggested a potential mechanism whereby LMP1-
expressing T cells in EBV-HLH could escape from cytokine-induced injury, although it must be 
noted that the pattern of EBV gene expression in EBV-HLH has not been clearly elucidated
122
. 
Interestingly, LMP1 also functions to suppress signals for lymphocyte activation molecule 
(SLAM)-associated protein (SAP)/SH2D1A gene expression in T cells, thereby inducing SLAM-
mediated enhancement of ERK/IFN- signalling
118
. This LMP1-induced transcriptional 
suppression of SAP is mediated via activating transcription factor-5 (ATF5)
119
. Such deregulation 
of SAP/SLAM/ERK by LMP1 and enhanced IFN-secretion by T cells prompts comparison with 
the pathogenesis of X-linked lymphoproliferative disease, where mutations in the SAP gene 
similarly results in Th1 cytokine production
123-124
. 
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Figure 3 Schematic of LMP1 and LMP2 expression 
A schematic of the region of the viral genome encompassing the LMP1, LMP2 genes and the terminal 
repeats. The arrows represent LMP promoters (L2Ap for LMP2A, L2Bp for LMP2B and 
EDL1p/TRL1p for LMP1). Shaded black segments represent coding exons and unshaded are non-
coding. Splicing patterns are indicated by diagonal lines. Grey rectangles are the terminal repeats (TR)  
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LMP2A and LMP2B 
Discovery  
Two polyadenylated RNAs of 1.7 and 2.0kb were first identified by Northern blot analysis in 1985 
and found to be constitutively expressed from the unique short region in latently infected B 
lymphocytes 
79
. Subsequent analysis of the cDNA sequence of the larger mRNA showed that the 
gene consisted of nine exons and that the transcription unit crossed the terminal repeats
125
. The 
latter observation suggested that creation of a functional transcription unit required circularization 
of the linear viral DNA molecule at the terminal repeat region. These mRNAs were initially termed 
TP (terminal protein) 1 (LMP2A) and TP2 (LMP2B) transcripts. Characterisation of the smaller, 
1.7 kb TP2 mRNA revealed its close relation to TP1 mRNA: the TP2 transcript was found to be 
expressed from a different promoter with a distinct 5' exon from TP1, but was also found to splice 
across the terminal repeats
126-127
. The remaining eight exons are common to the TP1 and TP2 
RNAs (Figure 3). The TP2 promoter was identified 3.3 kb downstream of the TP1 promoter and 
found to form part of a bidirectional latent EBV promoter region transcribing the TP2 and the 
LMP1 RNAs in rightward and leftward directions respectively
126
. One principal open reading 
frame was identified in each of the TP1 and TP2 mRNAs. The initial observation that these 
mRNAs were predicted to encode 54kDa and 40kDa integral membrane proteins in latently 
infected cells, led to the now established terminology of latent membrane 2A and 2B
127
.  
Expression and regulation  
The LMP2A first exon (here termed exon 1A) contains an initiator of translation resulting in a 119 
amino-acid (aa) terminal hydrophilic sequence. The LMP2B first exon (exon 1B) is non-coding 
and its translation initiates at a methionine codon (corresponding to aa 120 of LMP2A) near the 
beginning of exon 2, downstream of the TR region. This methionine codon immediately precedes 
the first of the 12 transmembrane (TM) domains, encoded by eight exons common to both LMP2 
species 
127
. The highly hydrophobic TM domains are separated by short reverse turns and 
followed by a 27 aa C-terminal cytosolic tail. 
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Initial attempts to immunoprecipitate LMP2A and LMP2B in vitro translation products with EBV-
immune human serum were unsuccessful and no antibody response could be elicited following 
early attempts of immunization of rats
127
. The relatively weak immunogenicity of the recombinant 
protein is likely attributable to the high degree of hydrophobicity
128
. Experimental confirmation of 
LMP2 protein expression in almost all cells in latently infected lymphoblastoid cell lines was 
achieved using antibodies purified from immunised rabbits
129
. Importantly, this study also 
provided evidence of the association of LMP2 expression with latent infection. 
Antibodies to LMP2A were subsequently detected in sera from 16 of 42 nasopharyngeal 
carcinoma patients
128
. Later studies generated rat monoclonal antibodies specific for the N-
terminal domain of LMP2A, by immunization with bacterial trpE-LMP2A fusion protein
130
, allowing 
its detection in tissue sections and cell lines
130-132
. To-date, there are no available reagents to 
detect the LMP2B protein which lacks the N-terminus. However, PCR-based methods to 
distinguish between the LMP2 species are well-established
76,133
, capitalising on the unique first 
exons for design of 5‟ PCR primers. 
Initial observations on EBV
+
 BL cell lines and LCLs showed that LMP2A was not expressed in the 
absence of the viral protein EBNA2
134
. It then became clear that regulation of LMP2 expression in 
B lymphocytes is dependent upon EBNA2, expressed early in the full growth transforming 
programme of the virus. This is achieved via transactivation of the LMP2A and 2B promoters
134
 
via an EBNA2 responsive cis-element
135
. However EBNA2 is not expressed in „latency II‟ tumours 
and alternate factors initiating LMP2 expression in this context have been less clear.  
Function  
LMP2A and LMP2B form aggregates in the plasma membrane of B lymphocytes
129
 and, whilst 
understood to be non-essential for EBV-induced B-cell transformation in vitro
136
, some evidence 
exists that LMP2A confers a proliferative and survival advantage to B cells in the absence of 
signalling through the B-cell receptor (BCR)
137
. The N-terminal domain of LMP2A has been 
shown to have important signalling function; altering B cell receptor signalling by interacting with 
16 
 
cellular tyrosine kinases, such as Lyn and Syk, via its ITAM motifs. Similarly to LMP1, LMP2A has 
been shown to have a pro-survival function in B cells
138-141
. LMP2A can activate the Ras/PI3K/Akt 
pathway
138,141-142
, the MAP kinase pathway
143, NFκB144-145 and Bcl-2 and Bcl-x141. In addition to 
providing a developmental signal that bypasses the requirement for Ig heavy chain gene 
expression in bone marrow, LMP2A appears to provide a pro-survival signal to progenitor and 
peripheral B cells as evidenced by the increase in CD19
+
IgM
-
 cells in the splenic tissue of Eμ-
LMP2A transgenic mice. Moreover, the Eμ-LMP2A transgene allows IgM- B cells to mature into 
CD43
-
 cells in the bone marrow and thereafter colonise the spleen in a RAG-1
-/-
 mouse model
137
. 
These data indicate that LMP2A can drive the proliferation and survival of B cells in the absence 
of signalling through the B-cell receptor.  
LMP2A contributes to transformation of epithelial cells in vitro and is thought to promote their 
adhesion and motility
146
, the latter effect mediated by the tyrosine kinase Syk
147
. A role for 
LMP2A in the pathogenesis of NPC is further suggested by its effect on epithelial cell migration
148
 
and invasion in primary epithelial cell models
149
. 
The function of LMP2B, in both B cells and epithelial cells, remains much less clear. LMP2B has 
been shown to co-localise with LMP2A in B cells although the exact nature of their interaction 
remains to be clarified
150-151
 and such co-localisation may not occur in epithelial cells
152
.  Co-
expression of LMP2B with LMP2A in a B cell model did not affect LMP2A localisation, but LMP2B 
did appear to block tyrosine phosphorylation of the amino-terminus of LMP2A.  By impairing 
phosphorylation, LMP2B is understood to restore normal BCR signal transduction and levels of 
Lyn protein
151
. The implication of this finding is that LMP2B expression negatively regulates 
LMP2A activity, at least in B cells. Over-expression of LMP2B in EBV
+ 
BL cells augmented 
switching from latent to lytic cycle following BCR cross-linking
153-154
, providing further supportive 
evidence for the „negative  regulation‟ of LMP2A by LMP2B. However, recent work in epithelial 
cells suggests a „positive‟ function of LMP2B showing that both LMP2A and 2B are able to 
attenuate cellular IFN responses by targeting the IFNα and IFN receptors for degradation155. 
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No data exists on the function of the LMP2 proteins in EBV-infected NK and T cells, indeed the 
level and pattern of expression in these cell types has not yet been clarified. 
Functional interactions of LMP1 and LMP2  
LMP1 and LMP2A/B, are frequently co-expressed in EBV-associated tumours such as NPC, HL, 
and PTLD 
75-76,107,156
 and share common features such as an integral membrane topology and 
signalling function mediated by their cytoplasmic domains. As discussed above, individually, 
these viral proteins have pleiotropic effects on cell phenotype. However, studies evaluating their 
functional relationship are limited, in contrast to the detailed analyses of CD40/BCR interactions 
in B cells
157-158
. 
Dawson et al 
152
 found that LMP2A augmented the signalling capacity of LMP1 by stabilisation 
and half-life prolongation of the LMP1 protein in epithelial cell lines. This indirect effect of LMP2A 
on signalling activation was found to be dose-dependent and postulated to be mediated by the N-
terminus, since LMP2B appeared not to augment LMP1 signalling. Although such an effect was 
not apparent in EBV
+
 immunoblastic lymphoma lines, knockdown of respective mRNAs 
demonstrated that the constitutive NF-κB activity requires both LMP1 and LMP2A; both proteins 
play a role in the activation of this pathway 
159
. Individual silencing of LMP1 and LMP2A in this 
system had comparable effects on increased sensitivity to apoptosis, although no synergistic 
effect was apparent. 
EBNAs 
EBNA1 
EBNA1 is expressed in all virus-infected cells, with the exception of Latency 0 memory B 
lymphocytes
160
, where it functions to maintain and replicate the episomal viral genome - achieved 
through sequence-specific binding to the plasmid origin of viral replication, OriP
29
. The interaction 
of cellular DNA, EBNA1 and oriP results in a single replication of the EBV genome during S 
phase, followed by equal segregation of replicated EBV genomes to progeny cells during cell 
division
161
. 
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The amino- and carboxy-terminal domains of EBNA 1 are separated by a variably-sized Gly-Ala 
repeat sequence, the chief function of which appears to be stabilisation of the mature protein, 
preventing its proteasomal breakdown degradation
162
 and/or suppressing EBNA1 mRNA 
translation initiation
163
. EBNA1 is not critical for B-cell transformation in vitro, but seems to 
substantially promote the efficiency of this process
164
. A more direct effect on lymphomagenesis 
is inferred by the ability of B-cell directed EBNA1 expression to produce B-cell lymphomas in 
transgenic mice
165
 and by evidence of pro-survival effects in BL cells in vitro
166
 
Expression of EBNA1 is augmented by a number of cellular factors, including the interferon 
regulatory factors, IRF1 and 2 and the cell cycle E2F transcription factors; all of which bind to 
distinct regions close to the (Fp/Qp) EBNA1 transcription initiation site
66,167
. In restricted forms of 
latency, EBNA1 restrains its own transcription by binding downstream of the transcriptional start 
site.  
The function of EBNA1 in EBV-associated NK and T lymphoproliferations has been largely 
uninvestigated. An isolated report showed that partial silencing of EBNA1 expression in an 
ENKTL line retarded cell proliferation, associated with an accumulation of cells in G0/G1 phase
168
, 
although the mechanism was not clearly delineated. 
EBNA 2 
An early clue to the essential role of the EBNA2 protein in B cell transformation came from the 
inability of the EBNA2 deletion mutant virus, the P3HR1 strain, to establish transformed primary B 
cells
169-171
.  Reinstatement of the deleted DNA region restored the virus‟ transformative 
properties, delineated its functional elements and confirmed EBNA2‟s critical role in B cell 
immortalisation in vitro
172
.  
EBNA2 functions as a potent transcriptional activator of both viral and cellular genes and 
upregulates specific B cell antigens such as CD21 and CD23, in addition to LMP1 and LMP2.  
The protein contains a number of distinct structural elements, most notably the RBP-Jκ binding 
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domain, the acidic activation domain and the homotypic association domains  - all considered 
essential to the transformation and transcriptional properties of EBNA2
29
.  
EBNA2 is not expressed in EBV
+
 NK and T cell lymphoproliferations or other tumours with 
restricted patterns of latency, where the Wp/Cp promoters are dormant, and will therefore not be 
discussed further. Similarly, other Latency III-associated proteins (LP, EBNA3A,B,C, BHRF1) are 
also not expressed in T/NK lymphoproliferations and will only be discussed briefly below. 
EBNA LP 
EBNA-LP, encoded by the leader of each of the EBNA mRNAs, encodes a protein of variable 
size according to the number of BamHW repeats within a given viral isolate
173
. The major role of 
EBNA-LP is to specifically potentiate the effect of EBNA2-mediated transcriptional regulation
174
 of 
both viral (eg LMP1
175
) and cellular genes – the latter exemplified by cyclin D2-mediated 
induction of G0 to G1 cell cycle transit
176
. 
EBNA 3 family 
Each of these large, related, multifunctional proteins has a highly charged N terminus, 
dimerisation domains and a nuclear localisation region. Despite expression of relatively few 
EBNA3 mRNA transcripts per infected cell, the stability of all 3 proteins results in intranuclear 
accumulation
177-179
. Degradation of the EBNA3s leads to the presentation of highly immunogenic 
peptides by surface MHC class I, serving as attractive targets for CD8
+
 CTLs
180
.  
The EBNA3 proteins impart significant influence on EBV-mediated viral and cellular transcription. 
A common conserved region allows binding of RBP-Jκ, resulting in competition with EBNA2 and 
Notch for RBP-Jκ and thus negatively regulating EBNA-2 activity181. EBNA3A and EBNA3C are 
essential for B-cell transformation in vitro
182
 ,whilst EBNA2B appears not be critical in this system.  
In addition to their key role as transcriptional regulators, accumulating evidence implicates the 
EBNA3 family in EBV-mediated lymphomagenesis
54
. For example EBNA3C is seen to cooperate 
with RAS in rodent-fibroblast transformation assays, deregulating cell-cycle checkpoints
183
. 
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Other proteins expressed in latent infection  
BHRF1  
Although primarily a lytic antigen, BHRF1 (a homologue of the cellular BCL-2 protein
94
) has 
recently been identified in the context of latent infection in LCLs and a subset of BL cells. The 
17kDa protein is thought to be non-essential for virus replication but may contribute to cellular 
transformation in vitro
184
. Notably, it is consistently expressed in BL cells where the Wp promoter 
(rather than Qp) is activated – termed Wp-restricted latency55. Such expression is thought to 
confer a survival advantage to the tumour cells.  
BARF1 
The BARF1 ORF encodes a soluble molecule of 33kDa that is quickly secreted into the medium 
of cultured cells
185-186
. Initially thought to be exclusively expressed during early lytic cycle, its 
presence in the context of NPC and BL – seemingly in the absence of replicative infection – 
prompted consideration of a putative oncogenic function
185,187
. Of interest, BARF1 transcripts 
were identified in cell lines derived from patients with extra-nodal NK/T lymphoma (ENKTL) and 
chronic active EBV (CAEBV), without evidence of full lytic cycle, at levels comparable to a LCL
188
. 
By contrast, levels of BHRF1 mRNA in these T and NK lines were considerably lower than the 
LCL control. 
Non-coding transcripts 
EBERs 
In addition to protein-coding transcripts, all types of latent EBV-infected cells contain abundant 
non-polyadenylated, non-coding transcripts generated by viral hijack of cellular RNA polymerase 
III. EBER1 (166 nucleotides) and EBER2 (172 nucleotides) form stem-loop structures by 
intermolecular base-pairing, resulting in double-stranded RNA (dsRNA)-like molecules which are 
the most highly expressed viral transcripts in latently infected cells
189-191
; estimated at 10
7
 RNA 
copies per B cell. That the EBERs are so widely and abundantly expressed in latently-infected 
cells, provides a highly sensitive and specific diagnostic indicator of EBV infection ex-vivo: both at 
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the single cell level via in-situ hybridisation
192
 and by RT-Q-PCR of RNA derived from tissue 
biopsies and cell lines
82
. Although seemingly ubiquitous in latent infection, irrespective of cell 
type, an isolated report has shown that cells undergoing replicative infection may not express 
EBERs – at least in the context of oral hairy leucoplakia193. 
Some controversy exists as to whether EBERs are required for transformation of B cells in vitro. 
Initial work indicated that they were dispensable
194
 whilst more recent studies found that loss of 
EBER2 but not EBER1 considerably impaired the B lymphocyte transformation ability of EBV
195
. 
With some difficulty, B cells could be transformed with the EBER KO recombinants but growth of 
the resultant EBER KO LCLs was sluggish although, interestingly, could be enhanced by IL-6 
supplementation. EBERs have also been shown to induce anti-inflammatory cytokines, such as 
IL10
196
 and type I interferon
197
, mediated through RIG-1 (retinoic acid-inducible gene-1). 
Recently, a paracrine effect of EBERs was demonstrated, inducing signalling through toll-like 
receptors (TLR) and the subsequent release of type I IFN and proinflammatory cytokines such as 
TNFα198. This „immune activating‟ effect may be relevant to the immunopathology of diseases 
such as IM, CAEBV and HLH, in which high levels of EBER1 were found in ex vivo serum 
samples from most cases examined
198
.  
Whilst the EBERs seem to have some influence upon cellular phenotype and play a role in 
immunomodulation, the mechanistic details are not well understood and their role in disease 
pathogenesis remains unclear. In particular, their impact on the phenotype of EBV-associated NK 
and T cell lymphoproliferations has not been investigated. 
BARTs 
Originally identified in NPC tissue, an intricate cluster of non-polyadenylated RNAs are 
transcribed from the BamHI A region
68,199
 and are collectively termed BamHI A rightward 
transcripts (BARTs). The primary transcripts contain a number of potential ORFs but uncertainty 
still exists as to whether or not these rightward transcripts encode protein
200-201
, but they do yield 
a number of EBV miRs (discussed below). Similarly to the EBERs they are found to be widely 
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expressed across the spectrum of EBV-associated malignancies
73,75,202
 and in peripheral blood B 
lymphocytes
203
. The biological function of the BARTs is not clear, but it has been proposed that 
they may potentially regulate gene transcription or modulate kinase activity
200
. 
EBV-encoded micro-RNAs 
Fully processed miRNAs (miRs) are short (21–24 nucleotides), single-stranded RNAs derived 
from double-stranded RNA precursors that post-transcriptionally regulate gene expression. This 
is most commonly achieved by binding to sequences within the 3‟ untranslated region (with partial 
or complete complementarity) of target mRNAs and thus inhibiting their translation or directing 
their degradation
204
 via RISC (RNA-induced silencing complex). 
Eukaryotic cells express a large number of miRs and, since the initial discovery of virus-encoded 
miRs in a BL cell line
52
, a number (>23) of EBV-encoded miRs have also been identified. The 
EBV miRs are derived from two separate regions of the viral genome: the BamHI H region 
(containing the BHRF1s miR sequences either side of the BHRF1 mRNA open reading frame); 
and the BamHI A region (encoding the BART miRs, within the intronic region of the BARTs). To-
date, aside from the prototype B95.8 EBV strain
22
 (which contains a 11.8 kbp deletion in the 
BART region), 25 EBV-encoded pre-miRNAs - resulting in 4 mature BHRF1 miRNAs and 40 
BART miRNAs - have been identified
51-52,205
. 
Analysis of NPC biopsies has shown high-level expression of most EBV miRNAs derived from the 
BART miRNA cluster, whilst the BHRF1 miRNAs are not expressed in primary NPC tissue
51,206
. 
As the Qp promoter is located between the BHRF1 and EBNA1 ORFs, viral RNA initiating from 
Qp cannot yield any of the BHRF1 miRNAs
52
. Current data is consistent with the notion that 
expression levels of BART miRNAs mirror that of the BART mRNA transcripts (Amoroso et al, 
Journal of Virology 2010 in press). Studied in the context of NPC, EBV miRs can evidently target 
other EBV transcripts including LMP1 and LMP2A
207-209
as well as cellular genes
210
. It should be 
noted, however, that high expression of a given miR may not consistently equate to the expected 
target effect in all tumours
210
.  
23 
 
In the context of NK/T lymphoproliferations, although certain cellular miRs have been proposed to 
confer a pro-survival advantage to ENKTL cells in vitro
211
, the expression and function of EBV 
miRs in this spectrum of disease has not yet been investigated.  
Lytic cycle genes 
For all herpesviruses, including EBV, the virus lytic cycle involves the sequential expression of: 
immediate early (IE) proteins, typically transactivators of viral early gene expression; early (E) 
proteins, including requisite components of the viral DNA replication complex; and late (L) 
proteins comprising many of the virion‟s structural proteins.  
In vivo, activation of the EBV lytic cycle is thought to be instigated by differentiation of infected B 
cells into plasma cells following antigen stimulation of the BCR
212
 or by differentiation of infected 
squamous epithelial cells 
213
. Various methods have been developed to induce lytic cycle in vitro 
but the most extensively studied is directed engagement of the B cell receptor
214
 in the Akata-BL 
cell line which results in synchronous and rapid induction of as many as 50% of cells into lytic 
replication
215
.  
Immediate early lytic gene products 
The IE genes products BZLF1 and BRLF1 are transcription factors that serve as master 
regulators of EBV‟s lytic cycle. They synergistically activate one another‟s promoters resulting in 
considerable amplification of the primary lytic stimulus
29
. Together they initiate a cascade of viral 
gene transcription, starting with several early genes after about 2 hours. The BZLF1 protein is a 
viral homolog of c-Jun and c-Fos, containing 3 separate functional domains to facilitate 
replication, transcriptional regulation and homodimerisation
216
. BRLF1 is also a DNA sequence 
specific acidic transactivator; it has some homology to c-myb, which can interact synergistically 
with BZLF1 in transactivation of the early lytic BMLF1 promoter
217
. 
Early lytic cycle 
Genome-wide studies have aided the identification of 38 early lytic mRNAs 
218
 including the EBV 
DNA polymerase (BALF5) and the major DNA binding protein (BALF2). Expression of these E 
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proteins ultimately leads to the production of a concatenated linear EBV DNA molecule; the 
replicative form of viral DNA
219
.  
Late lytic cycle 
Late lytic proteins are produced following DNA replication and, of the 40 known genes, 28 are 
transcribed into virion proteins including the EBV glycoproteins, capsid proteins, tegument 
proteins and the virion kinase. The viral protease BVRF2 thereon provides a scaffold for the 
assembly of viral particles in readiness for the encapsulation of viral DNA
29
.  
Non-structural late lytic cycle proteins include BCRF1, a viral gene highly homologous to human 
IL-10
220
. Similarly to human IL-10, viral IL-10 (vIL-10) is a growth factor with autocrine and 
paracrine effects including promotion of B cell survival and proliferation. 
221
. vIL-10 also mediates 
multiple and complex effects on the immune system, including downregulation of surface HLA-1 
through transcriptional inhibition of TAP-1
222
 and, conversely can promote the reactivation of anti-
EBV T and NK cell responses
223
. Maximum expression of late proteins, including structural viral 
capsid antigens (VCA) and envelope glycoproteins, is seen approximately 12 hours after 
expression of BZLF1 and BRLF1 and release of virions can be detected by approximately 
24 hours, although lytically infected cells can survive beyond this
29
. 
The relative deficiency of significant CD8
+
 T cell responses to late lytic proteins
224
 is now 
understood to reflect the temporal expression of viral immune-evasion genes. Four such genes 
(BNLF2a, BGLF5, BILF1 and vIL10) can demonstrably interfere with the HLA-I antigen 
presentation pathway and thus modulate the CD8
+
 immune responses to EBV
225
. 
EBV infection in vivo 
B cells and epithelial cells 
EBV transmission between humans usually occurs by contact with oral secretions
226
. The virus 
replicates within the oropharynx resulting in active shedding of virus in the vast majority of 
seropositive individuals
54,227
. It remains somewhat unclear whether oropharyngeal epithelial cells 
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or B lymphocytes are the primary site of replication
228-230
, although infected B cells identified in IM 
tonsils were seen to be predominantly latent, with no clear evidence of full viral replication
230
. 
Evidence of virus replication has been observed in squamous epithelial cells of the tongue in 
patients with acquired immunodeficiency syndrome (AIDS)
231
 and occasionally in post-mortem 
tissue from immunocompetent virus-carriers
232
. Viral shedding from the oropharynx is abrogated 
in acyclovir-treated patients, whilst the number of EBV-infected circulating B cells is unchanged 
by such treatment
233
. Taken together with data from ex vivo cultures of tonsillar epithelium
234
, this 
suggests that infection of oropharyngeal epithelium is an integral part of the in vivo EBV–host 
interaction.  
The process whereby oropharyngeal replicative infection results in latently infected B 
lymphocytes is not well understood, but tonsil sections from IM patients readily demonstrate 
EBER-expressing B lymphoblasts with a proportion of these cells co-expressing EBNA2 and 
LMP1
229-230,235
. Expression of these viral proteins is indicative of a growth-transforming infection 
akin to EBV-transformed lymphoblastoid cell lines in vitro, where the full spectrum of latent cycle 
genes (EBERs, BamHI A-encoded RNAs, EBNAs 1, 2, 3A, 3B, 3C, -LP, and LMPs 1 and 2) are 
expressed
54
.  In vivo, however, these EBV-transformed lymphoblasts appear to down-regulate 
viral antigen expression, resulting in a reservoir of EBER-positive antigen-negative memory B 
cells, considered to be in a resting state
160,236
 that persist within blood and oropharyngeal 
lymphoid tissues
54
. 
In normal adults, approximately 1 to 50 circulating B cells per million are infected with EBV, and 
the number of latently infected cells within a person remains stable over years
237-238
. Interestingly, 
the observation that EBV can be eradicated in bone marrow–transplant recipients undergoing 
myeloablative therapy
239
 (thus eliminating their hematopoietic cells but not their oropharyngeal 
epithelium) provided further evidence that B cells are the site of EBV persistence. 
26 
 
T cells  
Although distinctly B lymphotropic both in vivo and in vitro, the characterisation of a spectrum of 
EBV
+ 
T and NK cell lymphoproliferative diseases
240-242
 inevitably signifies an in vivo infection 
event of their T and NK counterparts, although conflicting data exists regarding the frequency and 
nature of these occurrences. 
In the context of primary EBV infection, Anagnostopoulos et al examined tissue sections from 
tonsils excised during the acute phase of IM
229
. EBV-harbouring T cells were consistently 
identified in 9/9 cases using in-situ hybridisation for EBERs combined with antibodies directed 
against CD45RO and, more specifically, the TCR -chain. The number of infected T cells was 
stated to be considerably lower than EBER
+ 
B lymphocytes within the same tonsil, though this 
observation was not formally quantified. The EBER
+ 
T cells were located predominantly within the 
inter-follicular areas and morphological differences were evident within and between tonsils; 
some T cells exhibited blastoid features whilst many appeared as small/medium-sized 
lymphocytes. Similar findings of appreciable T cell infection in the context of primary infection 
were reported by a Japanese group who examined the lymph nodes of IM patients
243
. By 
contrast, other studies of tonsils and lymph nodes from patients with IM - applying either CD3 or 
CD4/CD8 antibodies - could not identify any EBER
+
T cells
244-246
. In keeping with the latter data, a 
further study of 14 IM tonsils found no evidence of T cell infection, although it should be noted 
that 30-50% of EBER
+
 tonsillar lymphocytes in this study could not be clearly assigned a B or T 
lineage, using CD20, CD79a, CD3 and CD45RO as markers
247
.  
In the case of EBV persistence, studies of primary and secondary lymphoid tissue have 
suggested rare instances of EBER
+ 
T cells in vivo
248
, more often (at least in tonsillar tissue) of 
CD4
+
 phenoype
249
. Similarly, a study of reactive lymph node tissue from Peruvian patients, a 
region where the incidence of EBV-associated extra-nodal NK/T lymphoma (ENKTL) is thought to 
be relatively high
250-252
, found in a minority of lymph nodes ascertained to contain EBER
+
 
lymphocytes, that as many as 24% of EBER
+ 
cells per section
 
expressed CD3
253
. This contrasted 
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with a separate investigation of intramucosal lymphocytes in inflamed tissues where no definite 
evidence of T cell infection was seen
254
.  
Noting the characteristic anatomical presentation of ENKTL in the nasopharynx, small studies 
from China examined both normal nasopharyngeal tissue (obtained post-mortem
255,256
) and 
excised nasal polyps
257
. Very rare intraepithelial lymphocytes co-expressing EBER
+
CD3
+ 255
 and 
LMP1
+
CD3
+ 257,256
 were identified in a minority of cases and at a lower frequency than their 
EBER
+
B cell counterparts.  
NK cells  
EBV infection of NK cells in vivo has also been investigated using an IHC/ISH approach in IM and 
reactive tonsillar tissue. Trempat et al
246
 used an antibody directed to an NK-restricted epitope 
PEN5
258-259
 (see NK cell phenotype: page 34 and Figure 4) to identify EBER
+
 NK cells in the 
context of primary infection. Of the 6 cases of IM lymph nodes and tonsils examined, small 
EBER
+
PEN5
+
 cells were appreciable, albeit very infrequent; corresponding to 10
-2
 to 10
-3
 of all 
EBER
+
 lymphocytes. The vast majority of PEN5
+ 
cells
 
however
 
were EBER negative, and none 
expressed EBNA2. Applying similar methodology, Hudnall et al undertook a comprehensive, 
semi-quantitative analysis of 20 EBV
+
 tonsils obtained from donors undergoing routine 
tonsillectomy
249
. The majority (82%) of >1000 EBER
+
 cells weakly expressed CD20, while dual-
positive PEN5/EBER NK cells were very rare (1.7%); numerous NK cells identified beneath the 
crypt epithelium were EBER negative. Notably, and similarly to an IM study
247
, a population of 
cells (comprising 11% of EBER
+ 
lymphocytes) could not be assigned a lineage using B, T, NK 
and epithelial markers.  
Thus, within the limitations of dual IHC/ISH labelling on fixed tissue sections, the occurrence of 
EBV-infected T and NK cells in vivo, during primary infection and persistence, appears to be a 
relatively rare event.  
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EBV infection in vitro 
B cells 
The observation that EBV possessed the ability to infect and transform human B cells in vitro
15,260
 
was a critical discovery in the pursuit of understanding the pathogenesis of B lymphomagenesis. 
Continuously proliferating lymphoblastoid cell lines (LCLs) could be generated by infecting resting 
primary B lymphocytes, where the majority population do not replicate virus. B lymphocytes 
derived from peripheral blood, tonsils or foetal cord blood could all be readily infected in vitro 
15,260-263
. 
EBV‟s tropism for B lymphocytes is accomplished through engagement of the major viral 
envelope glycoprotein gp350 with the 145-kDa transmembrane, C3d complement receptor 
CD21
264
 on the B cell surface
265-267
. Thereafter, a second envelope glycoprotein gp42
268-269
 binds 
to cell surface HLA class II molecules
270
, initiating virus–cell fusion - a process requiring 
gp85/gp25 and the gp110 glycoprotein
271
 - and permitting viral entry. Expression of CD21 during 
B-lymphocyte development correlates with the efficiency of viral binding and EBV infection can be 
substantially reduced by blocking antibodies to CD21, purified CD21 or by saturation of B-
lymphocyte receptors with gp350/220
272-273
. However, although gp350 represents EBV‟s primary 
mechanism for B cell binding, a gp350 knock out (KO) recombinant EBV retains some ability to 
infect and transform B cells, albeit with considerably reduced efficiency
274
.
 
In vitro, although virus binding
 
to the B-cell surface is highly
 
efficient, only 10–15 % of bound virus 
genomes reach the cell nucleus
275
. Depending on the multiplicity of infection applied, 10-90% of 
cells will become latently infected
262,275
. Although the precise mechanisms of EBV capsid 
dissolution and genome transit to the nucleus have not been delineated, it is likely from analogy 
to other DNA viruses that EBV capsid transport to nuclear pores is mediated by the 
cytoskeleton
276
. Subsequent covalent closure of the linear viral DNA can then form the circular 
EBV genomes observed in virally infected cells
277-278
. The consequent growth-transforming effect 
of EBV, mediated by the co-ordinated expression of nine latent proteins results in the 
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establishment of a long-lived lymphoblastoid cell line (LCL), as discussed under latent gene 
expression (pages 4-7). 
Epithelial cells 
Epithelial cells do not express CD21 and infection by cell-free virus is much less well understood, 
but is thought to involve gp85/gp25 acting both as a ligand for binding (to a hitherto unidentified 
receptor) and, in concert with gp110, as a fusion complex
268,279
. Some uncertainty exists 
regarding the role of gp42 in epithelial cell infection, which may be a consequence of which 
experimental system is used
279-280
. Virions produced in HLA class II-positive B cells tend to be 
gp42-low, as a result of sequestering into endosomes by nascent HLA class II molecules, thus 
limiting its representation in virus particles. As a result, gp42-low viruses (produced in B cells) 
preferentially target epithelium, whereas gp42-high viruses (produced in epithelial cells) are 
equipped to efficiently infect B cells
279-280
. 
 
Efficient infection of epithelial cells in vitro has proved more challenging. Exposing squamous 
epithelial cells
281
 or the apical surface of columnar epithelial cells
282
 to cell-free virus in vitro 
results in very low rates of infection. When epithelial monolayers were co-cultured with EBV-
positive B cell lines containing lytic cells, infection of epithelial cells was somewhat augmented 
281
. More strikingly, virus bound to the surface of recently exposed primary B cells is highly 
infectious for epithelium, increasing the efficiency of infection by 10
3
-10
4
fold compared to cell-free 
virus preparations
280
. The function of gp350 in such „transfer infection‟ appears to act purely as a 
ligand for B cell binding. Interestingly, although apparently inactive in transfer infection, the gp350 
KO virus can directly infect epithelial cells
280
. This suggests that gp350, whilst of central 
importance for infection of B cells, may actually impair direct epithelial infection. A number of 
other studies have provided support for the existence of CD21-independent infection mechanisms 
T cells  
Following the discovery that B cells express a binding receptor for EBV
283-284
, but prior to the 
molecular characterisation of CD21 (CR2)
264
, it was found that such a virus receptor was also 
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present on a T cell leukaemia line
272,285
. This cell line, named „MOLT 4‟, was established from the 
peripheral blood of a patient with T cell acute lymphoblastic leukaemia
286
. Initial attempts by 
Menezes et al to infect MOLT 4 showed that although EBV could bind to the cell surface, there 
was no discernible virus penetration or EBV gene expression
285
. Separate studies appeared to 
corroborate the finding that the MOLT 4 CD21 is unable to facilitate viral entry, although it can 
bind and efficiently transfer virus to infect epithelial cells in vitro
280
. 
Subsequently, variable expression of CD21 was documented on a proportion of T cell 
lymphoma/leukaemia lines; HSB-2, Hut-78, CEM and T-ALL-1 were all CD21 negative whilst 
Jurkat expressed low surface levels and HPB-ALL expressed receptors at a higher density than 
several B-lymphoblastoid cells
287
. Limited N-terminus sequencing of the HPB-ALL CD21 
molecule confirmed its identity
287
. It is noteworthy that the CD21-positive T cell lines were 
established from lymphoblastic leukaemias, rather than mature T cell tumours.  
Importantly, CD21 was shown to be variably but consistently expressed on a proportion (8-18%) 
of primary human thymocytes, obtained from paediatric patients undergoing elective cardiac 
surgery
288-289
. An inverse correlation of CD21 intensity with CD3 expression was also apparent in 
these primary T cells - consistent with the view that these T lineage cells were relatively 
immature
288
. Moreover, convincing in vitro infection of primary thymocytes by co-culture with EBV 
was seen, with EBNA1 expression appreciable by immunoblotting after 12 days
289
 – although the 
efficiency of infection of CD21
+
 T cells was not clear. Thymocyte proliferation was augmented by 
EBV infection and a synergistic effect with IL2 treatment was also apparent. These data, 
alongside emerging reports of EBV
+
 T cell diseases
241-242, challenged the belief that EBV‟s 
tropism was restricted to B cells and epithelial cells and suggested a restricted pattern of viral 
gene expression. Further data concerning the pattern of EBV gene expression in T cells infected 
in vitro is limited, but the serendipitous establishment of EBV
+ 
T cell lines from peripheral blood T 
lymphocytes suggested a Latency II pattern of gene expression
290
.  
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In the case of expression of CR2/CD21 on mature peripheral blood T lymphocytes, the available 
data is somewhat conflicting. Fischer et al found low intensity CR2 expression on 30-40% of T 
cells (both CD4
+ 
and CD8
+
) using antibodies recognising 3 non-overlapping epitopes of CR2. 
However, the intensity of staining was approximately 10-fold lower than that of peripheral blood B 
cells
291
, consistent with recent quantitative analyses of virus binding
53
. A separate study could 
find no expression of CD21 on peripheral CD4
+
 and CD8
+
 cells but were able to infect a small 
proportion of these cells in vitro
292
. Applying different methodology, via dual staining with T cell-
specific MAbs and fluoresceinated viral preparations, Sauvageau et al found that 50% of CD8
+
 
(but not CD4
+
) T cells bound EBV specifically, albeit at an extremely low level
293
. This low-level 
interaction was apparently not impeded with an anti-gp350 antibody and is consistent with more 
recent data
53
. This may imply either a CR2-independent mechanism of infection – akin to 
epithelial cell infection
274,294
 – or possibly the presence of an alternate molecule with some 
homology to CR2
295
. Studies with murine T cells have demonstrated transcriptional upregulation 
of CD21 by deacetylase inhibition
296
, although the significance of this finding for EBV binding and 
entry was not investigated. 
Taken together, the published in vitro data is consistent with the idea that during T cell 
development in the thymus, transient expression of CD21 is sufficient to allow binding of EBV 
and, in certain circumstances, viral entry.  
NK cells 
HLA class II molecules are expressed on the cell surface of NK cells, but CD21 is absent and the 
process of virus binding and entry into NK cells remains wholly unclear.  
One biological mechanism to account for EBV infection in vivo is entry of the virus via an 
immunological synapse. In terms of a latently infected B cell, LCLs are generally resistant to NK 
cell lysis, although lines with aberrant loss of surface HLA class I expression are sensitive to NK 
cell killing
297
. NK cells have been shown however to kill EBV
+ 
B cells in lytic cycle, coincident with 
downregulation of HLA class I and inhibitory KIRs
298
. Within the tonsil, conjugate formation 
32 
 
between NK cells and autologous EBER
+ 
cells have been documented in the context of primary 
infection
246
 and healthy EBV persistence
249
. Confirming this latter observation in IM lymph nodes, 
Tabiasco et al
299
 undertook in vitro experiments to demonstrate that NK cells acquire CD21 on 
their surface following co-culture with CD21
+
 B cell targets. Such a phenomenon had been 
previously described and is not specific for CD21
300
. Nonetheless, target-to-effector transfer of 
the CD21 receptor occurred quickly following transient contact such that, within 1 h at 37°C, 
activated NK cells acquired up to 1% of the surface CD21 available on conjugated targets
299
. 
Moreover, the quantity of transferred CD21 was orientated and functionally sufficient to permit 
EBV binding to the NK cell surface, although viral entry was not pursued in this study. 
The only existing report of EBV infection of NK cells in vitro, published in 2004, unexpectedly 
described efficient infection of both EBV-negative NK leukaemia cell lines and primary human NK 
cells. Co-incubation of these NK cells with a recombinant, eGFP-expressing EBV at an extremely 
high m.o.i of cell-free virus, resulted in efficient infection rates.
301
. Highly pure, freshly-isolated NK 
cells from 3 different donors were shown to be infectable at efficiencies from 45-92% as 
determined by GFP expression at 48 hours. Aside from noting marked morphological changes in 
the infected population, this striking result was not further characterised and despite attempts at 
drug-selection, a stable cell line could not be established.  
Isobe et al instead focused on the NKL
302
 and NK-92
303
 cell lines that were infectable with 
reported efficiencies of 25-30%. Considering viral gene expression in these cell lines, the findings 
were most consistent with an abortive lytic infection (expression of BALF2 and BZLF1 mRNAs), 
and possibly an underlying latency I (expression of EBER and EBNA1 mRNA, in the absence of 
LMP1 and EBNA2) restricted pattern of latent gene expression. Although the majority of infected 
NKL cells became apoptotic after 72 hours, 2 EBV
+
NKL clones were eventually established using 
drug-selection. 
A subsequent study from the same group
304
 analysed sub-clones of EBV
+
NKL which had 
developed a Latency II pattern of gene expression, following very long periods in culture, 
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expressing a lower MW form of LMP1. The authors showed that although these EBV-containing 
NK cells had no proliferative advantage compared to the parent line, the presence of EBV 
appeared to confer resistance to apoptosis induction by the anthracycline doxorubicin
304
. This 
apoptotic protection was thought to be mediated, at least in part, through NFκB activation. LMP1 
expression in other cell types is known to activate the NFκB pathway100 as well as its ability to 
induce expression of other anti-apoptotic proteins such as BCL2
94
. 
Such in vitro infection of NK cells has not yet been reproduced by others, but if this efficiency of 
infection is feasible then opportunities exist – at least in the first 48-72 hours – to carefully 
examine the consequences upon viral and cellular transcription and cell phenotype. 
Natural Killer Cells 
Discovery 
Immune effectors with cytolytic potential, resembling NK cells, apparently constituted a 
component of innate immunity long before the development of T and B cells of the adaptive 
immune system approximately 500 million years ago
305
. However, orthologs of recently 
characterised NK cell receptor families are not found beyond mammals
306-307
, suggesting that the 
functional effector in humans that we now recognise as the NK cell emerged approximately 400 
million years after evolution of the vertebrate adaptive immune system
308
. 
Natural killer (NK) cells were first identified 35 years ago, in mice, as „small lymphocytes of 
undefined nature exerting spontaneous selective cytotoxic activity against Moloney leukemia 
cells
309
. This phenomenon was functionally defined as „natural cytotoxicity‟ but the contribution of 
other cell lineages to this cytolytic function could not be excluded.  Further work defined a specific 
cell population as the predominant and most abundant effectors of non-MHC-restricted 
cytotoxicity. Importantly, NK cells were recognised to constitute a population distinct from T cells 
in both lineage and antigen recognition
310
. They are functionally thymic-independent and do not 
undergo germline rearrangements of their receptors nor express T-cell receptor heterodimers. 
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Phenotype 
The phenotypic definition of NK cells (differing between human, mouse and rat NK cells
306
) is 
determined by their expression of a unique combination of non–NK-restricted surface antigens. In 
humans, NK cells are classically defined as CD56
+
CD3(αTCR)- lymphocytes311-312 and comprise 
approximately 10% of peripheral blood lymphocytes
313
. NK cells do not possess a complete TCR-
complex, but activated NK cells express the ɛ and  chains of CD3 in the cytoplasm. In NK cells, 
CD56 corresponds to the 140 kDa isoform of the neural cell adhesion molecule (N-CAM)
314
. 
However, a minority of T-cells
314-315
, muscle cells and neurons also express CD56, but it is not 
expressed by mouse NK cells. An apparently NK-restricted marker, PEN5
258
, is a post-
translationally-modified epitope on P-selectin glycoprotein ligand-1 (PSGL-1) where it serves as a 
unique binding site for L-selectin
316
. On the surface of NK cells, the expression of PEN5 is 
coordinated with the disappearance of L-selectin and the up-regulation of Killer Cell Ig-like 
Receptors (KIRa). Such a finding, an NK cell-restricted epitope, was encouraging but its 
expression is restricted to the CD56
DIM
 subset and it is down-regulated in response to proliferative 
stimuli, limiting its usefulness as an NK marker.  
Walzer et al have recently proposed that NKp46, a member of the highly conserved natural 
cytotoxicity receptor family of NK-activating receptors
317
 best defines NK cells across species
306
 
However, NKp46 is not an absolutely specific or sensitive NK cell marker as it is also expressed 
on a subset of human cytolytic T lymphocytes
306,318
 and a minor population of CD56
+
CD3- cells 
have low-density or absent expression.  
Thus, at present NK cells are determined by their expression of a combination of non–NK-
restricted surface antigens
308
. 
NK subsets 
More than 20 years ago it was recognised that two distinct subsets of human NK cells exist, 
based on their cell surface density of CD56
313
. It is now clear that these subsets differ 
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considerably in their proliferative response to IL-2, intrinsic
 
cytotoxic capability, NK receptor 
repertoire and adhesion molecule
 
expression
312
 (see Figure 4, adapted from reference
312
). 
The majority (approximately 90%) of peripheral blood NK cells are CD56
DIM
 and express high 
levels of Fc RIII (CD16). These cells express homing markers for inflamed peripheral sites and 
express perforin to rapidly mediate cytotoxicity
319-320
, consistent with early observations
313
. The 
remaining, approximately 10%, of peripheral blood NK cells are CD56
BRIGHT
 and CD16
DIM/NEG
. 
These NK cells have an important immunoregulatory role, rapidly secreting an abundance of 
cytokines
319-320
 (such as IFN- and TNF-α) when activated, yet have little or no ability to 
spontaneously kill tumour cell targets
321
.  The production of IFN, considered the prototypic NK-
cell cytokine, has pleiotropic effects including: induction of the Th1 immune response
322
; up-
regulation of HLA class I on antigen-presenting cells (APC)
323
; augmentation of macrophage 
killing
324
 and antiproliferative activity against viral- and malignant-transformed cells
325
 
 
In addition, they display homing markers for secondary lymphoid organs, namely CCR7 and 
CD62L
319
. In fact, a substantial number of human NK cells home to secondary lymphoid tissue 
(SLT), constituting approximately 5% of mononuclear cells in un-inflamed lymph nodes and 0.4–
1% in inflamed tonsils and lymph nodes
326-327
. Although, proportionally, CD56
BRIGHT
 NK cells are 
a minority population, because lymph nodes harbour 40% of all lymphocytes, (compared to 
peripheral blood which contains only 2% of all lymphocytes), NK cells in SLT are numerically 
substantially more abundant than peripheral blood NK cells. As may be anticipated from some of 
its functions, the CD56
BRIGHT
 NK subset resides primarily in the parafollicular T cell– and APC-rich 
region of SLT
326
. 
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Figure 4 Major NK cell subsets. 
The top cartoon represents the CD56
BRIGHT 
NK cell that produces high levels of cytokines when 
stimluated. Expression of CD16 is dim/absent with accordingly low antibody-dependent cytotoxicity 
and low natural cytotoxicity. CD94 expression is high but KIRs are low density. The high-affinity IL2 
receptor (IL2α) is also highly expressed. 
 
The lower cartoon represents the cytotoxic CD56
DIM
 subset with more granular morphology and high 
expression of CD16, PEN-5 and KIRs. They lack the high-affinity IL2R subunit α and have less 
cytokine-producing ability. Their predominant function is to execute natural and antibody-dependent 
cytotoxicity.  
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CD56
BRIGHT
 NK cells constitutively express the high- and intermediate- affinity IL-2 receptors 
(respectively heterotrimeric IL-2Rα, and heterodimeric IL-2R) and expand in vitro and in vivo 
in
 
response to picomolar concentrations of IL-2
328-329
. Co-expression of the c-kit receptor tyrosine 
kinase can enhance IL-2-induced proliferation
330-331
. By contrast, resting CD56
dim
 NK cells lack 
the high-affinity IL-2 receptor,
 
are c-kit negative, and proliferate weakly in response to high doses 
of IL-2 (1
 
to 10 nM) in vitro. 
CD56
BRIGHT
 NK cells also express L-selectin (CD62L), an adhesion molecule which mediates 
initial tethering to vascular endothelium
332
. CD56
DIM
 NK cells lack this receptor but, accompanying 
NK cell differentiation, express
 
PEN5 that
 
partially mediates the binding of L-selectin. This could 
function to help KIR
+
 NK cells home to specific tissues
316
, a concept supported by patterns of 
chemokine expression suggesting
 
differential trafficking of human NK cell subsets
 
in vivo
321
. 
Potential functional differences were also highlighted by a recent study that demonstrated a 
relative resistance of CD56
HIGH
 NK cells to treatment with the calcineurin inhibitor cyclosporin A, 
known to suppress T Cell function
333
. Whereas a dose-dependent selective inhibition of CD56
DIM
 
NK cell growth and cytolytic function was evident, CD56
BRIGHT
 NK cells were resistant to 
cyclosporin A treatment and indeed enhanced IFN- production was seen
334
.  
Natural killer receptor (NKR) repertoires also differ between the two NK subsets. All resting 
CD56
BRIGHT
 NK cells highly express CD94/NKG2 C-type lectin receptors
335
 whilst less than 10% 
expresses KIRs
316
. The converse is true of resting CD56
DIM
 NK cells; the majority are KIR
+
 with 
low levels of CD94/NKG2.  The cognate ligands for KIRs are classical MHC class Ia ligands 
(HLA-A, B, and C), whilst CD94-NKG2A heterodimeric receptors bind the non-classical MHC 
class Ib (HLA-E)
336
. Every NK cell with killing capacity appears to possess an inhibitory receptor 
that recognises at least one of the MHC class I molecules on the opposing cell‟s surface337. 
Engagement of the inhibitory KIRs with classical MHC class I results in a dominant signal 
(overriding any activation signals) that prevents the NK cell from lysing the candidate target 
cell
338
. 
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NK cell development 
Several studies have confirmed that NK cells are derived from CD34
+
 haematopoietic progenitor 
cells (HPCs)
339-341
, and thereafter a common T and NK lymphoid progenitor
342
, but a detailed 
characterisation of the site(s) and pathway of NK development is not yet fully understood. 
Taking Lanier‟s initial hypothesis, that CD56BRIGHT cells were less mature than their CD56DIM 
counterparts
313
, together with the finding that CD56
BRIGHT 
cells dominated in SLT
326-327
 suggested 
that the BM may not be the exclusive site of NK development. Selective enrichment of a unique 
population of CD34
+
 pre-NK cells (CD34
+
 CD45RA
+
 CD10- CD117
+ 
CD161
+/-
) in SLT
343
 (and 
subsequently in mucosa-associated lymphoid tissue in the gut
344
, at high levels compared to BM 
and blood, suggested that SLT may be a site for NK-cell development in vivo. The closely 
proximate and abundant APCs in these tissues, which express surface-bound IL-15
345
 required 
for NK development
346-348
, supported this possibility. Moreover, the orderly acquisition of NK cell 
receptors, with CD161 and NKp46 being among the first NK cell receptors to be evident, followed 
by CD94 and finally CD16 and KIRs
348-350
 suggested differentiation through distinct maturational 
stages. Detailed in vivo and ex vivo studies subsequently identified four populations that 
appeared to represent discrete stages of a human NK cell developmental continuum within SLT. 
Each population appeared capable of downstream NK cell differentiation ex vivo and manifest 
unique functional and phenotypic attributes. Progression through the stages was characterized 
with a progressive reduction in non-NK cell lineage differentiation potential and a concomitant 
increase in CD56 expression with functional features of CD56
BRIGHT 
NK cells
351-352
. Subsequent 
studies supported the derivation of CD56
DIM
 NK cells from their CD56
BRIGHT
 counterparts 
353-356
. 
Interestingly, a role for the CD56 antigen per se in terminal NK differentiation has recently been 
suggested
353
. 
Role of NK cells in control of EBV  
NK cells appear to play an important role in the early control of cytomegalovirus (CMV) infections 
in both mouse and man
357-359
 but seem to be less crucial for control of the -2 herpesvirus MHV68 
in mice
360
.  
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NK cell numbers (but not CD1-restricted NKT cells) are expanded in the blood of acute IM 
patients and, in a small study of patients with primary EBV infection, a relative increase in the 
CD56
HIGH 
subset was seen. Furthermore, there was an inverse correlation of NK numbers with 
EBV genome load in the peripheral blood of IM patients
361
.   
In vitro, NK cells can inhibit the EBV-induced transformation of resting B cells if introduced within 
a few days of infection, mediated at least in part,  by the release of IFN-
362
. Consistent with this, 
tonsillar NK cells can effectively inhibit in vitro transformation of EBV-infected B lymphocytes in 
the presence of mature dendritic cells
363
. Collectively, this data suggests that NK cells may be 
able to limit primary EBV infection in SLT until the adaptive immune system establishes specific 
control of the virus. 
However, indirect clinical evidence goes against a major role for NK cells in the control of 
transformation events in vivo since, in recipients of T-depleted stem cell transplants, EBV-driven 
lymphoproliferative disease occurs most commonly in the first 3-6 months post-transplant by 
which time NK cell numbers have recovered but the patients remain profoundly T cell-deficient
364
. 
NK cells do seem to have a role in the control of lytic infection; a reduction in surface HLA class I 
expression seen in lytically-infected cells in vitro is accompanied by increased sensitivity to NK 
cell recognition 
298
. Notably, an NK immune evasion strategy by EBV has not yet been identified, 
in contrast to numerous evasion mechanisms seen in both murine and human CMV infection
357-
358
, scenarios in which the NK response appears to be critical. 
T cell development, subsets and function 
The T cells of the adaptive immune system are heterogeneous and functionally complex and 
include naïve, effector (regulatory and cytotoxic), and memory T cells. T Cells are derived from 
common lymphoid progenitor in the bone marrow and migrate to the thymus where they 
differentiate into mature T cells during passage from the cortex to the medulla. It should be noted 
that although a common progenitor for T and NK cells exists, once committed to the NK cell 
lineage these cells lose the capacity to progress along the T cell developmental pathway
342
.  
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During thymic maturation, self-reactive T cells are culled whereas T Cells with appropriate HLA 
specificity are positively selected.
365
 
The definitive T cell lineage marker is the T-cell antigen receptor (TCR). There are two defined 
types of TCR, α or δ heterodimers, which are both disulphide-linked polypeptides with structural 
similarity. Both receptors associate with the 5 polypeptides that form CD3, and together constitute 
the TCR complex. The vast majority (>90%) of peripheral blood T cells are α T cells whilst 5-
10% are δ T cells. The α,, and δ genes of that encode the TCR polypeptides each include V, 
D, J and C regions. During T cell ontogeny, rearrangement of these gene segments occurs – 
similarly to immunoglobulin gene rearrangements in the B lineage. This potentially results in >10
8
 
specific TCR structures, with additional diversity facilitated by the enzyme TdT (terminal 
deoxynucleotidyl transferase) at the junction sites. The same recombinase enzymes utilised by B 
cells mediate re-joining of the TCR gene segments
366
.  
Such uniqueness of receptor genes affords diagnostic opportunity to establish clonality amongst 
T cell populations in blood or tissue, usually achieved by PCR-based techniques. Naive T 
lymphocytes that leave the thymus do not actively divide, unless they encounter an antigen-
presenting cell (APC) with cognate antigen and are thereon stimulated to clonally expand. 
Antigen-specific responses are predominantly generated in SLT
367
.  
α T cells are subdivided into two discrete populations. The CD4-expressing subset (the 
dominant population in peripheral blood and SLT) whose function is principally regulatory, acting 
via cytokine production (further divided into TH1 and TH2) and a CD8
+ 
subset that are chiefly 
cytotoxic. CD4
+
 antigen recognition is restricted by HLA class II molecules whilst CD8
+
 T cells 
recognise antigen in association with HLA class I. A minority of α T cells are termed „double 
negative‟ as they express neither CD4 nor CD8. Most peripheral blood δ T cells are also „double 
negative‟ although a proportion express CD8367. 
A significant minority of T cells express non-lineage-specific surface markers, including some in 
common with NK cells. For example: CD2, expressed by all T cells is also present on a majority 
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of NK cells; CD16 (FcRIII), expressed by a minority of T cells and most peripheral blood NK 
cells; CD56, expressed on a minority of cytotoxic T cells and on all NK cells with variable density. 
Virally-infected cells highlight themselves as a target for cytotoxic T cells via HLA class I surface 
display of peptides derived from processed intracellular viral proteins. The cytotoxic T cell TCR 
engages with the peptide–MHC complex and then kills the infected cell by two major 
mechanisms. Perforin insertion through the target-cell membrane creates pores through which 
granzymes can pass and thereon activate target cell caspases - inducing apoptosis. Alternatively, 
expression of Fas ligand on cytotoxic T cells binds to target cell Fas, which also results in 
caspase activation within the target cell and ultimately apoptosis
368
. 
Specific T cell responses to latent and lytic EBV-infected cells are critically important in 
preventing EBV-driven disease and maintaining the virus: host balance that exists in healthy 
persistence. 
Primary infection and infectious mononucleosis 
Clinical and epidemiological features 
Primary EBV infections are rare in the first year of life, presumably as a result of passively 
transferred EBV-specific maternal antibodies. In developing countries and lower socioeconomic 
groups, most individuals are exposed to EBV early in childhood. Primary infections in young 
children are either asymptomatic or manifest as nonspecific viral illnesses, in whom the 
characteristic symptoms of infectious mononucleosis (IM) are uncommon. However, IM in early 
childhood is thought to occur, albeit rarely
369
. 
The clinicoimmunological syndrome of infectious mononucleosis is more likely to occur if primary 
EBV infection is encountered during or after the second decade of life. Attributed to improved 
economic and sanitary conditions over recent decades, EBV infection in early childhood has 
become less frequent
370
, leading to more individuals potentially susceptible to „late‟ primary 
infection and thus IM. In a recent UK study of university students
371
, 25% of young adults were 
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EBV seronegative at the time of university entry (median 19 years) of whom 46% had 
seroconverted after 3 years. Of these „late‟ seroconversions, one-quarter of individuals had been 
diagnosed with IM.   
A majority of patients with infectious mononucleosis manifest fatigue, lymphadenopathy and 
pharyngitis, whilst hepatosplenomegaly is clinically evident in a third of individuals but fever is 
relatively uncommon
372
. Less common complications include haemolytic anaemia, 
thrombocytopenia, aplastic anaemia, myocarditis, hepatitis, genital ulcers, splenic rupture and 
neurologic complications such as Guillain–Barré syndrome, encephalitis, and meningitis373. So-
called „fulminant IM‟ cases, due to the development of haemophagocytic lymphohistiocytosis or 
clonal lymphoproliferation of infected T cells (discussed in detail later), are very rare but are 
associated with a high mortality. A Japanese survey
374
 estimated that the incidence of EBV-HLH 
was less than 1 case per million population each year, though diagnostic challenges and the 
nature of the study means that this is likely to be an underestimate. 
Most patients with infectious mononucleosis have an absolute leucocytosis in the peripheral 
blood, predominantly accounted for by increased T and NK cells (CD8
+
, δ and CD56+), but mild 
elevations of monocyte numbers also occur
372
. Mild neutropenia and thrombocytopenia are 
common and deranged liver biochemistry (most commonly elevated serum alanine transaminase) 
can be detected in the majority. Heterophile antibodies, detected via the monospot test, are 
present in all cases whilst anti-VCA IgM is almost as sensitive and affords more diagnostic 
specificity for IM
372,375
. 
The clinical manifestations of IM are thought to be, at least partly, attributable to the brisk and 
substantial T cell response and the associated cytokine release – particularly IFN and TNFα376. 
Moreover, a correlation between the intensity of T cell activation and the severity of symptoms 
has been described 
377
. Susceptibility to IM is bestowed by polymorphisms in genes encoding the 
regulatory cytokine IL-10
378
  and, interestingly, HLA class I
379
 possibly impacting on efficiency of 
viral peptide presentation.  
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 In the majority of immune-competent individuals, the illness is self-limiting and recovery can be 
anticipated within weeks, with resumption of normal activities after 2-3 months
372
. 
Cellular immune responses 
Most of the published data characterising cellular immune responses to primary EBV infection are 
derived from studies of IM patients, on the assumption that this immuno-pathological syndrome 
amplifies, but does not distort, the events of sub-clinical primary infection. (The role of NK cells in 
control of EBV has been discussed on page 38). 
CD8+ T cell responses 
The markedly expanded populations of CD8
+
 T cells in the peripheral blood during acute infection 
were shown to be distinctly oligoclonal in T cell receptor (TCR) usage
380
.  Moreover, ex-vivo 
assays demonstrated that these cytotoxic, perforin-expressing CD8
+
 cells were functionally EBV 
epitope-specific and were numerically dominant, as shown by HLA class I tetramer staining 
381
.  A 
comprehensive body of work has subsequently characterised and quantitated numerous EBV 
specificities in IM blood
381-385
. Responses to individual epitopes can account for 1-40% of the total 
CD8
+
 T cell population, with dominant reactivities to immediate early (IE) and some early (E) lytic 
antigens usually seen. Responses to latent viral proteins are numerically smaller; individual 
specificities accounting for 0.1-5% of the CD8
+
 T cell population. 
The EBV-specific CD8
+
 population express the activation marker CD38, the cell cycling protein 
Ki-67 and CD45RO, all consistent with recent antigen stimulation
381-382,386-387
 and die rapidly by 
apoptosis in vitro unless persistently stimulated. Consistent with this, low levels of Bcl-2 and Bcl-x 
proteins and high levels of the pro-apoptotic Bax protein are evident, accounting for the rapid 
culling of T cells in the immediate aftermath of acute IM when access to antigen becomes 
limiting
383
. 
 
In healthy EBV persistence, virus shedding in the throat is often very low
388
 and, of the total 
peripheral B lymphocytes approximately 1-50 cells/million are latently infected with EBV
238
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(>1000-fold less than seen in acute IM). Nonetheless, CD8
+ 
memory responses are maintained 
by low-level antigen stimulation and display a resting phenotype although a proportion do express 
perforin and are demonstrably cytotoxic ex vivo
386,389
. In healthy carriers, a significant fraction of 
the circulating CD8
+
 T cell pool is devoted to control of EBV and remains relatively stable over 
time (typically 0.2-2% of the CD8
+
 T cells specific for lytic epitopes and 0.05%-1% for latent 
epitopes)
383
.  
In the vast majority of individuals, both in the context of IM
385
 and healthy persistence
180
, CD8
+
 T 
cell responses to latent cycle antigens are highly focused on immunodominant epitopes from the 
EBNA3A, 3B, 3C family of proteins. Co-existing sub-dominant responses often map to epitopes 
either from the same EBNA 3 family or from LMP2, whilst responses to EBNA2, EBNA-LP, LMP1 
and EBNA1 are substantially less frequent. Such a hierarchy of immunodominance, however, 
may be influenced by the HLA repertoire of the geographical population studied
383
. 
LMP2 CD8+ responses 
More than 20 CD8
+
 epitopes from LMP2 have been described, the vast majority of which are 
derived from the transmembrane domains of the protein and thus common to both LMP2A and 
LMP2B
390-392
. A comprehensive study examined T cell responses in 32 healthy individuals with 
persistent EBV infection and 8 subjects with IM including 13 LMP2 epitopes, restricted through 8 
HLA class I elements, amongst a panel of 113 EBV-derived epitopes
392
. LMP2-specific responses 
were common in the setting of healthy persistence and, when seen, occurred in 25-60% of 
individuals. By contrast, LMP2-specific responses were relatively uncommon in the small number 
of IM patients tested; where EBNA3 and lytic responses dominated. Low frequency LMP2 
responses can also be detected in immunocompetent patients with EBV-associated 
malignancies
393-394
 and have recently been capitalised upon for adoptive cellular 
immunotherapeutic approaches
391,395-396
(discussed under HL, pages 51 and 52). 
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CD4+ T cell responses 
By contrast to their CD8
+
 counterparts, CD4
+
 T cell numbers are not expanded in IM and do not 
demonstrate the same oligoclonal skewing
397
. CD4
+
 epitope specificities have been more 
challenging to characterise ex-vivo, but CD4
+
 T cell responses to a lysate comprising both lytic 
and latent EBV proteins can be detected in IM blood at much lower frequencies than CD8
+
 
reactivities
398
. As for the CD8
+
 population, latent and lytic epitope-specific CD4
+
 T cell numbers 
are observed to peak during acute IM and promptly decline thereafter
383
. 
In terms of CD4
+
 T cell memory, multiple EBNA- and LMP- epitope specificities have been 
identified but are estimated to be at least 10-fold lower than typically seen for the equivalent CD8
+
 
T cell memory
399
. CD4
+
 memory responses to IE, E and late lytic cycle antigens have also been 
isolated in healthy carriers
383
. 
In terms of an immunodominance hierarchy, there appear to be no particular CD4 epitopes that 
consistently dominate the latent antigen-induced response
399
. The C-terminal domain of EBNA1 
provides an abundance of epitopes for a range of HLA class II alleles, to which CD4
+
 memory 
responses are frequent
400-401
. EBNA2 and EBNA3C are also relatively frequent epitope sources 
for CD4
+
 recognition. More recently CD4
+
 T cell clones specific for a range of LMP1- and LMP2-
derived epitopes were shown to efficiently recognise latently infected targets and prevent their 
outgrowth through perforin-mediated cytolysis
402
. 
Interestingly, a component of the LCL-stimulated CD4
+
 T cell response of EBV-immune and –
naive donors, despite recognising the autologous LCL in a classically HLA-class II-dependent 
manner, is not EBV antigen-specific
403. These cytotoxic „LCL-specific‟ (Figure 5) cells appear to 
recognise cellular targets, whose expression is specifically upregulated as an early event in EBV-
induced transformation. Such T cells recognise a broad range of human B-lymphoma-derived cell 
lines in vitro including BL and HL lines irrespective of EBV genome status, providing those lines 
express the relevant HLA class II restricting allele. 
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Figure 5 Latent antigen specificities of EBV-specific CTLs 
A schematic representing the specificities and frequencies of effector T cells generated using 
conventional LCL stimulation protocols (adapted from reference
404
). CD8
+
 T cells of indicated 
specificity are shaded blue, whilst CD4
+
 effectors are orange; the number of cells shown indicates 
their relative frequency within the polyclonal populations. The width of each arrow represents the 
potential contribution of the respective T cell sub-population to target malignancies displaying 
alternate patterns of latency.  
 
  
47 
 
Post-transplant lymphoproliferative disease 
Association with EBV 
The importance of intact T cell immunity in controlling EBV‟s transforming and replicative 
capabilities is exemplified by EBV-positive lymphoproliferative diseases opportunistically arising 
in the context of inherited or acquired compromise of T cell number and/or function. Histologically 
diverse lymphoproliferations arising as a result of iatrogenic immunosuppression following solid-
organ or haematopoietic stem-cell transplantation (SOT or HSCT) are the best studied of these 
diseases and are termed post-transplant lymphoproliferative diseases (PTLD).  
The risk of PTLD increases with the degree of T-cell impairment; thus, T-cell depletion of the graft 
or using incompletely human leukocyte antigen (HLA)–matched grafts that require greater 
immunosuppressive therapy will increase PTLD incidence. EBV-positive tumours occur earlier 
following allografting (3-6 months for HSCT, 12-24 months for SOT) when immunosuppression is 
most severe
405-406
. In most such cases of PTLD the proliferating cells express the full growth-
transforming programme of EBV-latent proteins
39,63
, akin to EBV-transformed LCLs in vitro, 
although EBNA2/LMP1-negative cases have been described
407
.  
Pathology 
 
PTLD represents a pathological spectrum that can resemble reactive and neoplastic lymphoid 
and plasmacytic proliferations, in terms of their histological appearance and cell of origin. A 
significant minority of cases (20-30%) arising following SOT are EBV negative, whereas almost 
all post-HSCT are EBV-associated. Most SOT PTLD are of host origin and the converse is true 
for HSCT PTLD; where most arise from a donor lymphocyte
408
. 
The WHO
409 classifies PTLD into: „early lesions‟ akin to reactive proliferations resembling IM; 
„polymorphic PTLD‟ comprising heterogeneous populations of lymphocytes and plasma cells with 
architectural destruction of the host tissue, of which there is no immunocompetent counterpart; 
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„monomorphic PTLD‟ that most commonly resemble Diffuse Large B cell lymphoma (DLBCL), 
plasma cell neoplasms, occasionally classical HL, or rarely T or NK cell lymphoma.  
B cell PTLD not only arises from the pool of antigen-selected memory cells in which EBV resides 
in healthy persistence, but from a range of B cells at all stages of the normal differentiation 
process. Tumour development seems often to be associated with the EBV-facilitated rescue and 
expansion of B cells that have failed the physiological process of germinal centre selection into 
memory
407
. Malignant cells displaying germinal centre (GC) markers, post-GC characteristics or 
plasmacytic/plasmacytoid features can be seen
410
. 
PTLD of T or NK cell origin account for approximately 7–15% of PTLD in Western countries and 
appear to be more common in Japan, though incidence data is limited
411
. Compared to their B 
cell counterparts, T or NK PTLD tend to occur later in the post-transplant period (median 4-5 
years) and are less commonly EBV-associated; EBV is demonstrable in 30-40% of cases. 
Peripheral T cell lymphoma unspecified and δ-hepatosplenic lymphomas are the most frequently 
identified subtypes but very rare cases of extranodal NK/T lymphoma have been reported; the 
latter usually harbour clonal EBV 
411-412
. 
EBV-specific T cell therapy 
Although the advent of Rituximab, a therapeutic monoclonal antibody that targets the pan-B cell 
antigen CD20, has changed the treatment paradigm of PTLD, a significant proportion of patients 
will not respond to, or relapse following such treatment
405-406
. In this setting, EBV-specific 
adoptive T cell therapies have a potentially important therapeutic role. 
The latent viral proteins that drive B cell PTLD also constitute the target antigens through which, 
in healthy EBV carriers, virus-transformed cells are recognised and destroyed by virus-specific T-
cell surveillance. Accordingly, PTLD provides an ideal opportunity for the application of adoptive 
cell therapy using EBV-specific T cells. In the context of HSCT, early attempts to treat PTLD 
using total peripheral blood mononuclear cells from the EBV-immune stem cell donor were 
marred by collateral graft-versus-host disease (GVHD) 
413
. To negotiate this problem, existing 
49 
 
laboratory methods for in vitro generation of EBV specific cytotoxic T-cell (EBV-CTL) preparations 
(see figure 5) were adapted for use in vivo, and, by 1995 (a year before others showed proof of 
principle in a SCID mouse model
414
) clinical efficacy against PTLD was demonstrable
415
. The 
long-term safety and efficacy of EBV-CTL infusions in a post-HSCT setting is now patent. Ten 
year outcome data now exists on the largest cohort treated with CTLs post-HSCT
416
. One 
hundred and one high-risk patients have been treated prophylactically resulting in a fall in EBV 
genome load in the circulating B-cell pool; more importantly, none of these patients developed 
PTLD, compared with an observed incidence of 11% in a control cohort receiving similarly T cell–
depleted allografts. A further 13 patients received EBV-CTLs therapeutically for either biopsy-
proven EBV-positive PTLD or probable disease diagnosed on radiologic and clinical grounds. 
Complete responses were confirmed in 11 of 13 patients, some with extensive extra-nodal 
disease including 1 patient with biopsy-proven monoclonal lesions in the central nervous system. 
Dramatic inflammatory reactions at the site of disease (shown to be mediated by infiltrating EBV-
CTLs) occurred in 2 patients, both of whom fully recovered, but no other toxicity or GVHD 
attributable to EBV-CTLs was observed. Gene-marking of the CTLs enabled in vivo tracking. The 
CTLs persisted in the circulating memory pool for as long as 105 months after infusion and 
remained capable of expanding in vitro in response to EBV antigen challenge.  
The situation is somewhat different in the setting of SOT, where the challenge lies in generating 
autologous EBV-specific CTLs that can function and persist in the face of ongoing 
immunosuppression. Although EBV-specific CTLs can indeed be expanded in vitro from such 
patients and significant short-term clinical responses
417
and/or reductions in EBV DNA 
load
418
following CTL infusion have been demonstrated, questions remain over the long-term 
persistence of the transferred CTLs. Two recent studies have attempted to address this issue by 
generating EBV-CTLs resistant to Calcineurin inhibitors (e.g. Tacrolimus (FK506) and 
Cyclosporin A), a commonly used class of immunosuppressive drugs in this context. Employing 
different mechanisms to render the EBV-CTL resistant to these agents, the authors demonstrated 
that the modified T cells were shown to expand in the presence of drug without impairment of 
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cytotoxicity or antigen specificity
419-420
. These data suggest that such genetically modified EBV-
CTLs may be of clinical value where ongoing immunosuppression is required.  
Two considerable disadvantages of the above strategies however, are the time required for CTL 
production (6-12 weeks) and the necessity to generate a separate line for each patient. To 
address this, Haque et al generated a bank of 100 polyclonal CTL lines from EBV-seropositive 
blood donors (i.e. third parties), potentially available to treat patients with PTLD following SOT 
421
. 
CTLs for infusion were selected on the basis of the best HLA match and specific in vitro 
cytotoxicity. Overall response rates were encouraging (17/33 patients at 6 months), with five of 
the responders having previously failed to achieve a sustained response to Rituximab and/or 
chemotherapy. Patients receiving more closely HLA-matched CTLs and those receiving higher 
numbers of CD4
+
 cells achieved significantly better responses when assessed at six months. 
Hodgkin Lymphoma 
Association with EBV and pathogenesis 
 
This is an unusual malignancy in that the malignant clone of Reed-Sternberg (RS) cells is a 
minority population within the tumour tissue; vastly outnumbered by pleomorphic reactive 
lymphocytes and granulocytes. Approximately 40% of cases of classic Hodgkin lymphoma in the 
developed world are associated with EBV and tend to co-segregate with the mixed-cellularity 
histological subtype. In HIV-infected individuals, instances of HL are almost all EBV associated
422-
423
. Risk of EBV
+ 
HL is thought to be increased in individuals who experienced IM as a result of 
primary EBV infection
424
. 
In EBV-positive tumours, the clonal viral genome is present in every RS cell and expresses the 
EBNA1, LMP1 and LMP2 latent proteins in addition to the non-coding EBER and BART mRNAs – 
a latency II pattern
75
. The identification of RS cells as failed products of germinal-centre reactions 
by Ig genotyping
425
 indicated a conceivable pathogenic role for the virus, based on rescuing RS 
progenitors from apoptosis.  EBNA1 may directly contribute to the pathophysiology of Hodgkin 
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lymphoma by upregulating CCL20, enticing regulatory T cells (TReg), and/or by downregulating 
potential tumour suppressor genes
426
. LMP1 aggregates in the RS cell membrane and mimics an 
active CD40 receptor, thereby inducing constitutive NF-κB activation96in addition to multiple 
downstream effects, as discussed earlier. LMP2A expression serves as a surrogate BCR
137,140
 
and can provide a variety of pro-survival signals
139,141-142
, but the expression and role of LMP2B 
in HL has not been established. Given that signalling though the BCR and CD40 are two major 
survival signals for germinal centre B cells
427
, the principal hypothesis is that EBV has hijacked 
these pathways to facilitate survival of GC cells
428
. It has also been proposed that LMP1 and 
LMP2A contribute to the loss of B-cell phenotype in EBV
+
 HRS cells
429-430
. 
EBV-specific T cell therapy 
Although a large majority of HL patients are cured with dose- and time-intense, multi-agent 
chemotherapy regimens with or without adjuvant radiotherapy
431
, a significant minority fail to 
respond to conventional treatment or relapse following an initial remission. A proportion of 
patients with relapsed disease will respond to high-dose chemotherapy with autologous stem cell 
support
432
 and evidence has also emerged of a graft-versus-HL effect in the context of allogeneic 
stem cell transplantation
433
. However, these approaches are associated with considerable 
morbidity and mortality, prompting investigators to ask whether the success of EBV-specific CTL 
therapy in PTLD
416
 can be applied to EBV
+ 
HL. 
Early clinical studies using CTLs that had been expanded in vitro by stimulation with LCLs, 
expressing the full range of latent viral proteins, produced limited tumour responses. A major 
hindrance to this approach was that the CTL lines contained a preponderance of specificities 
directed towards the immunodominant EBNA 3A, 3B, 3C antigens (see figure 5) or against early 
lytic cycle proteins – all of which are absent in HL. However, the small numbers of LMP2 CTLs 
present within the administered CTL preparation were seen to expand and persist in-vivo
434
. 
The consistent expression of LMP2A in Reed-Sternberg cells and the apparent conservation of 
LMP2 epitope sequences between viral strains and within HL biopsies
156,390,435
 renders LMP2 an 
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attractive target, if an appropriate biased CTL product could be generated from HL patients. Thus, 
recent research has used LMP2-expressing dendritic cells (DCs) to reactivate LMP2 reactivities 
and expand this CTL population using autologous LCLs over-expressing LMP2 from a chimeric 
adenovirus vector (Ad5F35-LMP2)
391,396
. Such an approach increased the frequency of LMP2-
specific T cells by up to 100-fold in the resultant polyclonal line, which contained both CD4
+
 T-
helper cells and CD8
+
 CTLs, targeting multiple LMP-2 epitopes. These LMP2-containing CTL 
preparations have produced encouraging clinical results in patients with relapsed/refractory HL, 
some of whom achieved sustained complete remissions following the infusion
395
.  
Recognising that EBV
+
 NK cell lymphoproliferative diseases also display a latency II pattern of 
viral antigen expression, a small number of such patients were also treated with LMP2-containing 
CTLs within the same study. Notwithstanding the uncertainties relating to LMP2 expression in 
these malignancies, a particularly striking clinical response was experienced by one patient with 
multiply relapsed ENKTL - who achieved a complete response lasting nine months following CTL 
therapy
395
.  
Nasopharyngeal carcinoma 
Association with EBV 
EBV infection of epithelial cells has been associated with various tumours including 
nasopharyngeal carcinoma (NPC), a subset of gastric adenocarcinomas and certain salivary 
gland carcinomas
436
. The undifferentiated form of NPC (WHO type III) is most consistently 
associated with EBV, with particular geographical predilection for areas of China and south-east 
Asia
437
. Genetic and dietary cofactors are well described
54
. NPC tumours characteristically 
contain a prominent lymphocytic infiltrate alongside the undifferentiated carcinoma cells. EBV 
latent gene expression in NPC (latency II) is predominantly restricted to EBNA1, LMP2A and the 
BamHIA transcripts, whilst approximately 20% of tumours also express the LMP1 protein
436
 and a 
minority also express relatively low levels of LMP2B
76
. Southern-blot hybridization of DNA from 
NPC confirms viral monoclonality, indicating the presence of EBV prior to expansion of the 
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malignant clone
436
. Seroepidemiological studies in high-incidence regions have shown that 
elevated EBV-specific antibody titres, particularly IgA directed to the EBV capsid antigen and 
early antigens have proved useful in diagnosis and in monitoring the effectiveness of therapy
438
. 
Carcinomas with similar features to undifferentiated NPC, occurring at various anatomical sites 
including the thymus, tonsils, lungs, and skin, have been referred to as lymphoepitheliomas and 
are variably associated with EBV
439
. 
EBV-specific T cell therapy 
Several small studies have treated patients with relapsed and refractory NPC with autologous
440-
443
 and allogeneic
444
 (from an HLA-identical sibling) EBV-specific CTLs, generated by in vitro 
stimulation with LCLs. Although some studies have reported increases in circulating LMP2-
specific CTLs, reductions in blood viral load
440
 and evidence of CD8
+
 tumour-infiltrating cells
444
 
following CTL infusion, significant clinical responses are uncommon
440,442-443
. Recently, 
lymphodepleting strategies, designed to augment expansion of infused CTLs using anti-CD45 
MAbs prior to CTL infusion, have not improved tumour responses substantially although one 
patient did achieve a sustained CR
441
.  
Burkitt lymphoma 
EBV and pathogenesis 
EBV is present in all cases of „endemic‟ (that is, holoendemic malarial regions of Africa and New 
Guinea) Burkitt lymphoma (BL) and in up to 85% of cases in areas of intermediate incidence such 
as Brazil and North Africa, but in only 15% of the low-incidence „sporadic‟ tumours seen in the 
West. The exception to the latter situation is EBV‟s more frequent association in those cases of 
BL arising in CD4 deficient HIV-infected persons
439
. The unifying feature of all BL cases is the 
translocation of MYC to one of the, constitutively active, Ig heavy or light chain promoters – 
resulting in a recurrent t(8,14), t(2,8) or t(8,22)
445-447
. Although deregulation of the C-MYC proto-
oncogene is of fundamental importance in BL pathogenesis
448
, commonly occurring in 
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association with defects in the p53 protein
449
, EBV is thought to play a key and complementary 
role in pathogenesis. 
The typical phenotype of BL cells (CD10
+
, CD77
+
, BCL6
+
) is commensurate with germinal 
centroblasts being the „normal cell counterpart‟ for these tumours450, and the detection of ongoing 
Ig-gene mutation in tumour cells
451
 is indeed consistent with a GC origin.  
Most cases of EBV
+
BL are regarded as Latency I: expression of EBNA1 initiated from the Qp-
promoter, in addition to the non-coding EBERs, BARTs and viral miRs. However, two other types 
of latent gene expression have been described in association with BL. The first involves 
expression of all six EBNAs in the absence of LMP1 and LMP2. This is considered to be very 
unusual and may occur as a result of viral genome integration into a cellular chromosome
452
. The 
second is a latent infection that lacks EBNA2 and LMP1, LMP2 but unusually expresses the 
EBNA3 proteins. This is thought to occur in approximately 15% of endemic BL cases
453-454
 and is 
due to a deletion including the EBNA2 gene. In this scenario, the Wp promoter rather than the Qp 
promoter initiates EBNA transcription; hence the term „Wp-restriction‟. Such Wp-restricted latency 
BL cells express BHRF1, a viral protein previously thought to be exclusively lytic
55
. 
 
There are two hypotheses as to how EBV might contribute to BL pathogenesis. One is that the 
virus might increase the likelihood of the characteristic C-MYC translocations and the second is 
that EBV might complement the activity of c-myc, perhaps by suppressing the apoptotic activity of 
the oncoprotein – a feature of MYC that co-exists with its potent proliferative effect455. The viral 
mediator(s) of the putative MYC complementation are unclear: EBNA1‟s role in this setting 
remains controversial; BHRF1 has anti-apoptotic activity but is only expressed in the Wp-
restricted subtype; and the functions of EBERs, BARTs and the EBV miRs remain under 
investigation in this context
439,455
. 
Therapy 
The development and application of non-cross resistant, dose- and time-intense, multi-agent 
chemotherapy regimens that, importantly, contain central nervous system-directed drugs
456-457
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have revolutionised the therapy of BL (where access to such therapies exists). Where this (or 
similar) therapeutic protocol(s) can be successfully delivered, a large majority of patients expect 
to be cured of BL; this highly proliferative disease is inherently chemo-sensitive. 
Thus, together with the low frequency of EBV
+
 BL in the developed world, the case for 
development of EBV-directed therapies for BL is weaker than for the other EBV-associated 
tumours. Furthermore, BL presents the greatest challenge for immunotherapy due to the limited 
repertoire of available viral antigens in association with global deficiency in HLA class I antigen 
processing, impairing CD8
+
 T cell recognition
458-459
. According to some reports, BL tumours retain 
class II processing function and some EBNA1-specific CD4
+
 T cells can recognize and kill HLA-
matched EBNA1-positive BL cells – although this is somewhat controversial.404  
Association of T and NK lymphoproliferations with Epstein Barr Virus 
EBV is so markedly B-lymphotropic when exposed to human lymphocytes in vitro that the 
association of EBV with rare but distinct types of T and NK cell lymphoproliferations was quite 
unexpected. A spectrum of such lymphoproliferations have only been relatively recently 
characterised but are now recognised to comprise a heterogeneous spectrum of diseases, 
affecting humans through all stages of life and conferring considerable morbidity and mortality.  
In substantiating the association with EBV, studies throughout the 1980s and 1990s examined 
both biopsy tissue and circulating lymphocytes for the presence of EBV in patients with a range of 
unusual clinical syndromes. In some cases of systemic, apparently infectious, illness there 
followed the development of EBV-positive malignant T cell lymphomas
241
. Similarly to the findings 
in lymphoma tissue
460-462
, clonal forms of the virus were identified in circulating NK cells, CD8
+
 
and CD4
+
 lymphocytes in patients across a clinical spectrum of lymphoproliferations
242-243,245,463-
471
.  
The fundamental unifying feature of such illnesses appears to be the clonal expansion of EBV-
infected T and/or NK cells, although the specific viral and host factors initiating and potentiating 
the disease processes remain largely unresolved. Furthermore it remains quite unclear why  
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infection of similar or identical cell types is associated with such a diverse spectrum of clinical 
illnesses, occurring both in previously EBV-naive and ostensibly EBV-immune individuals. A 
relationship between the phenotype of the infected cell and the nature of the clinical presentation 
has been suggested, at least for the systemic childhood illnesses
472
. Thus, in the context of 
chronic active EBV (CAEBV – discussed later), the predominantly infected cells appear to be 
either CD4
+
 T lymphocytes or NK cells, whereas the dominant infection in HLH is found within the 
CD8
+
 lymphocyte fraction
471
. However, this is not evidently the case for ENKTL in adults, where 
the normal cell counterpart is an NK cell or cytotoxic T cell – with apparently indistinguishable 
clinical presentations
473-474
.  
The clinical, pathological and biological features of the individual diseases will be detailed 
separately. However it is interesting to note that their characterisation and association with EBV 
began with clinical observations on unusual illnesses, in small numbers of patients, with 
corresponding analysis of clinical material with emerging molecular biological techniques, rather 
than routine clinical diagnostic tools. Such progress in understanding the pathobiology of this 
group of diseases would not have been achieved without close clinical-scientific collaboration.  
EBV-positive T-cell lymphoproliferative disorders of childhood 
WHO definition 
“‟Systemic EBV+ T-cell lymphoproliferative disorders of childhood‟ are life-threatening illness of 
children and young adults characterised by a clonal proliferation of EBV-infected T cells with an 
activated cytotoxic phenotype. It can occur shortly after primary infection or in the setting of 
chronic active EBV (CAEBV).”  
Haemophagocytic Lymphohistiocytosis 
History 
The earliest description of a distinct clinical syndrome associated with histological evidence of 
erythrophagocytosis was detailed in the Lancet in 1939 by two Oxford Pathologists
475
. A detailed 
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clinical and pathological description of four fatal cases, termed „histiocytic medullary histiocytosis‟ 
was summarised as follows. “These cases illustrate what we have come to regard as the typical 
clinical course of the disease: fever, wasting and generalised lymphadenopathy are associated 
with splenic and hepatic enlargement and in the final stages jaundice, purpura and anaemia with 
profound leukopenia may occur. Post mortem examination shows a systematised hyperplasia of 
histiocytes actively engaged in phagocytosis of erythrocytes”. These prescient observations 
remain central features of internationally agreed diagnostic criteria of the present-day 
clinicopathological syndrome now termed Haemophagocytic Lymphohistiocytosis (HLH)
476
 (Table 
1, page 63). 
Reports of similar clinicopathological entities accumulated in the literature under various 
terminology, including familial haemophagocytic reticulosis
477
, familial erythrophagocytic 
lymphohisticytosis
478
, histiocytic medullary reticulosis
479
 and malignant histiocytosis
480
. These 
reports included seemingly inherited syndromes and some attributable to, or associated with, 
malignancy although many cases remained of uncertain aetiology. Although a possible link with 
viral infection had been suggested, it was not until a study of HLH in a group including 
immunocompromised patients that a causative link with viruses was formally considered likely
481
. 
Fourteen of 19 patients studied (median age 28 years) were immunosuppressed with 
Azathioprine and Prednisolone, following in vivo T cell depletion (with anti-lymphocyte globulin) 
and splenectomy at the time of renal transplantation. The remaining five patients were previously 
healthy. All 19 patients presented with high fever and constitutional symptoms consistent with a 
viral illness in conjunction with evidence of histiocyte proliferation and haemophagocytosis in the 
bone marrow (Figure 6). Consistent with subsequent characterisation of HLH
476
, abnormalities of 
liver enzymes, coagulation dysfunction including hypofibrinogenaemia were noted in some cases. 
Serological or culture evidence of active viral infection was obtained in the majority of cases, of 
which the members of the herpes virus family dominated. This entity was termed virus-associated 
haemophagocytic syndrome
481
 (VAHS) and two cases with high IgM titres to EBV, suggested a 
role for this virus in disease pathogenesis - at least in some cases of HLH.  
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Figure 6 Bone marrow haemophagocytosis in virus-associated haemophagocytic syndrome 
From Risdall et al
481
, the first description of VAHS in 1975. A photomicrograph of a bone marrow 
smear which shows mature histiocytes with abundant vacuolated cytoplasm. Many histiocytes contain 
haematopoietic cells.  
 
 
Association with EBV 
Stronger evidence of an association of EBV infection with HLH accumulated. These diagnoses 
were initially founded on typical clinicopathological features of the HLH syndrome, in association 
with high serum titres of anti-EBV antibodies
482-484
 followed by the finding of viral particles or DNA 
in affected tissues
485
. The increasing recognition of EBV-HLH and the apparent association with 
primary EBV infection prompted a detailed analysis of 52 cases of fatal IM that, following a 
characteristic clinical presentation of IM, severe pancytopenia developed, with bone marrow 
evidence of infiltration by lymphoid cells, cellular necrosis and marked histiocytic 
haemophagocytosis. The median survival time of these patients was six weeks, in whom an 
Epstein-Barr virus-associated haemophagocytic syndrome was strongly implicated in the cause 
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of death
486
. It is now clear that EBV is the most frequent cause of acquired HLH in the 
immunocompetent
374,487-488
. 
A major breakthrough in implicating EBV as a key aetiological agent in HLH was the identification 
of viral genomes within T lymphocytes in tissue biopsies of affected individuals
240,489-490
. 
Molecular findings in the majority of these cases confirmed, by southern blot analysis of viral 
terminal repeats, that EBV was present in monoclonal form. Moreover, clonal rearrangements of 
germline TCR gene sequences provided supportive evidence of clonal proliferation of a T cell 
infected with EBV. This notion was supported by studies employing lineage-specific markers with 
EBER in-situ hybridisation. Kawaguchi et al detected EBER-specific signals exclusively within a 
CD45RO
+ 
TCR
+
 population; importantly, EBERs were not detectable in B cells or 
macrophages
465
. Notably, the findings of some reports indicated that EBV
+
T cell lymphoma could 
arise from, or co-exist with, HLH
489
 although clear delineation between the two entities is not 
always straightforward
245,491-492
.  
The majority of published data has confirmed that CD3
+ 
T cells, most often the CD8
+
 subset, both 
in tissue biopsies
240,245,464-465,467,469,493
 and circulating lymphocytes
471,494
, are the dominant 
infected population in EBV-HLH. By contrast to CAEBV 
472
, definitive evidence for EBV infection 
of NK cells in HLH (in the absence of co-existing NK leukaemia
495
) has not been available.  
The pattern of EBV gene expression in EBV-HLH remains unclear. EBERs are frequently 
expressed by infected T cells and are a useful diagnostic target for in-situ hybridisation on tissue 
biopsies
465
. However, whether such EBV
+
 T cell lymphoproliferations display a Latency II pattern 
of viral gene expression - in keeping with the related T or NK diseases CAEBV
496
 and ENKTL
73
 - 
has not been adequately studied. A limited study analysed mRNA from splenic and peripheral 
blood mononuclear cells in 3 patients with EBV-HLH and found expression of EBERs, Wp/Cp- 
and Qp-initiated EBNA1, EBNA2, LMP1 and LMP2A transcripts
122
. This suggested alternate 
promoter usage in different cell populations and suggests the possibility of B cell derived 
transcripts, limiting interpretation of the data. An animal model of EBV-HLH, using the baboon 
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lymphocryptovirus herpesvirus papio (HVP), found mRNA transcripts using end-point PCR to 
detect HVP-EBNA1, HVP-EBNA2 and HVP-LMP1 in affected tissues
497
. However, interpretation 
of this study is again limited by lack of analysis at the single-cell level, compounded by lack of 
MAbs to HVP-encoded latent proteins.  
Epidemiology and risk factors 
The majority of cases of EBV-HLH occur in the context of primary infection
240,485-486,490
 in children 
and adolescents
498-500
. Adult cases of HLH are rare and usually have an underlying cause other 
than EBV infection, usually attributable to malignancy and most commonly lymphoma
374,501
. In 
common with other entities within the spectrum of EBV
+
 T and NK lymphoproliferations, the 
literature is dominated by a majority of EBV-HLH cases arising from study groups in East Asia
499
. 
However, reports in patients of European
240,494
, Middle Eastern
492
, North American and 
Hispanic
245
 ethnicities have been described. 
Although rare, inheritance of specific immune defects is recognised to be an important and strong 
predisposition for the development of HLH. The majority of such inherited abnormalities are 
associated with impaired NK and/or cytotoxic T cell function
502-503
. Familial HLH (FHLH) is an 
autosomal recessive condition originally described in 1952
477
 with an estimated incidence of 1 in 
50,000 births. HLH is the primary clinical feature and usually occurs within the first year of life. 
Several independent genetic loci related to cytolytic granule release by the effector T or NK cell 
have been implicated in the pathophysiology of genetic HLH. In 1999 mutations in the perforin 
gene at locus 10q24 were described in 8 patients with FHLH.
504
 and a number of further defects 
have been subsequently characterised
502,505
. Other autosomal recessive immunodeficiencies 
such as Chédiak-Higashi syndrome
506
 and Griscelli syndrome
507
 are also recognised to 
predispose to HLH, which occurs frequently albeit sporadically and often later during the natural 
history of their disease
502
. 
XLP (X-linked Lymphoproliferative Disease), initially described in 1975
508
 and molecularly 
characterised in 1998
509-510
 is a condition associated with mutations in the signalling lymphocytic 
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activation molecule (SLAM) associated protein (SAP/SH2D1A). SAP functions as an adaptor, 
binding to and recruiting signalling molecules to SLAM family receptors expressed on T and NK 
cells. XLP is associated with marked sensitivity to primary Epstein-Barr virus (EBV) infection, 
often leading to a lethal infectious mononucleosis and/or HLH
510
. 
Notwithstanding the original report of VAHS in a largely immunocompromised patient group
481
 – 
in which EBV was implicated in at least two cases, as discussed earlier - most patients presenting 
with EBV-HLH do not have apparent immunodeficiency. In the context of iatrogenic immune 
dysfunction CMV appears to be a more frequently implicated agent, although EBV-HLH has been 
reported and can be associated with a poor outcome
511
.  
Clinical and laboratory features 
Awareness of the clinical presentation and established diagnostic criteria
476
 for HLH (Table 1, 
page 63) is of fundamental importance to allow the prompt initiation of appropriate therapy.  
In keeping with Scott and Robb-Smith‟s original description of a HLH syndrome475, the cardinal 
clinical features of EBV-HLH are prolonged high fever, hepatosplenomegaly
 
and cytopenias. 
Lymphadenopathy, jaundice or neurological manifestations
512-513
 such as cranial nerve palsies or 
symptoms of encephalitis may also be present.
 
Characteristic laboratory findings include elevated 
serum triglycerides,
 
ferritin (often extremely high and a sensitive marker of disease activity)
514
, 
LDH
494
, transaminases, bilirubin and hypofibrinogenaemia
515
. Although not routinely assayed in 
UK clinical laboratories, serum levels of soluble IL-2 receptor-α (CD25) are frequently elevated in 
HLH
516
, form one component  of the diagnostic criteria
476
 and appear to be a sensitive marker of 
disease activity with some prognostic value
517
. 
Involvement of the central nervous system is common and an elevated cerebrospinal fluid protein 
with a moderate pleocytosis can be seen
512,518
. Cytopathological evidence of haemophagocytosis 
is often not evident on initial bone marrow biopsy, particularly if performed early, but is usually 
manifest as the disease progresses
502
. The apparent absence of haemophagocytosis on initial 
biopsy, can compound the diagnostic uncertainty related to the non-specific clinical features 
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which can mimic a wide range of infective and inflammatory conditions
487
, including IM
486
. 
However, evidence of progressive hepatosplenomegaly, cytopenias and biochemical parameters
 
should alert the physician to the possibility of HLH.  
Elevated VCA-IgM or -IgG antibodies in the serum, in the absence of EBNA antibodies, may 
reveal a primary EBV infection, whilst elevated EADR-IgG or -IgA antibodies are thought to 
represent a reactivation phenomenon
519
. However, serological assays may not always be 
definitive
492,500
 and have been complemented by a substantially more powerful diagnostic tool: 
quantitative PCR for EBV genomes. Although the biological significance of plasma or serum EBV 
DNA levels are not clear, cell free viral load is frequently elevated across a range of EBV-
associated diseases
520-521
 and has also been the assay of choice for some studies on HLH. At the 
time of active disease, EBV copy numbers ranging from 10
2 
to 10
7
/ml of plasma
522-523
 or serum
524
 
have been documented. Such levels usually exceed those seen in cases of uncomplicated IM 
assayed in parallel
494,524
. More limited data is available on the viral load in circulating 
lymphocytes, although a recent European study found copy numbers of 10
3
 to 10
5
 (per million cell 
equivalents) in B lymphocytes and 10
2
 to 10
6
 in total T cells
494
.  
Pathophysiology 
The clinical manifestations of HLH are, at least in part, a result of a dramatically dysregulated 
inflammatory
 
response due to release of pro-inflammatory cytokines
 
including interferon (IFN)-, 
tumour necrosis factor (TNF)-α, IL-6, IL-10 and macrophage-colony-stimulating factor (M-
CSF)
525
.
  
These mediators are secreted by activated T-lymphocytes and
 
infiltrating
 
histiocytes, 
which can instigate tissue
 
necrosis and organ dysfunction.  In particular, CD8
+
 T lymphocytes and 
IFN have been shown to be necessary mediators of the disease process in an in vivo model
526
. 
Inflammatory cytokines
 
are also responsible for the haematological and biochemical 
manifestations such
 
as cytopenias, coagulopathy and elevated triglycerides
502
. Serum levels of 
Fas ligand (a membrane protein expressed on cytotoxic T and NK cells) has also been noted to 
be elevated in patients with HLH
527
 and may explain features such as liver dysfunction, as is the 
case in NK leukaemia
528
.  
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Table 1 Diagnostic criteria for EBV-HLH 
 
Clinical and Laboratory features*  
 
Ranges/Parameters 
 
Original criteria
529
 
Fever 
 
Splenomegaly  
Cytopenias 
(≥2 lineages) 
Hb  ≤9g/dl 
Plt  ≤100x10
9
/l 
Neuts ≤1 x10
9
/l 
 
 
Hypertriglyceridaemia ≤3mmol/l 
Hypofibrinogenaemia ≤1.5g/l 
Haemophagocytosis
†
 (BM, spleen, liver, LN) 
  
New criteria
476
 
Low or absent NK activity 
 
(local lab. reference range) 
Elevated serum ferritin ≥500μg/l 
Elevated soluble serum CD25 
(soluble IL2 receptor)  
 
 
Supportive features 
CSF pleocytosis and/or elevated protein 
Histological evidence of hepatitis  
 
 
Features consistent with the diagnosis 
Cerebromeningeal symptoms 
Lymphadenopathy 
Jaundice 
Oedema 
Skin rash 
Hepatic enzyme derangement 
≥2400U/l 
 
 
 
 
(local laboratory reference ranges) 
(may resemble chronic persistent hepatitis) 
 
 
 
 
 
                                                          
*
 Note that patients with a molecular diagnosis consistent with HLH do not necessarily need to fulfil the criteria 
here. 
 
†
 Note that initial biopsy/ies may lack evidence of haemophagocytosis or be inconclusive. Further biopsies are 
encouraged if a strong clinical suspicion exists. 
 
Hb=Haemoglobin, Plt=platelet count, Neuts=neutrophil count, BM=bone marrow, LN=lymph node, NK=Natural 
killer cell, CSF=cerebrospinal fluid 
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Immunocompetent rabbits, infected with HVP, a baboon lymphocryptovirus
530
, developed a HVP-
driven, fatal monoclonal/oligoclonal T cell lymphoproliferative disease with similar 
clinicopathological characteristics to EBV-HLH
497
. Another study, employing the same in vivo 
model of EBV-HLH described the emergence of erythrocyte and platelet antibodies at the time of 
peak HVP genome load. This appearance of antibody-coated erythrocytes anteceded 
erythrophagocytosis in tissues and heralded the onset of the full clinical syndrome. Such 
phagocytosis was shown to be specifically mediated by Fc-mediated macrophage activation
531
. 
Impairment of the cytotoxic function of NK cells and CTLs seems to be a common denominator 
across both inherited and acquired HLH syndromes
488,532
, although the mechanisms leading to 
cytolytic defects in immunocompetent patients with EBV-HLH are not clear. Elevated levels of 
cytokines such as IL-12 have been shown to impact on NK function
533
. Lastly, the apparent 
geographical disparities in the incidence of EBV-HLH may suggest a hitherto unidentified genetic 
susceptibility resulting in a dysfunctional immune response to infected cells. 
Prognosis and Therapy  
The aims of HLH therapy are to suppress the augmented inflammatory response with 
immunosuppressive/immunomodulatory agents, support and restore organ function, and (in the 
case of EBV-HLH) eliminate EBV-harbouring T cells with cytotoxic drugs. 
A key therapeutic advance in HLH was the observation that use of the epipodophyllotoxin 
derivatives etoposide, and later teniposide, in combination with corticosteroids could induce 
prolonged symptomatic resolution
534-536
. Moreover, the early application of etoposide (within 4 
weeks of diagnosis) has been shown to substantially improve outcome in EBV-HLH537. 
Intravenous (human) immunoglobulin usually results in sub-optimal responses
537
. The 
immunosuppressive drugs cyclosporin (CSA) 
538
 and anti-thymocyte globulin (ATG) are also 
effective in FHL
539
. CSA has shown to be of clinical value in improving cytopenias in the context 
of an Etoposide-based regimen
540
. In the international HLH-94 protocol (initially designed for 
familial HLH
541
 and later adopted for patients with acquired disease, including EBV-HLH 
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patients
476,542
, etoposide and dexamethasone were combined with CSA
541
. Due to the concern of 
CNS morbidity and mortality
512-513
, dexamethasone is the preferred corticosteroid as it penetrates 
the blood-brain barrier. Intrathecal Methotrexate has also been used for cases of CNS 
involvement, particularly if no improvement with systemic therapy is seen
541
. For those patients 
with refractory disease
500
 and those with familial defects
543
, allo-HSCT can result in long-term 
disease-free survival. 
Focusing on the prognosis of patients with EBV-HLH, Imashaku et al described the outcome of 
78 consecutive children. Although treatment was somewhat heterogeneous, the majority received 
an etoposide-containing regimen – many as part of a therapeutic protocol based on HLH-94 
immunochemotherapy
541
. With a median follow-up of 43 months, evidence of disease 
recrudescence was noted in 13 patients (19.4%) and a total of 12 patients required allo-HSCT, of 
whom 9 are alive and well. Haemorrhage and infections accounted for the 11 early deaths, whilst 
late deaths were due to relapse (4 patients), transplant-related mortality (3 patients) and 
secondary leukaemia (1 patient). Overall, after a median follow-up of almost 4 years, 59 (75.6%) 
of the cohort are alive and well, indicating the effectiveness of similar immuno-chemotherapy 
protocols as used for familial disease
476,541
. The prognosis and outcome of adult patients with 
EBV-HLH has been less well studied. One study analysed the outcome of 20 young adults (aged 
17-33 years) treated for EBV-HLH
495
. At a median follow-up of 2.5 years, 32.5% of patients 
remained alive and well – although a caveat is that some cases in this cohort had co-existing NK 
leukaemia, conferring a poor prognosis. Patients treated with Etoposide appeared to have a more 
favourable prognosis. Nonetheless, the available published data
245,492,495,501
 suggests a more 
adverse prognosis for adults with EBV-HLH than in children, although a higher incidence of co-
existing lymphoma in adults, and inter-study treatment heterogeneity should be noted. 
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Chronic Active EBV 
History and terminology 
In 1948, Isaacs described a cohort of patients with fatigue, fever, splenomegaly and small volume 
lymphadenopathy persisting for 3 months to over 4 years after an initial episode of clinically-
defined infectious mononucleosis 
544
. All patients were found to have variable numbers of 
mononuclear cells termed „infectious mononucleosis cells‟ in their peripheral blood although the 
absolute peripheral blood counts were normal. A subsequent study that examined antibody 
responses to EA following acute IM noted that although many patients had an unremarkable 
clinical course, a subset of patients experienced protracted symptomatology over periods of 4 to 
28 months. These patients tended to have late anti-EA antibody responses and relatively high 
persistent VCA titres
545
.  
Reports of patients with clinical syndromes consistent with „chronic symptomatic EBV infection‟ 
accumulated 
546-549
 although terminological inconsistencies caused some confusion in the 
literature. Reference to 'chronic mononucleosis' was considered misleading, as the chronic illness 
was not associated with persistent lymphocytosis and in many cases was not preceded by acute 
IM
550
. On the basis of available clinicopathological data, diagnostic criteria based on clinical and 
serologic findings were proposed
551-552
. The term chronic active Epstein–Barr virus (CAEBV) 
disease was applied for patients with a systemic EBV-positive lymphoproliferative disease 
characterised by fever, lymphadenopathy and splenomegaly developing after primary EBV 
infection in patients without known immunodeficiency
552
. Proposed diagnostic guidelines required 
persistence of symptoms for at least 6 months associated with high IgG antibody titres to the viral 
capsid antigen (VCA) and early antigen (EA). This definition arose from observations on affected 
children from the Western hemisphere and was proposed to result from progressive EBV 
infection of B cells, although this was not formally proven.  
The evidence for a causal relationship between persistent EBV infection and a chronic IM-like 
disease strengthened with reports of patients in whom chronic symptoms first appeared following 
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proven IM, with a serological picture (high anti-EA, very low or absent anti-EBNA titres) that never 
developed beyond that expected exclusively during acute primary infection. All four patients in 
this study had reduced EBV-specific cytotoxic T-cell activity, without apparent impairment of other 
CTL responses
553
. 
Infection of T and NK cells 
The first evidence of an association of CAEBV with infection of non-B cells arose from a detailed 
clinicopathological study of a young child with clinical and serological evidence of CAEBV
242
. 
EBNA
+
 cells were detected in blood, bone marrow and lymph node and, unexpectedly, clonal 
EBV genomes were identified in peripheral blood CD4
+
 T lymphocytes. There followed a series of 
reports, predominantly arising from Japan and East Asia, that contributed to an emerging picture 
of the clinical and virological features of CAEBV
463,469-470,554-555,523,555-559
. The striking pathological 
feature evident within these studies was the finding of EBV-infected T or NK cells in the blood or 
tissue of affected patients
463,469-470,554-555,471,556
. Importantly, Southern blot analysis of viral 
terminal repeats consistently demonstrated clonal or oligoclonal EBV genomes
463,469-470,554-555,556
, 
implicating the virus in the early stages of disease pathogenesis. 
The advent of quantitative PCR for EBV genome load in peripheral blood and tissue biopsies
560
 
has proved invaluable and is considered a more sensitive diagnostic parameter than EBV 
serology data, which can be normal in a minority of patients with clear clinicopathological 
evidence of CAEBV 
556
. The published data suggests that patients with clinically apparent 
CAEBV, assessed prior to therapy, have viral load values in the order of 10
3
-10
7
 genomes/million 
PBMC
556,561
 and 10
2
-10
6
 copies per ml of plasma
523,557-558
. One study analysed whether viral 
loads correlated with disease severity: patients experiencing 2 or more life-threatening 
complications had significantly higher viral loads than those with fewer complications 
(p=0.046)
556
. 
On the basis of analyses of EBV-encoded proteins in cell lines established from patients with 
CAEBV
562
, the available data suggests a Latency II pattern of viral gene expression in EBV-
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infected T and NK cells, at least in vitro. Studies examining viral gene expression in ex-vivo 
lymphocytes from CAEBV patients have been scarce. Iwata et al
563
 recently described a pattern 
of EBV latent antigen expression including Qp-initiated EBNA1, LMP1, and LMP2. Although this 
study used RNA extracted from total PBMC, the viral load in each case was confirmed to be 
predominantly within the T or NK population. In particular, LMP2 was consistently expressed 
amongst CAEBV patients although the PCR assay did not distinguish between LMP2A and 
LMP2B. EBNA2 and lytic transcripts were absent; thus the pattern was representative of „Latency 
II‟. This was consistent with previous, non-quantitative PCR studies on CAEBV PBMC ex-vivo564-
565
. 
Although monoclonal or oligoclonal EBV has been consistently identified in the infected T/NK 
populations of patients with CAEBV, further details relating to the genome copy number per cell 
and whether the virus genome is episomal or integrated (or both) into cellular chromosomes, are 
limited. An early study examined lymph node tissue from 4 patients with CAEBV and found, by in-
situ hybridisation studies, evidence of viral genome integration into the host chromosomes. For 
two cases in which integration events were more frequently identified, an abnormal karotype was 
also evident: one with an oligoclonal abnormality of chromosome 6 and one case with a clonal 6
th
 
deletion (del(6)(q15q23)). Further data on EBV genome integration in CAEBV has not been 
forthcoming, but metaphase analysis of a larger number of patients with CAEBV has confirmed 
the frequent finding of associated chromosomal aberrations
556
. PBMCs from 10 of 20 patients 
examined exhibited a range of chromosomal abnormalities, some complex, but no evidence of 
recurrent abnormalities.  
Clinical features, prognosis and therapy 
A detailed Japanese study of 30 CAEBV cases
556
, followed by a nationwide survey that captured 
data on 82 patients
561
, included elevated EBV DNA load in blood or tissue as a diagnostic 
criterion alongside the increasingly recognised clinical features (including fever, hepatitis, 
lymphadenopathy, hepatosplenomegaly, pancytopenia, uveitis, interstitial pneumonia, hydroa 
vacciniforme
566
, or hypersensitivity to mosquito bites
555
). Patients in these analyses could be 
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delineated into two groups according to whether T cells or NK cells were the predominant EBV-
harbouring cell, as assessed by quantitative PCR or in-situ hybridisation. Interestingly, although 
all patients fulfilled the stipulated diagnostic criteria, the two respective groups seemed to exhibit 
different clinical features and prognosis. T cell-type infection was characterised by fever and high 
titres of EBV-specific antibodies, whereas patients with NK cell–type infection exhibited 
hypersensitivity to mosquito bites and high titres of IgE as distinguishing features. Importantly, 
patients with T cell–type infection appeared to have significantly poorer outcomes556,561,564.  
The relatively large study of 82 patients
561
 provided a more representative insight into the natural 
history and prognosis of CAEBV, at least for East Asian cases. The mean age at onset of 
symptoms was 11.3 years (range 9 months to 53 years). Consistent with previous descriptions, 
fever, hepatomegaly, splenomegaly and liver dysfunction were manifest in almost all cases 
whereas lymphadenopathy, thrombocytopenia and anaemia featured in 40-45% of patients. The 
previously reported phenomenon of hypersensitivity to mosquito bites
555 
was seen in one-third of 
patients and skin rash was noted in 25%. Life-threatening complications were common and 
included haemophagocytic syndrome (24.4% - no data was available for whether these HLH 
cases were of T of NK origin), malignant lymphoma (18.3%), disseminated intravascular 
coagulopathy (15.9%), hepatic failure (14.6%), digestive tract ulcer/perforation (11.0%), coronary 
artery aneurysms (8.5%), CNS involvement (8.5%), myocarditis (6.1%), interstitial pneumonia 
(4.8%), and leukaemia (4.8%).  
Survival probabilities for the whole cohort were estimated at 68% (range 62-76%) and 58% (51-
65%) at 5 and 10 years respectively. Patients with T cell-type infection fared much worse, with 
59% probability of survival at 5 years compared with 87% for those with predominantly NK-type 
infection. Other adverse prognostic features evident on multivariate analysis included the severity 
of thrombocytopenia at diagnosis and age >8years at disease onset. The impact of therapy in this 
retrospective study could not be assessed due to the wide range of treatment approaches 
undertaken in multiple study centres. However, given the generally poor outcomes following 
immunoregulatory drugs and antiviral agents, one study group has investigated a new therapeutic 
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algorithm for CAEBV comprising sequential immuno-chemotherapy, combination chemotherapy 
and allogeneic hematopoietic SCT
567
 (allo-HSCT) in an attempt to reduce and/or eliminate EBV-
infected T/NK cells. In the experience of the investigators, complete responses are rare with a 
correspondingly high relapse risk and therefore allogeneic haematopoietic stem cell 
transplantation (allo-HSCT) is considered for all patients in whom evidence of residual disease 
exists. Since the first report of allo-HSCT for severe CAEBV in 2000
568, Dr Kawa‟s group have 
undertaken allo-HSCT for 29 patients with CAEBV, using either conventional myeloablative (MA) 
conditioning (11 patients) or reduced-intensity conditioning (RIC) (18 patients). A recent analysis 
of their clinical outcomes
567
 showed a high transplant-related mortality in the MA group (45%), 
resulting in a 3 year event-free survival (EFS) and overall (OS) of 54.5±15.0% for both outcome 
measures. By contrast, the 3-year EFS for the RIC group was 85.0±8.0% and the 3-year OS was 
95.0±4.9%. Importantly, for both groups, a plateau in the survival curves is evident – indicating 
the remarkable potential of allo-HSCT to achieve long-term disease-free survival for patients with 
severe CAEBV.  
Extra-nodal NK/T-cell lymphoma, nasal type 
World Health Organisation definition 
„A predominantly extra-nodal lymphoma characterised by vascular damage and destruction, 
prominent necrosis, cytotoxic phenotype and association with Epstein-Barr virus (EBV). It is 
designated “NK/T” (instead of “NK”) because while most cases appear to be genuine NK-cell 
neoplasms, some cases show a cytotoxic T-cell phenotype‟474. 
History 
Extra-nodal NK/T-cell lymphoma (ENKTL) is a relatively recently characterised clinicopathological 
entity, being formally incorporated into the WHO classification of haematopoietic and lymphoid 
tumours in 1999
569
. However, a historical trail of descriptive clinical and pathological literature 
suggests that this entity was recognised over a century earlier and provides a fascinating insight 
into early attempts to characterise, classify and understand this initially enigmatic disease.  
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The first clinical description of a disease resembling what is now recognised as the most common 
manifestation of ENKTL – a destructive nasal lesion – was recorded in 1897 by McBride who 
described a patient in whom an ulcer developed on the left lateral surface of the nose that within 
a year, at the time of death, had extended to both cheeks causing extensive tissue damage to the 
nose and upper lip
570
. Although syphilis and tuberculosis were not specifically excluded as 
diagnoses, a review of tissue sections by a pathologist (Dr. Muir) was “strongly of the opinion that 
the disease does not correspond to any type with which we are familiar.” 
A perhaps clearer account was subsequently published by Sir Robert Woods in 1921
571
 when he 
described two patients with destructive nasal lesions, in whom syphilis was excluded as a 
diagnosis and no infectious organism could be identified. He described the lesion as a "wave of 
granulation tissue advancing irregularly into healthy parts, breaking down behind as it advanced 
in front, so that there was never any great depth of pathological growth present.” The term 
"malignant granuloma" was suggested by his colleague Dr. O'Sullivan. Further clinical and 
histological accounts of such a disease accumulated over the following decades
572
 
573-579
.  
However, in spite of the increasing recognition of this disease as a distinct entity, confusion of the 
nature of the lesion remained. It had been recognised that  patients with „Stewart‟s nasal 
granuloma‟ may eventually die with disseminated malignant lymphoma580 but difficulties remained 
in distinguishing a malignant nasal lymphoma from non-malignant conditions such as Wegner‟s 
granulomatosis
581
. Harrison suggested that this was likely to be due to the frequently „under-
representative‟ biopsy material available for pathological study581 and went on to review the 
clinical and pathological cases of 28 patients with non-healing granuloma. He proposed that 
„where the lesion remained localized to the nose or pharynx, irrespective of the histological 
appearances, then this condition should be considered as a neoplasm, probably attenuated to a 
varying degree by the individual's own immunological defences‟. Harrison also made the 
prescient observation that patients with localised lymphoma „may have a surprisingly good 
prognosis when treated with radiotherapy‟, in fact  a documented response to radium therapy was 
also described in one of Robert Woods‟ original cases571. 
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Phenotype and genotype 
Following the development and application of immunological techniques to pathological 
diagnosis, a study by Ishii et al
582
 was the first to demonstrate that the malignant cells in cases of 
„lethal midline granuloma‟ or „rhinitis gangrenosa progressiva‟ (other terms included polymorphic 
reticulosis or malignant midline reticulosis) reacted with anti-sera directed to T cell, but not B cell, 
antigens
582
. Importantly, a separate analysis of DNA derived from such tumours found evidence 
of rearranged TCR genes indicating a clonal T-cell proliferation
583
.  
The apparent T-cell origin of this lymphoma was corroborated by further pathological studies in 
East Asia
584-585
 and the United States
586
. However, the development of antibodies against the 
CD56 antigen questioned the T cell phenotype of the malignant cells
587-590
. A body of evidence 
then emerged supporting the notion that the majority of these tumours were of natural killer cell 
origin, with germline T cell receptor gene configurations
461,588,591-595
. The reactivity of polyclonal 
anti-CD3 antibodies with the cytoplasmic subunit (ε-chain) of the CD3 molecule in formalin-fixed 
tissues is the likely explanation for the original phenotypic interpretation
596-599
.  
Emile et al
600
 hypothesised that lymphomas expressing some T-cell-associated antigens, but 
without surface expression of either a αβ or γδ TCR, may have arisen from NK cells. Of 35 „TCR-
silent‟ lymphomas identified, 15 were found to have rearranged TCR  genes with a clinical 
presentation predominantly involving lymph nodes (14/15). By contrast, 16 cases were CD56
+
 
and of 9 cases analysed for TCR γ gene rearrangements, 8 cases were negative. Of note, all but 
one of these cases had an extranodal presentation, and 11 of 16 fulfilled the criteria for the entity 
termed nasal T/NK cell lymphoma
594,601
. This study provided support to the concept that nasal 
T/NK cell lymphoma is a distinct entity and substantiated the case for a derivation from NK rather 
than T cells, although did not investigate the EBV status of the tumours. 
Consequent upon such difficulties in morphological and phenotypic characterisation was that the 
evolving lymphoma classification systems - Rappaport
602
, Kiel
603
 and the Working Formulation
604
 
- did not include ENKTL as a distinct entity. In the Revised European and American Lymphoma 
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(REAL) Classification
605
, the entity „angiocentric lymphoma‟ was used, although it has since been 
recognised that this pathological description is not unique to ENKTL. 
The characteristic phenotype of ENKTL is now understood to comprise CD2
+
, CD56
+
, surface 
CD3- (as demonstrated on fresh/frozen tissue) and cytoplasmic CD3ε (as demonstrated on FFPE 
tissues). Although CD56 is a very useful marker for NK cells, it can also be expressed on 
peripheral T cell lymphomas, particularly those that express the δ T cell receptor
474
. The largest 
clinicopathological study of ENKTL since its incorporation into the WHO classification
474,569
 has 
provided further information on the phenotype of the tumour cells. The International T cell project 
studied 136 cases of ENKTL and confirmed the expression of CD56 and cytotoxic markers (TIA-1 
and Granzyme) in a majority of cases, but also identified a minority of tumours (14%) with a CD8
+
 
phenotype. Rearranged T cell receptor genes (by Southern Blot analysis) were found in 
approximately one-third of 52 cases tested
473
. Note that such a proportion of cases with TCR 
rearrangements is greater than might be expected from the phenotypic studies, indicating that 
further detailed phenotypic/genotypic correlative studies are required. 
Association with EBV 
The first compelling evidence that EBV infection could be implicated in the development of T and 
NK lymphomas arose from a report that described 3 patients with clinical and serological features 
suggesting a background of chronic active EBV (CAEBV) who subsequently developed fatal T 
cell lymphoma
241
. These tumours were shown to contain clonal EBV as determined by viral 
terminal repeat analysis. Subsequent studies identified EBV genomes and/or EBV-encoded 
RNAs (EBERs) within the tumour cells of both nasal and extra-nasal T and NK lymphomas 
arising in children and adults
460-462,589,593
. The association with EBV was observed to be most 
robust in extra-nodal lymphomas and those arising in the nasopharynx
606
. The clonal and 
episomal form of the virus in the tumour cells
607-608
, together with the expression of EBV-encoded 
transcripts and proteins
73,469,607-609
, suggested a causative role for the virus in disease 
pathogenesis. 
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Although the incidence of ENKTL is higher in East Asia and South America than in Europe and 
North America, an invariable association with EBV is apparent irrespective of geographical 
origin
473
. Indeed, demonstration of the virus in the malignant cells, usually by virtue of EBER in-
situ hybridisation, is virtually a requisite for diagnosis
474
.  
Viral gene expression in ENKTL  
Initial analyses of six cases of ENKTL, confirming the presence of the virus within the malignant 
cells
607
, also performed immunostaining for LMP1 and found numerous positive cells in four of six 
cases. A follow-up study from the same group in Hong Kong comprehensively analysed 23 cases 
of ENKTL, to establish a more comprehensive picture of EBV gene expression at the mRNA and 
protein level
73
. Immunostaining for LMP1 revealed heterogeneous membrane positivity in a sub-
population of EBER
+
 cells in 15 of 23 cases. Of note, both cases of extra-nasal tumours analysed 
were LMP1 negative and, importantly, none of the 23 cases expressed EBNA-2 or BZLF1 protein. 
Further characterisation was performed at the RNA level by conventional end-point RT-PCR. The 
BARTs were expressed in the majority of cases, whilst EBNA-1 transcripts were present in 15/23 
cases and, similarly to BL
74
 and NPC
76
 confirmed to be Qp-initiated. LMP1 transcripts were 
readily detected in all cases, whilst LMP2A and LMP2B mRNAs were low or absent in the 
majority of tumours. A similar study examining Japanese cases of ENKTL found comparable 
results: LMP1 and Qp-initiated EBNA-1 were detected in all seven cases at the mRNA level. Data 
from a study of 7 European cases was also in keeping with the East Asian data
610
. QUK spliced 
EBNA1 was present in the majority of cases, whilst LMP1 was variably expressed at the mRNA 
level in 5 of 7 biopsies examined. By contrast, a small study could find no LMP1 mRNA or protein 
in 4 cases
611
 although two tumours were not phenotypically characteristic of ENKTL (CD4 
positive, CD56 not tested) and, unusually, a leukaemic phase was manifest in all cases. 
Moreover, the gene expression analyses were performed on the circulating tumour cells, rather 
than the tissue from the primary tumour, and may therefore not be representative of the original 
malignant population. 
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Taken together, the burden of published evidence
73,469,608-610,612-614
 is most consistent with a 
„Latency II‟ pattern of gene expression akin to HL75 and NPC76, although intra-tumour 
heterogeneity exists. In particular, LMP1 expression is variable and heterogeneous at the single 
cell level in ENKTL
73,614
, whereas LMP2 mRNA levels appear low or absent in analysed 
cases
73,610,612
.  
Epidemiology  
Extra-nodal NK/T lymphoma (ENKTL) is an aggressive malignancy with a unique geographical 
distribution; rare in Western countries and more frequently encountered in East Asia and 
Central/South America
250-252,473,615-618
. Importantly, only studies applying the WHO diagnostic 
criteria for ENKTL
474,569
 can be expected to provide a meaningful estimate of incidence. A single-
centre study documented that ENKTL comprised 6.27% of almost 1000 incident NHL cases 
studied – equating to over one-third of all T and NK cases in this Chinese NHL population617. 
Similar incidence data was recently published from a large Korean study
616
 – in which ENKTL 
accounted for 4% of all NHL cases and 30% of mature NK and T cell neoplasms. By contrast, the 
best estimate of incidence in Europe and the United States is that ENKTL represents 4% of all 
NK and T cell lymphoma subtypes
473
 - equating to approximately 0.5% of all NHLs
619
. 
Patients with ENKTL are usually immunocompetent. The median age of presentation is 45-50 
years with a male: female ratio of 2-3:1
473,616,620-622
 but it should be emphasised that much of the 
basic demographic data on this disease relating to incidence, age/sex distribution and patient 
ethnicity is not well characterised outside East Asia. 
Clinical Features 
ENKTL commonly affects the upper aero-digestive tract (characteristically the nasal cavity), 
though extra-nasal disease (for example skin, gastrointestinal tract, testis) can account for one 
quarter of cases
473
. Primary nodal involvement, in the absence of extra-nodal disease, is rare. 
Bone marrow involvement at diagnosis, as determined by conventional immunohistochemistry, 
occurs in a minority (6-14% of cases
473,623
) although this may be an underestimate
624
. Clinical 
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presentation is typically referable to local symptoms from a nasal mass, including obstructive 
symptoms and bleeding. Hoarseness of voice, dysphagia, proptosis, ophthalmoplegia and 
dysphonia can also occur according to the extent of local tumour invasion
625
.  
In contrast to the more prevalent high-grade lymphoma subtypes, clinical outcome is not 
accurately predicted by the traditional prognostic index (IPI)
626-627
. This is partly attributable to the 
younger median age of patients with NK/T lymphoma and the high frequency of stage I/II disease 
(present in approximately three-quarters of patients
473,623
). Published data suggests that a poorer 
prognosis is conferred by local invasiveness, elevated serum LDH, advanced stage disease and 
the presence of B symptoms
623
, termed the NKIPI and recently validated in a separate, multi-
institutional cohort
473
. 
Therapy  
Conventional chemo-radiation 
ENKTL is clinically aggressive, displaying inherent resistance to anthracycline-based 
chemotherapy regimens such as CHOP
628
 thought to be mediated, at least in part, by expression 
of the drug-efflux pump P-glycoprotein (PGP); encoded by the MDR1 gene
629-630
. The outcome of 
extra-nasal and advanced stage disease is extremely poor
473,623
 with little therapeutic progress 
achieved in this group of patients
631
. By contrast to their documented chemo-resistance, the 
tumours are usually sensitive to radiation therapy which, when given at relatively high doses
632
, 
forms an integral and effective part of front-line therapy for limited-stage disease
633
. However, in 
spite of high rates of initial response following involved-field radiotherapy, up to 50% of those with 
localised disease will experience relapse, usually within a year of completing first-line 
therapy
625,633-635
. Recently published data from early phase clinical trials examining the role of 
concurrent chemo-radiotherapy (using non-cross resistant, non-PGP chemotherapy agents) in 
localised ENKTL are encouraging
636,637
, but remains to be tested in randomised phase III clinical 
studies.  Encouraging data has also emerged, both from retrospective
638-639
 and early phase 
prospective studies
640
, on the activity of L-Asparaginase in relapsed/refractory ENKTL when 
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combined with chemo/radiotherapy. Studies are in progress to further delineate its therapeutic 
utility for patients with ENKTL. 
Nevertheless, despite signs of therapeutic progress, an extremely poor outcome is anticipated for 
the majority of patients with this disease. This is exemplified by data from the retrospective 
international T cell project study
473
, in which the median overall survival for the whole study cohort 
was 7.8 months, representing the poorest survival of all T cell lymphoma subtypes examined
641
. 
High-dose therapy and autologous stem cell transplantation  
Attempts to improve outcome in ENKTL have included studies of high-dose therapy (HDT) and 
autologous stem cell transplantation (ASCT), primarily undertaken in East Asia. The key question 
is whether HDT-ASCT can overcome the primary chemotherapy resistance frequently associated 
with ENKTL, reduce rates of recurrence and lead to improved outcomes. The majority of 
published data is based on retrospective analyses of relatively small cohorts
642-644
. 
Au et al
642
 examined data on 18 patients who received HDT-ASCT for histologically confirmed 
ENKTL, three of whom were included in an earlier report
645
. The majority of patients (72%) had 
Stage I disease and seven patients underwent ASCT in first complete remission (CR1).  Half of 
this cohort experienced relapse, all within six months following ASCT. Overall survival (OS) 
plateaued after six months, at 39% (Confidence intervals [CI] 26.6-51.4%). Interpretation of this 
outcome data is limited owing to the relatively large proportion of patients with Stage I disease in 
CR1. However it does suggest that employing ASCT as salvage therapy beyond CR1 is 
associated with a poorer outcome than initially suggested
645
. A comparative study from Korea
646
 
identified 16 patients, from a large database of NK/T lymphomas
623
, who had received 
HDT/ASCT as post-remission or salvage therapy. This cohort comprised mainly younger patients 
(median 36 years), although the majority had poor prognostic features by virtue of having stage II-
IV disease (63%) and a minority (19%) being in CR1 at the time of ASCT. With a median follow-
up of 22 months, progression-free survival (PFS) was 25.8% (CI 11.5%-40.1%) and OS of 71.3% 
(CI 58.9-83.7%); the latter explained in part by successful salvage of post-ASCT relapses by 
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allogeneic HSCT or additional chemotherapy. Comparison with a non-ASCT cohort demonstrated 
no significant survival advantage for patients undergoing ASCT and meaningful interpretation of 
sub-group analyses is not possible due to small patient numbers.  
The data from these two studies and a further cohort from Japan
644
 were subsequently pooled 
and analysed as a multicentre, matched controlled study. Multivariate analyses on this group of 
47 patients suggested a survival advantage for those undergoing ASCT, although the survival 
benefit appeared small. Disease status at ASCT appeared to be the strongest prognostic factor 
for OS and PFS. The authors tentatively recommend consideration of ASCT for patients with high 
risk NKIPI in CR1, but acknowledge that longer follow-up of a larger cohort is required. Overall, 
the published data on the role of ASCT in the management of ENKTL are not definitive and larger 
collaborative studies are necessary. 
Allogeneic haematopoietic stem cell transplantation  
The notion of harnessing a graft-versus-lymphoma effect against malignancies inherently 
resistant to conventional therapies is attractive and clearly has a role for some patients with more 
common subtypes of T cell lymphomas
647-648
. The invariable presence of EBV in the tumour cells 
of ENKTL, expressing the viral antigens EBNA1, LMP1 with/without LMP2, provides additional 
allo-reactive T cell targets. In vitro data (based on ENKTL cell lines) suggests that EBNA1
649
 and 
LMP1
650
 peptides can serve as targets for CD4
+
 effector T cells. Moreover, preliminary in vivo 
studies have adoptively transferred autologous, ex-vivo-stimulated, LMP2-specific cytotoxic T 
lymphocytes to patients with ENKTL with encouraging results
395,651
. 
The role of allogeneic HSCT for patients with ENKTL remains unclear; the two largest reported 
series comprise six
644
 and twenty-two
652
 patients. Murashige et al
652
 studied a total of 28 patients 
with NK cell malignancies, of which 22 were classified as ENKTL (the remaining cases comprised 
3 blastic NK lymphomas and 3 aggressive NK leukaemias), although the outcome data is 
presented on the whole cohort. The majority of patients received allogeneic stem cells from a 
sibling donor following a myeloablative (MA) conditioning regimen. Sixteen patients (57%) were 
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defined as chemo-refractory, 19 patients (68%) had stage IV disease and 8 (29%) were in CR at 
the time of allo-HSCT. The one-year transplant-related mortality (TRM) in this poor-risk group of 
patients was 29%, with a further 29% experiencing disease relapse/progression at a median time 
of 1.8 months post-HSCT. Notably, all patients who remained relapse-free at 10 months post-
HSCT continued in CR at a median follow-up of 34 months. Eight patients developed de novo 
chronic graft-versus-host disease; no donor lymphocyte infusions were administered. Suzuki et al 
644
 analysed six young patients (median 23 years) with ENKTL, as a sub-group of a larger study 
who received a MA allo-HSCT, all of whom had stage II-IV disease and 5 of whom (83%) were 
defined as chemo-refractory at the time of allo-HSCT. Two patients died of TRM and one patient 
experienced relapse. Interpretation of the data is clearly limited owing to the small subgroup, but 
it is noteworthy that 3 patients experienced long-term disease-free survival (30, 56 and 78 
months) following allo-HSCT despite having primary refractory disease (2 patients) or extra-nasal 
disease beyond CR1 (one patient). A further study from Japan, encompassing a total of 74 cases 
of EBV-associated T/NK lymphoproliferative disease in children and adults, included a sub-group 
of 9 patients with ENKTL whose outcome was not separately analysed
653
. 
The totality of published data on the role of high-dose therapy and autologous or allogeneic 
HSCT is therefore limited and to-date has been almost exclusively studied by clinical study 
groups in East Asia.  
Aggressive NK leukaemia 
WHO definition 
„A systemic neoplastic proliferation of NK cells almost always associated with Epstein Barr virus 
and an aggressive clinical course.‟ 
History 
Descriptions of chronic expansions of Large Granular Lymphocytes in the peripheral blood
654
 
(now understood not be associated with EBV), were initially incorporated into the REAL
605
 
classification system alongside an emerging, clinically aggressive entity
655
. The first distinct report 
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of an aggressive NK cell leukaemia in an adult
656
 was described in a 71 year old white man from 
the United States, although the majority of subsequent reports from East Asia have occurred in 
younger individuals
657
. Establishment of a cell line from this case retained morphological, 
immunologic, and functional characteristics of NK cells
656
. Further reports of clinically aggressive 
leukaemias displaying neither a B nor T cell phenotype
588,656,658-659
 suggested that such 
malignancies can arise from non-T cell large granular lymphocytes - or NK cells. The WHO 
subsequently recognised this aggressive leukaemia as a distinct clinicopathological entity and 
ANKL was separately incorporated into the lymphoid tumour classification
569
. 
Clinical features, prognosis and therapy 
ANKL is extremely rare, with approximately 100 published cases worldwide
660
. The disease 
typically affects young to middle age patients (mean age approximately 40 years), with a slight 
male predominance. Patients with ANKL are almost always systemically unwell at presentation, 
usually with a high fever and constitutional symptoms such as sweats and weight loss. 
Hepatosplenomegaly are frequent, but peripheral lymphadenopathy is less common
588,658-659
 
657,659,661
. Mucosal involvement - such as small intestine, salivary glands and testes - is also 
frequently observed. A leukaemic picture is invariably found, associated with prominent 
thrombocytopenia and variable degrees of anaemia and neutropenia
660
. However, an important 
feature of ANKL, unlike most leukaemias, is the patchy and sometimes minimal involvement of 
the bone marrow, even with co-existing involvement of the peripheral blood. Consequently, it has 
been suggested that the bone marrow may not be the primary site of neoplastic transformation
662
, 
although this remains to be clarified. 
Circulating leukaemic cells can appear morphologically similar to normal LGLs, or display atypical 
nuclear features. Prominent azurophilic granules within a pale cytoplasm are usually seen. Bone 
marrow examination frequently shows reactive histiocytes and haemophagocytosis
660
 (Figure 7). 
Admixed apoptotic cells, stromal degeneration and necrosis are commonly seen on tissues 
sections and angioinvasion can also be seen
474,660
. Cytogenetic abnormalities are seen in at least 
two-thirds of cases and are often complex
657,660
.  
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Most cases of ANKL pursue an inexorable clinical course, frequently displaying resistance to 
cytotoxic therapies. Complications such as coagulopathy, haemophagocytic syndrome and multi-
organ failure are not uncommon. In spite of treatment with intensive chemotherapy, mortality from 
ANKL is virtually inevitable with a median survival of less than 2 months
657,663-666
. Even for the 
minority of patients who experience an initial remission following an anthracycline-based regimen, 
relapse occurs invariably and attempts to improve outcome by the use of allogeneic bone marrow 
transplantation
667
 have not proved widely successful
665
. 
 
 
 
 
Figure 7 Haemophagocytosis in EBV-associated aggressive NK leukaemia 
A photomicrograph of a bone marrow aspirate (original magnification x200) from a UK patient with 
EBV-associated aggressive NK leukaemia. An area of marked macrophage activity and 
haemophagocytosis is evident. Lipid-laden macrophages are seen to engulf haemopoeitic precursors.  
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Association with EBV  
In the initial reports of ANKL, studies for EBV were not always performed
656,658-659
. Several small 
studies documented the presence of clonal episomal EBV in cases of large granular lymphocyte 
leukaemia 
463,668
. Hart et al
669
 described a patient who died soon after presenting with an acute 
hepatitis and rapidly increasing numbers of large granular lymphocytes in the peripheral blood. 
EBV DNA was found in clonal episomal form within the proliferating cells providing evidence of 
involvement of the virus in the early stages of leukaemogenesis. It is now recognised that >90% 
of ANKL cases harbour clonal, episomal EBV
463,666,670
.  
Due to the rarity of this disease and the often rapidly fatal course, analyses of the pattern of EBV 
gene expression in ANKL have been scarce. A study from Shanghai found that nine consecutive 
cases of (EBER
+
) ANKL were LMP1 negative by immunostaining with CS1-4 MAbs 
660
.  
Differences between ANKL and ENKTL  
ANKL shares many features with extra-nodal NK/T lymphoma, including cytological findings of 
azurophilic cytoplasmic granules in the neoplastic cells, an almost identical immunophenotype
594
 
(CD2
+, CD3ε+ and CD56+) although CD16 is thought to be more frequently expressed on ANKL 
than ENKTL 
665,671
. Both entities lack T-cell receptor (TCR) gene rearrangements
594,660
 and are 
seen with increased incidence in Asian populations.  
However, clinical features of ANKL such as a younger median age at presentation, the absence 
of a localised mass, invariable involvement of the blood or bone marrow and refractoriness of 
most cases to therapy allows this entity to be distinguished from ENKTL. In the vast majority of 
cases these diseases can be clearly delineated although rare patients with NK/T nasal lymphoma 
may progress to a more aggressive, systemic disease akin to ANKL
601,672
.  
Cellular genetic changes in ANKL and ENKTL 
Initial cytogenetic studies of NK lymphoma and leukaemia demonstrated a common region of 
genomic loss at 6q21-q25, suggestive of a recurrent chromosomal aberration
673
. Data from 
subsequent comparative genomic analyses identified further regions of chromosomal loss and 
85 
 
gain
674-675
. Although these early studies provided an indication of the genetic complexity of these 
malignancies, they did not distinguish between ANKL and ENKTL.  
A larger study
676
 investigated differences between patterns of genomic abnormalities in 17 cases 
of ENKTL and 10 cases of ANKL - all tumours were EBV-positive and classified according to the 
WHO system.  In cases of ANKL, loss of 7p and 17p13.1 and gain of 1q occurred frequently but 
loss of 6q did not. By contrast, loss of 6q21-q22.1, 6q22.33-q23.2, 6q25.3, and 6q26-q27 
occurred more frequently in the ENKTL group, implicating tumour suppressor genes within these 
regions in the development or potentiation of ENKTL. By demonstrating consistent differences in 
patterns of genomic aberrations between ANKL and ENKTL, this study provides further support to 
the separation of ENKTL and ANKL as distinct clinicopathological entities 
A more recent study employed higher resolution array comparative genomic hybridization (aCGH) 
technology to analyse NK cell lines and primary tumours and, importantly, correlated genomic 
abnormalities with transcriptional profiles of genes residing in regions of abnormality
677
. Notably, 
less than half of such genes showed corresponding increased or decreased expression, 
compared to normal and activated NK cells.  Despite this apparent lack of correlation, many of 
the upregulated genes in regions of gain are thought to be functionally important for neoplastic 
proliferation. Those genes downregulated in regions of loss included many transcription factors or 
repressors, tumour suppressors or negative regulators of the cell cycle. Three candidate genes 
were identified within the minimal common region of deletion in 6q21 (PRDM1, ATG5 and AIM1) 
and showed generally low expression. Complementary functional studies in cell lines showed that 
reversal of methylation by decitabine induced expression of PRDM1 and resulted in cell death, 
implicating PRDM1 as an important target gene in the context of del6q21.  
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AIMS OF THESIS 
 
1. Investigate the frequency and phenotype of EBV-infected T and NK cells in vivo 
in peripheral blood and secondary lymphoid tissue in the context of primary 
and persistent infection. 
 
2. Examine the antigen-processing function of EBV-associated T and NK tumour 
cell lines and their sensitivity to EBV-specific T cell responses.  This aspect of 
the thesis was subsequently developed to investigate the expression of LMP2 
in NK and T cell lymphoproliferations and its utility as an immunotherapeutic 
target. 
 
3. Develop an inducible LMP1-expression vector suitable for transduction and 
expression in primary NK cells to facilitate analysis of the associated genotypic 
and phenotypic cellular changes. 
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Materials and Methods 
Donors and Patients  
Ethical approval for the work within this thesis was provided from the West Midlands Research 
Ethics Committee (REC: 07/H1208/62). 
Healthy donors working within the School of Cancer Sciences consented to donate peripheral 
blood for isolation of PBMC. Patients from University Hospital Birmingham (UHB), Queen 
Elizabeth and the Birmingham Children‟s Hospital NHS trust undergoing tonsillectomy for acute 
or chronic tonsillitis provided consent to donate excess tonsillar tissue. In some instances, 
matched peripheral blood samples were also donated. Newly diagnosed patients from with acute 
IM were identified via a positive Monospot test performed at UHB Clinical Haematology 
diagnostic laboratory, and consent gained thereafter from the patients for peripheral blood 
donation. For analyses of IM tonsils, viable tonsillar mononuclear cells stored in liquid nitrogen 
and originally obtained through collaboration between Professor Alan Rickinson and Dr Wolfgang 
Bergler (University Hospital Mannheim, Germany) were used. All such IM patients had undergone 
tonsillectomy indicated for acute IM with associated airway compromise. A clinical diagnosis of IM 
was corroborated by a positive heterophile (Monospot) test. 
The patients with EBV-HLH were initially referred to our institution for diagnostic investigations 
with anonymised clinical data subsequently provided by the referring clinicians, in accordance 
with the REC approval. The ENKTL biopsy sections used for LMP2A immunohistochemistry 
fulfilled the W.H.O. diagnostic criteria
409
, including EBER-positivity, and were reviewed by two 
expert haematopathologists in the United Kingdom (Dr Simon O‟Connor and Dr David M. Clark, 
Nottingham University Hospitals, UK). ENKTL frozen tissue for PCR studies had undergone 
histology review in the United States (Professor W C Chan) for inclusion in a previous study
677
. 
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Isolation and manipulation of cells 
Isolation and manipulation of tonsil mononuclear cells 
Fresh tonsillar tissue was typically processed within 1 hour of tonsillectomy. The tissue was 
washed briefly in phosphate-buffered saline (PBS) prior to processing in „tonsil media‟ = RPMI-
1640, with 10% v/v FCS and Gentamicin (Sigma) at a final concentration of 8μg/ml and 100U/ml 
penicillin/streptomycin (pen/strep) 100U/ml final concentrations). Tonsil mononuclear cells (T-
MNC) were disaggregated to form single-cell suspensions by carefully incising the tissue and fine 
mincing with sterile scalpels. Isolated mononuclear cells were strained through a 40μm filter 
(Partec), aliquoted, cryopreserved, and stored in liquid nitrogen or as cell pellets (at -80°C) for 
extraction of DNA or RNA.  
As B cells constitute a considerable proportion (30-70%) of total tonsillar lymphocytes, B cell 
depletion with CD19 Dynabeads (see below) was performed on ex-vivo tonsillar MNC prior to 
MAb staining and sorting in order to reduce subsequent B cell contamination of sorted T and NK 
cell fractions. 
Separation of PBMCs from whole blood 
50-100ml of peripheral blood was diluted 1:1 with PBS and layered onto Lymphoprep™ iso-
osmotic medium (Axis-Shield) in a 250ml centrifuge tube (Corning). This was centrifuged for 30 
minutes at 1800rpm, without a brake to maintain the density gradient. PBMCs were extracted 
from the interface using a Pasteur pipette. The PBMCs were then washed twice in sterile PBS by 
centrifugation at 1600 rpm for 10 minutes and then 1200 rpm for 5 minutes. Viable PBMCs were 
either processed immediately for NK cell isolation or frozen in 10% dimethyl sulphoxide (DMSO) 
for future cell sorting.  
Isolation of B cells 
Expression of the pan-B cell marker CD19 allows the specific isolation/depletion of B lymphocytes 
from PBMC and tonsil MNC. Magnetic polystyrene beads coated in a CD19 MAb (Dynabeads 
CD19 Pan B, Invitrogen 111.43D) were used. The equivalent of 4 Dynabeads per B cell were 
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added to PBMC/T-MNC (assumed 5% B cells in PB and 50% B cells in T-MNC) at a 
concentration of 10
7
 Dynabeads per ml in a 14ml round bottomed tube and incubated at 4°C for 
20 minutes (isolation) or 30 minutes (depletion) in RPMI-1640 with 1% v/v FCS (used throughout) 
on a roller. A magnet was then applied for 2 minutes, allowing removal of non- B cells with a 
Pasteur pipette followed by washing of the Dynabead-bound B cells; this cycle was repeated 5 
times.  Dynabead-bound B cells were re-suspended in 1ml with 50µl of Detachabead
TM
 CD19 
(InvitrogenCat. no. 125.06D) and incubated at room temperature for 45 minutes on a roller. The 
bead/cell mix was resuspended in 9ml and the Dynabeads removed from the B cells by exposure 
to a magnet. This was repeated once, the unattached B cell suspensions combined and used in 
subsequent experiments. 
Isolation of primary NK cells from PBMC 
NK cells were isolated from 5-20 x10
7
 PBMC using a commercially available kit (Dynabeads® 
Untouched
TM 
Human NK cell kit – Invitrogen) and following the manufacturers protocol, without 
methodological modification. The principle of isolation is one of „negative selection‟, whereby the 
application of a mixture of biotinylated monoclonal antibodies („Antibody mix [human NK cells]‟, 
Invitrogen) directed against antigens expressed on T cells, B cells, monocytes, dendritic cells, 
platelets, macrophages, granulocytes and erythrocytes, allows their specific removal from PBMC 
using superparamagnetic 1μm polystyrene beads coated with streptavidin. Figure 8 is a 
schematic of the isolation procedure. The isolated bead- and antibody-free NK cells were 
subsequently analysed by FACS to assess purity. 
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Figure 8 Schematic of NK cell isolation from peripheral blood mononuclear cells 
 
  
PBMC 
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Cell culture  
All cells were grown in tissue culture-treated plates (Iwaki) in a humidified incubator at 37°C, 5% 
CO2. Primary lymphocytes were cultured at a density of 1-2 x 10
6 
cells per cm
2
 in 6-, 12-, 24- or 
48-well plates. Suspension cell lines were cultured at densities of 0.5-1.5 x 10
6
 per ml in 25cm
2 
flasks. 
Culture of tonsil mononuclear cells 
Tonsillar mononuclear cells (T-MNC) were cultured in „tonsil media‟ (RPMI-1640, with 10% v/v 
FCS and Gentamicin (Sigma) at a final concentration of 8μg/ml and 100U/ml pen/strep). For 
some experiments, IL-2 (Proleukin, Novartis) was added to give a final concentration of 175U/ml. 
Culture of primary NK cells 
Primary NK cells were cultured in CellGro® SCGM (stem cell growth medium - CellGenix™), 
supplemented with 10% heat-inactivated (56ºC for 45 minutes), sterile-filtered (0.22μm), human 
serum (HS) (Sigma), pen/strep 50U/ml and IL-2 175u/ml. 
Culture of SNK and SNT cell lines 
The SNK and SNT cell lines
562
 were kindly provided by Dr Norio Shimizu, Tokyo and cultured in 
conditions recommended by the originators: RPMI-1640 supplemented with 10% HS (prepared 
as for primary NK cells), 6mM L-glutamine (Invitrogen), 50U/ml pen/strep, 1mM Sodium Pyruvate 
(Sigma), 0.13mg/ml Oxalacetic Acid (Sigma) and IL-2 700U/ml (Novartis). The cell suspensions 
were „split‟ twice a week at a ratio of 1:2 - 1:4 according to growth rate and density. 
293FT epithelial cells 
The lentivirus-packaging cell line 293FT was cultured in 100mm plates (Iwaki) in RPMI-1640 with 
10% v/v FCS with the aminoglycoside antibiotic G418 (Invitrogen) added at 200 µg/ml for 
maintenance. 
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Cryopreservation of cells 
Where appropriate, 5x10
6
 – 200 x 106 cells were pelleted by centrifugation at 350g-force (g) for 5 
minutes and re-suspended in 0.5-1.5ml of „freezing mix‟: RPMI-1640 supplemented with 30% v/v 
FCS, 10% v/v dimethylsulphoxide (DMSO) and 2mM glutamine. Vials were subjected to 
controlled freezing by placing in a „Mr Frosty‟ container surrounded by a sponge soaked in 
propan-2-ol and stored overnight at -80°C, followed by transfer to the vapour stage of a liquid 
nitrogen freezer at -180°C for long term storage.  
In vitro EBV infection experiments 
Production of 2089 virus from 293 cells 
293 cell clones stably transfected with the recombinant 2089 B95.8 EBV genome
678
 were plated 
into 6 well plates 24-48 hours before transfection. When the cells were 70% confluent they were 
transfected with 0.5µg of BZLF1 and 0.5µg of BALF4 (gp110) plasmid
678-679
 per well using 
Lipofectamine (Invitrogen) reagent in Optimem minimal medium (Gibco) according to 
manufacturer‟s instructions, and incubated for 3 hours at 37°C, 5% CO2. After 72 hours, the 
supernatant was centrifuged at 900g for 5 minutes and sterile-filtered to 0.45µm. If not 
immediately used it was stored in aliquots at -80°C. A 50µl aliquot of virus supernatant was 
reserved for genome quantitation. 
Production of Akata EBV from Akata-BL cells 
Akata virus was generated from an EBV-loss clone of Akata-BL, which had previously been re-
infected with recombinant GFP-expressing EBV („Akata virus‟)680. Approximately 50x106 cells (at 
4x10
6
 cells/mL) were stimulated to produce virus by 2 hours incubation with 0.5% v/v anti-human 
IgG Fab 2 antibody at 37˚C, 5% CO2. The „cross-linked‟ cells were cultured at a density of 3x10
5
 
cells/ml in RPMI 10%FCS at 37˚C, 5% CO2, for 72 hours. Viral supernatant was harvested and 
stored as described for 2089 EBV. 
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Quantitation of EBV titre by Q-PCR 
An equal volume of lysis buffer (100mg/ml proteinase K (Roche), 10mM Tris-HCL pH 8.8, 1.5ml 
MgCl2, 50mM KC:, 0.1% v/v Triton X-100) was added to the virus supernatant and incubated at 
55°C for 1 hour. Q-PCR for EBV BALF5 (page 101 and reference
560
) was undertaken using a 
PCR input volume of 5µl of processed viral supernatant per well.  
Infection of cell lines and primary cells with EBV 
Infection of 1x10
7
 – 108 target cells was achieved by incubating in a volume of PCR-quantitated 
viral supernatant, calculated to equate to a multiplicity of infection (m.o.i) of 10-100, 
supplemented by 20% v/v FCS, for 4-8 hours in 50ml tubes (Falcon) at 37˚C, 5% CO2. The 
incubated cells were gently mixed at 1-2 hourly intervals to augment viral binding.  The cells were 
pelleted by centrifugation at 1400rpm and resuspended in the relevant culture media at an 
appropriate density. 
Flow cytometry and cell sorting 
MACS buffer (PBS with 2mM EDTA, adjusted to pH 7.5) with 5% v/v HInGS (heat-inactivated 
normal goat serum) was used as a staining and suspension solution throughout.  
Surface staining  
Table 2 details the conjugated monoclonal antibodies used for FACS analysis and cell sorting on 
the MoFlo. Target cells were re-suspended in microcentrifuge tubes at staining volumes of 5 
x10
7
/ml for MoFlo sorting and 1-5 x 10
7
/ml for FACS analysis. Staining was performed for 30 
minutes at 0-4°C and cells were washed once with MACS buffer prior to transfer to FACS tubes 
and analysis.  
Flow cytometric analysis  
One and two-colour flow cytometric analysis was performed on a Coulter Epics XL-MCL
TM 
Flow 
Cytometer (Beckman Coulter). The appropriate MAb isotypes were used as negative controls and 
individual MAbs for surface antigens were used separately for positive controls and to allow for 
fluorochrome compensation. Data was analysed using FlowJo software version 7.6 (Treestar). 
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Table 2 Conjugated monoclonal antibodies used for flow cytometry analysis and cell sorting  
Target  Clone
‡
  
Conjugated 
fluorochrome  
Working 
Dilution  
Incubation  Isotype  
CD19  SJ25-C1  PE-Cy5  1:20  
30 minutes 
0-4°C  
IgG1  
CD19  LT19  APC  1:20  
30 minutes 
0-4°C  
IgG1  
CD3 LT8  FITC  1:20  
30 minutes 
0-4°C  
IgG1  
CD3 UCHT1  PE-Cy5  1:20  
30 minutes 
0-4°C  
IgG1  
CD4  RPA-T4  APC  1:20  
30 minutes 
0-4°C  
IgG1  
CD8  LT8  FITC  1:20  
30 minutes 
0-4°C  
IgG1  
CD16  DJ130c  PE  1:20  
30 minutes 
0-4°C  
IgG1  
CD56  C5.9  PE  1:20  
30 minutes 
0-4°C  
IgG2b  
CD138  BA-38  FITC  1:20  
30 minutes 
0-4°C  
IgG1  
CD7  MEM-186  PE-Cy5  1:20  
30 minutes 
0-4°C  
IgG1  
 
  
                                                          
‡
All conjugated antibodies were purchased from AbD Serotec, UK 
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Fluorescence activated cell sorting  
Three or four-colour fluorescence activated cell sorting (FACS) was used to sort PBMC (typically 
20 - 50x10
6
) or T-MNC (typically 50 -150 x10
6
)
 
into lymphocyte sub-populations using the desired 
combination of MAbs and gating strategy (see Results Part I). Following surface staining and 
prior to sorting, cell suspensions were strained though 40μm filters (Partec). After sorting, where 
cell numbers permitted, a small aliquot of each sorted population was reanalysed by flow 
cytometry to assess purity. For GFP-expressing NK cells transduced with the TREX-regulated 
LMP1-lentiviral vector (see Results Part II), 10ng/μl Doxycycline was added 48 hours prior to 
sorting. All cell sorting was performed courtesy of the MoFlo
TM 
(Beckman Coulter) cell-sorting 
service (operated by Dr Roger Bird) at the Institute of Biomedical Research (IBR), University of 
Birmingham. 
Protein analysis 
Western blotting 
Preparation of gel samples 
Protein preparations were prepared from whole cell lysates of 1x10
6
 - 1x10
7
 cells according to 
availability. Cells were washed twice in PBS to remove FCS and the cell pellet lysed in 100μL 
urea buffer (9M urea, 50mM Tris, pH 7.5). Disruption of genomic DNA by 10-30 seconds of 
sonication using an ultrasonic cell disruptor (Misonix) was undertaken to reduce viscosity. The 
protein concentration was determined using a Bio-Rad DC protein assay kit according to the 
manufacturer‟s instructions.   
For Western blot analysis of all proteins except LMP2A, the following procedure was performed: 
An equal volume of 2x urea gel sample buffer (62.5mM Tris pH6.8, 4% w/v sodium dodecyl 
sulphate (SDS), 5% B-mercaptoethanol, 0.01% w/v bromophenol blue, 5M urea, 10% glycerol) 
was used to dilute the samples to 1-2mg/ml and diluted samples were denatured at 100˚C for 3 
minutes.  
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For Western blot analysis of LMP2A protein, the following procedure was undertaken: Sonicated 
cell lysates were denatured with NuPAGE® LDS Sample Buffer (4X) (Invitrogen Cat. No. 
NP0007) heated to 70°C for 5 minutes and reduced with NuPAGE® sample reducing agent (10X) 
(Invitrogen NP0004) immediately prior to loading into the wells. Cell lysates were stored at -80°C, 
whilst protein samples in gel sample buffer were stored at -20°C. 
SDS-PAGE (sodium dodocyl sulphate-polyacrylamide gel electrophoresis) 
SDS-PAGE and Western blotting were undertaken in XCell Surelock
TM
 mini cells (Invitrogen). 
Pre-cast NuPAGE
®
 Novex
®
 Bis-Tris 10 well gels (Invitrogen) were loaded with 20-40µg of protein 
alongside 15µl of Seeblue plus 2 pre-stained protein standards (Invitrogen). Electrophoresis was 
carried out in MOPS SDS running buffer (Invitrogen) at 78V for 3 hours in the XCell SureLock™ 
Mini-Cell (Invitrogen). 
Blotting 
Invitrolon™ polyvinylidine difluoride (PVDF) membranes (Invitrogen) were briefly exposed  to 
100% methanol prior to soaking in blotting buffer (25mM TRIS-BASE, 192mM glycine and 20% 
v/v methanol) for 5 minutes. Once the dye front had progressed sufficiently down the gel, 2 
sponges and a sheet of filter paper (Invitrogen) soaked in blotting buffer were placed on the 
cathode side of the blotting cassette. The gel was layered onto the filter paper, followed by the 
PVDF membrane and a second pre-soaked filter paper. Air bubbles were carefully eliminated 
between the gel and the PVDF membrane and 3 further wet sponges were placed on top. The 
blotting cassette was filled with blotting buffer and the outer chamber of the tank filled with 
distilled water to prevent over-heating of the module during transfer. The gel was typically blotted 
at 30V, 250mA for 120 minutes. The PVDF membrane was then incubated in I-Block/Tween 
buffer (IBT) (0.4% w/v casein powder (I-Block™, Applied Biosystems), 0.05% v/v Tween-20, 
0.02% sodium azide (NaN3)) on a shaker at room temperature for 1 hour to prevent non-specific 
antibody binding. PVDF membranes were then incubated with primary antibody (see table 3), 
diluted in blocking buffer overnight at 4°C. PVDF membranes were then washed 3 times, each 2 
minutes, in PBS/0.1% Tween-20 detergent. The appropriate secondary antibody conjugated to 
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alkaline phosphatise (Biorad) diluted in blocking buffer was then incubated with the PVDF 
membrane at room temperature on a rocker for 30 minutes. The membrane was then washed ≥5 
times, each for 5 minutes, in PBS/Tween-20. 
 
Table 3 Primary and secondary antibodies used for Western blotting, immunofluorescence and 
immunohistochemistry  
Target  Primary 
Antibody  Species  Application  
Working 
Dilution  Incubation  
Secondary 
Antibody  
Working 
dilution  
EBNA1  „AM‟ sera36  human  Western  1/200  4°C 
overnight  
AP-anti-
human IgG 
(Biorad)  
  1/10,000  
EBNA2  PE239  mouse  Western  1/25  4°C, 
overnight  
AP-anti-
mouse IgG  1/10,000  
LMP1  CS1-4681  mouse  Western  1/300  4°C 
overnight  
AP-anti-
mouse IgG  1/10,000  
LMP1  CS1-4681   mouse  IHC  1/50  4°C 
overnight  
HRP-anti-
mouse  1/500  
LMP1  CS1-4681   mouse  IF  1/100  37°C for 30 
mins  
Anti-mouse-
Alexafluor594  1/500  
LMP2A  14B7130  rat  Western  1/25,000 4°C 
overnight  
AP-anti-rat 
IgG  1/10,000  
LMP2A  15F9131  rat  IHC  1/50  4°C 
overnight  
HRP-anti-rat 
IgG  1/500  
TAP 1  148.3682   mouse  Western  1/100 
(supernatant)  
4°C 
overnight  
AP-anti-
mouse IgG  1/10,000  
TAP 2  435.3§  mouse  Western 1/100 
(supernatant)  
4°C 
overnight  
AP-anti-
mouse IgG  1/10,000  
HLA class I 
heavy 
chain  
HC-10
683  mouse  Western 0.2μg/ml  4°C 
overnight  
Ap-anti-
mouse IgG  1/10,000  
Calregulin  H-170**  Rabbit Western  1μg/ml  4°C 
overnight  
AP-anti-goat 
IgG  1/100,000  
BZLF 1  BZ1213  Rabbit IF  1/300  
(supernatant) 
37°C for 30 
mins  
Anti-rabbit 
Alexafluor488  
1/500  
Minor 
capsid 
protein 
(p18)  
OT15E
††  Rat  IF  1/300  
(supernatant) 
37°C for 30 
mins  
Anti-rat-
Alexafluor594  1/500  
                                                          
§
 The murine mAbs specific for the TAP1, 148.3 and TAP2, 435.3, were kindly provided by R. Tampe (Wolfgang 
Goethe-University, Frankfurt) and by P.M. van Endert (Institute Necker, Paris) respectively. 
**
 H-170 was purchased from Santa Cruz Biotechnology 
††
 The OT15E antibody to p18 was a kind gift from Professor Jaap Middeldorp (Vrije Universiteit Medical Centre, 
Amsterdam, Netherlands.) 
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Detection by chemiluminescence  
Alkaline Phosphatase (AP) chemiluminescence was used to visualise antibody bound proteins 
probed with an AP-conjugated secondary antibody. PVDF membranes were incubated twice in 
10ml AP buffer (0.1M diethanolamine pH 9.5, 1mM MgCl2,) and transferred to Saranwrap where 
0.8ml of CDP-star™ developer (Invitrogen) was uniformly applied to the membrane and 
incubated for 15 minutes. Excess reagent was removed, the Saranwrap sealed and placed in an 
autoradiograph cassette, with Kodak X-omat film, for detection. 
Stripping PVDF membranes 
The secondary antibody used during western blotting can be removed (stripped) to allow re-
probing of the same blot with a further MAb and secondary antibody raised in an alternative 
species. The blots were stripped by incubation with Ponceau S stain (1% Ponseau S w/v (Sigma) 
in 3% v/v trichloroacetic acid (TCA)) at room temperature for 3 minutes with rocking. The 
membrane was washed with tap water initially followed by ≥3 times, each for 5 minutes, in PBS 
Tween and subsequently re-blocked in blocking buffer for 1 hour. Blots were either re-probed 
immediately or stored at 4°C in Saranwrap. 
Immunohistochemistry 
4μm sections of formalin-fixed paraffin embedded (FFPE) tissue mounted on slides (courtesy of 
Mrs Sue Sharpe, Histopathology department, University Hospitals Birmingham) were de-waxed in 
Histo-clear® (Fisher Scientific) for 10 minutes followed by a series of rehydration steps through 
gradated ethanol (100% for 5 min, 90% for 5 min, 70% for 5min).The slides were rinsed in 
running tap water for 5 minutes followed  by endogenous peroxidise blocking in 0.3% hydrogen 
peroxide (H2O2) in water for 15 minutes and further rinsed in tap water. 
Antigen retrieval 
The process of formalin-fixation can render proteins within tissue to be relatively inaccessible to 
detection with antibodies. The process of antigen-retrieval, based on heat treatment at optimised 
acidic or alkaline pH, serves to „re-expose‟ masked antigens, with varying efficiency, to allow 
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access for primary antibody binding. The previously published Agitated Low Temperature Epitope 
Retrieval (ALTER) method
684
 was used. Briefly, EDTA buffer (pH 8) with 0.1% Tween-20 was 
pre-heated on hot-plate-stirrer (600rpm) to a stable temperature of 65°C and the slides incubated 
herein overnight (16-20 hours). The slides were then allowed to cool down slowly ≥1 hour at RT, 
before washing in very slow running tap water. 
Immunostaining 
Each slide was carefully dried and each section marked using the hydrophobic „pap pen‟ 
(Abcam), followed by conditioning in TBS buffer (pH 7.6) for 5 minutes. Each section was then 
blocked with 100-300μl of 1% casein (in TBS) and incubated for ≥10 minutes. The primary 
antibody (see table 3, page 94) was diluted 1:50 in PBS, 100μl applied to each section and 
incubated overnight at 4°C. The slides were then washed in TBS-tween (0.1%) buffer (pH 7.6) 
thrice, 5 minutes each and the appropriate secondary antibody (Dako, 1:500) in PBS was applied 
for 30 minutes. Further washing in TBS-tween was followed by the application of Real Envision 
DAB (950μl supplied diluent and 20μl DAB) (Dako) for 1-2 minutes. For counterstaining, the 
slides were washed in TBS-tween for 5 minutes, then in tap water, followed by counterstaining in 
Mayer‟s Haematoxylin solution (2 minutes). A further wash in warm tap water (5 minutes) was 
followed by gradated dehydration in ethanol (70% for 5 mins, 90% for 5mins, and 100% for 5 
mins). Finally, the slides were placed in Histo-clear® (Fisher Scientific) for 10 minutes and 
mounted in DPX (Surgipath). 
Staining was visualised with a Nikon Eclipse E400 microscope (optical magnification x100-400) 
and images captured with a Nikon Coolpix E995 digital camera. 
Immunofluorescence  
Cell fixation 
Cells were washed once and re-suspended at 10
6
/ml in PBS. Aliquots of 10µl (10,000 cells) were 
spotted onto each window of a 10 window multisport microscope slide (Hendley-Essex) and air 
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dried. The slide was incubated at -20°C in a pre-cooled fixative solution of methanol and acetone 
(1:1 v/v) for 30 minutes, followed by air drying and either immediate use or storage at -20°C. 
Cell staining 
Slides were not permitted to dry out from this stage of the protocol onwards. To rehydrate the 
cells, 30µl of PBS/10% HINGS was added to each window spot and incubated at room 
temperature for 20 minutes. This was aspirated and carefully replaced with 30µl of the primary 
antibody (Table 3, page 94), or 30µl of HInGS alone for control staining, and incubated in a moist 
container for 30 minutes at 37°C. Following 2 washes in PBS, 30µl of secondary antibody (Alexa 
Fluor
TM
 488 or 594: Zenon kit, Invitrogen) was applied to each window, incubated as before and 
visualised immediately after mounting in Vectashield mounting medium with DAPI (Vector 
Laboratories) or 1 drop of 90% glycerol and prior to application of a 20x70mm cover slip. 
T cell assays 
IFN ELISA 
The epitope specificities and HLA-restriction of the LMP2-specific CD8
+
 T cell clones tested are 
detailed in table 4. Known numbers of T cells (100-2500) were incubated in U-bottom or V-bottom 
microtest 96-well plates with specified numbers of target cells to achieve the desired effector: 
target ratio (autologous LCL and HLA -mismatched LCLs as controls), with/without pre-loading for 
1 hr with 5µM peptide (or an equivalent concentration of DMSO solvent as a control).  
In blocking assays, targets were pre-incubated with saturating concentrations of mAbs specific for 
HLA class I (clone W6-32
683
) or HLA-DR as a control (YE2/36-HLK antibodies
685
) for 1 hr before 
T cell addition to the assay.  The supernatant medium harvested after 18 hrs was assayed for 
IFN by ELISA (Endogen) following the manufacturer‟s recommended protocol. 96-well Maxisorp 
plates (Nunc) were coated with 50μl of a 0.75μg/ml solution of a mouse IgG1K anti-human IFNγ 
mAb (Pierce, Endogen) overnight at 4°C. The following morning the antibody was tapped out of 
the wells which were subsequently blocked at RT for 1hr with 1% BSA, 0.05% Tween 20 in PBS. 
The plates were then meticulously washed x6 in wash buffer (0.05% Tween 20 in PBS) and 50μl 
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of neat or a specific dilution of supernatant from the T cell assay was added to each well and 
incubated at RT for 2-4hrs. The supernatant was discarded, plates washed x6 in wash buffer and 
a biotinylated mouse IgG1K anti-human IFNγ Mab (Pierce, Endogen) applied at 0.375μg/ml for 
incubation at RT for 1-2hrs. Further washing was performed and extravidin peroxidase conjugate 
(SIGMA) applied for 30mins. After a final 8 washes of the plate in wash buffer, 100μl of the 
developing solution TMB (tetramethyl benzidine, Tebu-Bio laboratories) was added and left at RT 
for typically 1-3 minutes to allow the colour to develop. The reaction was terminated by the 
addition of 100μl 1M HCL per well and absorbencies were read at 450nm, using a microplate 
reader (Bio-Rad model 680) with software Microplate Manager v. 5.2.1. All results represent the 
mean value of samples assayed in triplicate. 
51Cr-release killing assays 
CD8
+
 T cell clones were tested for cytotoxicity against target cells by chromium-release assays. 
Pelleted target cells (1x10
6
)
 were resuspended in15μl (75μCi) of 51Cr- sodium chromate (Perkin 
Elmer) and incubated at 37°C, 5% CO2 for 90 minutes to allow intracellular uptake of the 
radioisotope. Where appropriate, 5μM of epitope peptide (or an equivalent volume of DMSO 
solvent as a control) was added for the final hour of the incubation. In the meantime, the effector 
T cell clones were diluted in RPMI-1640/10% FCS and aliquoted in 100μl into 96-well, V-bottom 
plates at the requisite number to achieve specified effector: target ratios. The target cells were 
washed twice with RPMI/10% FCS and diluted to achieve 2500 cells per 100μl aliquot and added 
to each well containing the T cell clones. For each target, the radioactivity spontaneously 
released from the labelled cells when incubated with 100μl of medium alone and the maximum 
radioactivity released when incubated with 100μl 1% SDS solution served as controls. The plates 
were centrifuged at 1200rpm for 3mins and incubated for 5hrs at 37°C, 5% CO2. Aliquots (100μl) 
of supernatant were then harvested from each well into LP2 tubes (Luckman), the radioactivity of 
which was measured on a gamma-counter (Cobra Auto-Gamma counting system, Hewlett 
Packard). Results for the CTL assays are expressed as percent specific lysis whereby: 
% specific lysis = [(release from target with T cells - spontaneous release)/maximum release]x100 
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Table 4 Epitope specificities and HLA-restriction of LMP2-specific CD8+ T cell clones 
Minimal epitope 
sequence  
Peptide position
‡‡ HLA class I 
restriction  
FLYALALLL  356-364  HLA-A*0201  
TYGPVFMCL  419-27  HLA-A24  
LLWTLVVLL  329-337  HLA-A*0201 
CLGGLLTMV  426-434  HLA-A*0201 
SSCSSCPLSK  340-349  HLA A*1101  
 
DNA and RNA work 
DNA extraction  
DNA was extracted from between 1x10
4
 and 5x10
6
 cells according to availability. Cells were 
washed in 1x PBS to remove serum, and DNA was extracted using the Qiagen DNeasy kit by 
adhering strictly to the manufacturer‟s protocol. DNA was eluted in 30-100μL nuclease-free water 
(Ambion) and the resultant concentration determined using a Nanodrop (Thermo Scientific). 
Where low DNA yields were anticipated due to low cell numbers, the elution step was repeated, 
re-using the „first-pass‟ eluate. For samples with high DNA concentrations, an aliquot was diluted 
with nuclease-free water to achieve ≤50ng/μL for use in Q-PCR assays. 
RNA extraction  
RNA was extracted from 5 x 10
5
 – 5 x 106 cells after washing in 1x PBS to remove serum. The 
RNeasy
TM
 kit (Qiagen) was used in compliance with the manufacturer‟s instructions. RNA was 
                                                          
‡‡
 Based on the B95-8 LMP2A protein sequence 
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eluted in 30μL water (Ambion) and the concentration determined using a Nanodrop (Thermo 
Scientific). For samples >100ng/μL, aliquots were diluted to 100ng/μL and stored at  - 80˚C.  
DNase treatment of RNA 
The RNeasy RNA extraction kit is designed to minimise DNA contamination in the eluted RNA. 
However, although a majority of the downstream RT-Q-PCR assays involve either a primer or 
probe designed to span an exon-exon splice boundary, this was not the case for all assays; some 
were designed within an exon.  Thus, to ensure that only cDNA transcripts were amplified during 
the PCR reaction, 1µg aliquots of RNA were treated with DNase I using the Turbo DNase kit 
(Ambion) according to the manufacturer‟s instructions, prior to reverse transcription. 
Reverse Transcription 
400ng of RNA was heated to 90˚C for 3 minutes within a thin walled, 0.5ml PCR tube and then 
immediately placed on ice. Reverse transcription of denatured RNA was carried out in a 20μL 
reaction containing 1x avian myeloblastosis virus reverse transcriptase (AMV-RT), reaction buffer 
(Roche), 200μM each of dATP, dCTP, dGTP and dTTP (Roche), 50pmoles of random hexamers 
(Promega) and left at RT for 5 minutes prior to a 42˚C incubation for 1 hour. cDNA was diluted to 
a total of 80μl and stored at -20˚C until required. Negative controls with no reverse transcriptase, 
EBV-negative RNA and nuclease-free water were routinely employed. 
TaqMan quantitative polymerase chain reaction (Q-PCR) 
Real time PCR allows the relative or absolute quantitation of a specific gene – against a known 
standard - during the exponential phase of cDNA/DNA amplification, when the quantity of PCR 
product is directly proportional to the amount of nucleic acid template.  
Each well of a RT-Q-PCR assay typically comprised a 25µl reaction volume
133
 including 5μl of 
input cDNA/DNA.  However, where cDNA from primary tissue was limited, 2ul input cDNA (with 
identical final concentrations of primers/probe) in a reaction volume of 20ul was used. For the 
EBV-encoded gene/transcript of interest, the probe was labelled with FAM at the 5‟ end and a 
TAMRA quencher at the 3‟ end (Eurogentec). For endogenous control genes, the probe was 
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labelled with VIC® at the 5‟ end and BHQ (black hole quencher) at the 3‟ end (Applied 
Biosystems). Thermocycling and fluorescence detection were carried out in a 7500 Real-Time 
PCR System (Applied Biosystems). Initial heating to 95°C for 10 minutes activated the ApliTaq® 
Gold polymerase enzyme, followed by 40 cycles of denaturation at 95°C for 15 seconds and 
primer annealing and extension at 60°C for 60 seconds. Data was analysed using 7500 system 
software v1.4.0 (Applied Biosystems) and Excel (Microsoft 2007). 
EBV genome load was assayed by RT-Q-PCR as previously described
560
. Triplicate aliquots of 
DNA (maximum 250ng per well) were subjected to a multiplex PCR using primer/probe 
combinations specific for the EBV BALF5 (POL) and the human 2 microglobulin (2m) 
sequences. In parallel, serial DNA dilutions of the Namalwa BL line (known to contain 2 
integrated EBV copies per cell
686
) were also amplified and used to create standard curves for 
absolute quantitation in the test samples. In each case, the number of POL copies per sample 
was normalized using the corresponding 2m value and the final result expressed as EBV 
genomes per 10
6
 cells  
QRT-PCR assays for the EBV latent transcripts
133
 and the EBER1 and EBER2 transcripts
82
 have 
been previously described, whilst new assays were designed for LMP2 using Primer Express 
software v2.0. A list of primer and probe sequences for the new LMP2 assays are shown in table 
5. EBV coordinates are based on the revised B95.8 sequence
687
.  
5′ Rapid amplification of cDNA ends (RACE)  
5´ RACE is a procedure for amplification of an mRNA template between a defined internal site 
and unknown sequence at 5´ -end of the mRNA
688
, allowing sequencing and identification of 
unknown 5´ origins of mRNA. Figure 9 shows a summary schematic of the method. The 
manufacturer‟s protocol (5´ RACE System for Rapid Amplification of cDNA Ends,v 2.0 Invitrogen) 
was followed without adaptation. To summarise: First strand cDNA synthesis was primed using a   
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Table 5 Oligonucleotide sequences of LMP2 primer and probe combinations used for RT-Q-PCR 
assays 
LMP2 assay  Primer/probe  
combination  Oligonucleotide sequence (5'-3')  
EBV genome  
coordinates
§§
  
LMP2A  
conventional  
F LMP2A  
R LMP2  
LMP2 probe  
CGGGATGACTCATCTCAACACATA  
GGCGGTCACAACGGTACTAACT  
CAGTATGCCTGCCTGTAATTGTTGCGC  
166412-35  
163-142  
66-92  
LMP2B  
conventional  
F LMP2B 
R LMP2 
LMP2 probe 
CGGGAGGCCGTGCTTTA  
GGCGGTCACAACGGTACTAACT  
CAGTATGCCTGCCTGTAATTGTTGCGC  
169421-37  
163-142  
66-92  
Exon 2  
F2 primer  
R2 primer  
Exon 2 probe  
CTGTAATTGTTGCGCCCTACCT  
TGCTGCCAAGAGTAGAAGTGAGA  
CTATTGCCGCCTCGTGTTTCACGG  
78-99  
199-177  
114-137  
TR-LMP2  
TR-F primer  
TR-R primer  
TR exon 2 probe  
ACTTTTCTTCTTGCCCGTTCTCT  
GAAACACGAGGCGGCAATAG  
CAGTATGCCTGCCTGTAATTGTTGCGC  
28-50  
133-114  
66-92  
Exon 6  
F5-6 primer (exon5/6 junction)  
F6 primer  
R6 primer  
Exon 6 probe  
TGGACACTTGTGGTTCTCCTGAT  
GGTTCTCCTGATTTGCTCTTCGT  
CGCGGAGGCTAGCAACA  
TCCTTCTGGCACGACTGTTCCTATATGCTC  
942-951/1026-1038  
1027-1049  
1129-1113  
1074-1103  
 
  
                                                          
§§
 Location of primer and probe sequences based on EBV genome sequence accession number NC007605. 
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gene-specific primer (GSP1= LMP2 R6, see table 5). The first strand product was then purified 
from unincorporated dNTPs and GSP1. TdT (Terminal deoxynucleotidyl transferase) was used to 
adjoin homopolymeric tails to the 3' ends of the cDNA. Tailed cDNA was then subjected to first 
round PCR amplification used a combination of the Abridged Anchor Primer (AAP) and GSP2 
(LMP2 R5, 3′ primer sequence AGTGACGCTAGCAGTGCCAGA), followed by a second round of 
amplification using the Abridged Universal Amplification Primer (AUAP) and nested LMP2 R4 (3′ 
primer sequence AGAGGACGAAAGCCAGTAGCAG). PCR products were analysed by agarose 
gel electrophoresis and cDNA recovered from excised bands (QIAquick Gel Extraction Kit, 
Qiagen) for cloning and sequencing.  
Cloning of cDNA sequences 
To allow efficient and accurate sequencing of individual cDNA products obtained following the 
RACE procedure, the pGEM®-T Easy Vector System I (Promega) kit was used to clone the PCR 
products. The manufacturer‟s instructions were followed. pGEM®-T is a linearised vector with a 
single 3′ terminal thymidine at both ends. The T-overhangs at the insertion site greatly improve 
the efficiency of ligation of PCR products by preventing recircularization of the vector and 
providing a compatible overhang for PCR products generated by certain thermostable 
polymerases (such as high-fidelity Taq, Roche). The vectors contain T7 and SP6 RNA 
polymerase promoters that flank a multiple cloning region within the α-peptide coding region of 
the enzyme β-galactosidase. Insertional inactivation of the α-peptide allows identification of 
recombinants by blue/white screening on indicator plates. Selected white colonies were 
inoculated into 3mls of Ampicillin-containing LB-broth, incubated at 37°C on a shaker overnight 
and plasmid DNA extracted the following morning using the Qiagen miniprep kit. Sequencing of 
products was performed using a M13 (reverse) universal primer, and courtesy of Dr Anthony 
Jones, Functional Genomics, Biosciences, University of Birmingham.   
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Figure 9 5′ rapid amplification of cDNA ends 
Overview of the 5’ RACE procedure (adapted from Invitrogen 5´ RACE System for Rapid 
Amplification of cDNA ends, version 2.0, catalog no. 18374-058 Version E 6 December 2004)  
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EBER in-situ hybridisation on fixed cells 
A commercially-available (Dako) EBER PNA (peptide nucleic acid) probe, complementary to 
sequences common to EBER1 and EBER2 was used to detect EBER expression in sorted 
tonsillar lymphocyte populations. Primary cells and control cell lines suspended at 10
4
 cells/10µl 
(due to small numbers of available purified primary cells) were spotted onto each window of a 10 
window multisport microscope slide and fixed in methanol/acetone (as for immunofluorescence, 
pages 96-7) prior to the EBER in-situ hybridisation protocol.The Dako EBER kit was used 
according to the manufacturer‟s instructions. Briefly, initial digestion at RT with diluted Proteinase 
K (1:10,000 – note that this is 100-1000 times less than the concentration typically used for FFPE 
sections), followed by washing, dehydration in ethanol and drying, before adding 1-2 drops of 
fluorescein-conjugated PNA probe or control probes. Hybridisation was achieved during 90 
minutes incubation at a humidified 55°C, followed by a prolonged washing with a stringent wash 
solution sustained at 55°C. AP-conjugated anti-FITC antibody was then added to each section 
and incubated for 30 minutes followed by washing and addition of the substrate 
(BCIP/NBT/levamisole, as supplied in kit) to allow detection of EBER-positive cells by 
microscopy. Strict precautions to avoid RNAse contamination were adhered to throughout. 
Conventional RT-PCR  
To a thin-walled PCR tube was added 50μl reaction mix containing 20ng of random-primed 
cDNA, 1x PCR reaction buffer with magnesium(Roche), 5μl of 2mM dNTPs (Roche), 5μl of 10μM 
gene specific primers (Table 5, page 102) and 1μl of high-fidelity Taq polymerase (Roche). The 
Taq enzyme was typically added after initial heating to 90°C for 1 minute (i.e. a „hot-start‟ PCR). 
Samples were heated to 94˚C for 5 minutes in an Eppendorf Thermocycler and incubated through 
35 cycles of 94˚C for 1 minute to denature the DNA strands, 50-60˚C for 1 minute to allow the 
primers to anneal to the DNA and 72˚C to allow extension of the product. The annealing 
temperature and extension time at each stage varied according to the specific primers and the 
anticipated product size of each PCR. Products were separated by agarose gel electrophoresis.  
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Agarose gel electrophoresis 
DNA samples were mixed with 1:6 v/v with gel loading buffer (0.25%w/v xylene cyanol, 0.25% 
w/v bromophenol blue, 30% v/v glycerol) and separated by gel electrophoresis at 90-120 volts 
through a 1 x TBE (0.09M Tris-borate, 0.002M EDTA), 1% agarose gel (Eurogentec). The „1kb 
plus‟ DNA ladder (Invitrogen) was loaded into one lane to determine PCR product size. The gel 
was then stained in a bath of 1 x TBE containing 0.5μg/ml ethidium bromide to allow visualisation 
of DNAbands via UV light on a transilluminator. A Polaroid photograph of the gel was taken 
where appropriate.  
Extraction of DNA from Agarose gel 
PCR products visualised using a UV transilluminator allowed the desired band to be accurately 
excised from the gel using a sterile scalpel. DNA was extracted using the DNA gel extraction kit 
(Qiagen) according to the manufacturer‟s instructions.  
Digestion of DNA with restriction endonucleases 
Plasmid DNA was digested by addition of 10x restriction endonuclease buffer (New England 
Biolabs or Roche), 1μL of the appropriate restriction endonuclease, and water (Ambion). A final 
volume of 20μL was typical and the quantity of restriction endonuclease never exceeded 10% of 
the total reaction volume. Reactions were incubated at 37˚C for 2-14 hours and an aliquot 
separated by gel electrophoresis. Digested DNA products required for DNA ligation were purified 
by gel extraction (Qiagen). 
Bacteriology 
All lentiviral plasmid vectors were grown in STBL3 bacteria (Invitrogen) and other plasmids in 
DH5α bacterial cells.  
Bacterial growth medium 
Liquid bacterial cultures were grown in Lennox Broth (L-Broth) medium. 2.5% w/v L-broth (Fisher 
Scientific) was dissolved in 400ml distilled water and sterilised before use by autoclaving at 
121°C, 15psi for 15 minutes. Bacterial colonies were cultivated on L-Broth Agar (L-agar) plates. 
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1.5% w/v of agar (Fisher Scientific) was dissolved in 400ml of deionised water and sterilised by 
autoclaving at 121°C, 15psi for 15 minutes. The L-agar was re-melted by microwaving, cooled, 
and ampicillin added to achieve 100µg/ml. 20ml of L-agar was poured into Petri dishes and used 
following solidification or stored at 4°C for a maximum of one week. Before use plates were 
warmed/dried at 37°C. 
Back-transformation of competent bacteria 
Aliquots of competent bacteria (DH5α or STBL3 (Invitrogen) ) were thawed on ice and 100µl 
transferred to an autoclaved 1.5ml microcentrifuge tube containing 10ng of plasmid DNA or the 
product of a DNA ligation reaction. The mixture was incubated on ice for 30 minutes and then 
heat-shocked for 90 seconds at 42°C. 900µl of S.O.C medium (Invitrogen) was added and 
incubated at 37°C for ≥1 hour. The bacteria were briefly centrifuged and an aliquot – according to 
expected colony density - spread onto L-agar/ampicillin plates and incubated overnight at 37°C. 
Preparation of plasmid DNA 
A single bacterial colony was picked with a sterile loop and used to inoculate 3ml of L-Broth 
containing the appropriate antibiotic (typically ampicillin at 100µg/ml). Cultures were incubated 
with shaking at 37°C for 6 hours. A fraction of the culture (typically 200μl) was inoculated into 
200ml of L-Broth containing the appropriate antibiotic in a 250ml conical flask and incubated at 
37°C in a shaker overnight. The next day the bacteria were pelleted by centrifugation at 75,000g 
for 10 minutes and plasmid DNA extracted using the midi-prep system (Jetstar) according to the 
manufacturer‟s instructions. The DNA pellet was then air dried before re-suspension in 200µl of 
TE buffer. The concentration of the plasmid DNA was determined using a Nanodrop (Thermo 
Scientific) according to manufacturer‟s instruction. Plasmid DNA was typically diluted to 1µg/µl 
and stored at -20°C until required.  
Transfection of cultured eukaryotic cells by electroporation 
Cell lines in the exponential growth phase were used. Target cells were pelleted by centrifugation 
(350g) and resuspended to a density of 2x10
7
 per ml in Optimem serum-free media (Invitrogen). 
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1-5µg of the plasmid of interest was added to 0.4 mm gap sterile electroporation cuvettes 
(Geneflow) with 0.5ml cell suspension (10
7 
cells) and carefully mixed by gentle pipetting. 
Electroporation was undertaken with a Bio-Rad Gene Pulser II with a capacitance of 975μF and a 
voltage of between 210 and 270, optimised for individual cell lines. Electroporated cells were 
transferred immediately to 8ml of warmed appropriate medium in one well of a 6-well plate and 
incubated at 37˚C, 5% CO2 overnight. At 24hours, the cells were often centrifuged on a density 
gradient (Lymphoprep, Axis Shield) to eliminate dead cells and debris. Transfection efficiency and 
viability was determined by flow cytometry after 48 hours. For some difficult to transfect lines, 
similar experiments were done using the Amaxa®Nucleofector
TM
 (Lonza) with supplied reagents 
and in accordance with the manufacturer‟s optimised protocol (VX-001). 
Lentiviral vectors 
Generation of a lentivirus expressing inducible LMP 1 is discussed Results part II, pages 178-
184) 
Lentivirus packaging and synthesis 
Typically, 3 x 10
6
 293FT epithelial cells (Invitrogen) were placed into 10cm plates in RPMI-
1640/10% heat-inactivated (HI) FCS (no G418),  to result in 70-90% cell confluence the following 
day, ready for plasmid transfection. The culture medium was carefully replaced 2 hours prior to 
transfection with 10ml pre-warmed RPMI/10% HI FCS. For each plate, 36l Lipofectamine L2000 
was mixed with 1.5ml OptiMEM (Invitrogen). A further 1.5ml OptiMEM per plate containing 4g 
LMP1 plasmid (FTREX(LMP1)UTG), 2g envelope plasmid (pMD2G codes for the broad range 
VSV-G envelope)and 6g packaging plasmid psPAX2 was prepared. Both were incubated for 5 
minutes at RT, mixed together and incubated for a further 20 minutes at RT. 3ml of the 
transfection mix was carefully added to the 10ml medium already on each plate of 293 FT cells. 
The following day, the media was replaced with 10ml pre-warmed RPMI/10% HI FCS 
supplemented with 100l 1M sodium pyruvate (Sigma). The medium was harvested 3 days post 
transfection and centrifuged for 5 minutes at 350g to pellet cell debris. The supernatant was then 
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sterile-filtered through 0.45m syringe filter (Millipore) and either frozen in aliquots at -80C for 
future use, or concentrated and used immediately.  
Virus concentration 
Virus supernatants were concentrated by ultracentrifugation (19,500rpm) in a Beckman SW40 
swing-out rotor for 2 hours at 16C in a Beckman 14ml polyallomer tube. A friable, near-
translucent pellet was just visible after centrifugation. The supernatant was carefully removed and 
the pellet resuspended in 200µl media, appropriate for the target cell population, and immediately 
used. 
Lentiviral transduction of NK cells  
Pure populations of IL2-stimulated primary NK cells were infected with the FTREX(LMP1)UTG 
lentivirus (LMP1-LV) typically at least 2 weeks after initial isolation to ensure the majority of cells 
displayed a CD56
HIGH
 CD16
DIM/NEG
 phenotype, as ascertained by flow cytometry. Aliquots of 5 x 
10
5
 NK cells were suspended in 150μl of NK media (see page 88, culture of primary NK cells) 
and placed in one well of a 48-well plate (Iwaki), combined with 100μl of re-suspended, 
concentrated LMP1-LV. Control wells comprised 5 x 10
5
 NK cells without LV and, in initial 
experiments, 5 x 10
5
 LCL to serve as a comparator for transduction efficiency. The plate was 
incubated overnight at 37°C and, the following morning, a further 500μl of relevant media was 
added to each well. Transduction efficiency was assessed by flow cytometry for GFP after at 
least 72 hours and the cell populations subsequently expanded in culture to attain sufficient 
numbers for cell-sorting, guided by GFP.  At 48 hours prior to cell sorting, 10ng/µl of Doxycycline 
was added to the media to induce expression of LMP1. This was to allow sufficient time for LMP1 
to be expressed and influence the cellular transcriptome, in readiness for RNA extraction from the 
purified GFP
+
 population immediately after sorting. 
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Results (I): In vivo and in vitro EBV infection of non-malignant NK 
and T cells  
Introduction 
The intimate association of EBV with a diverse spectrum of rare but well-defined 
lymphoproliferations of NK and T cell origin raises important questions about the biology of these 
particular virus-cell relationships. Of fundamental importance is consideration of the mechanism 
by which the virus enters these cell lineages. Related to this, of equal importance, is 
understanding the frequency with which EBV infection of NK and T cells occurs in the absence of 
disease. Is this a rare event, with erroneous infection of such cells provoking a relatively high 
likelihood of clonal proliferation/malignancy? Alternatively, is T or NK infection quite common in 
vivo, but in most such cases the infected cell is destined to die by apoptosis or lay exposed to 
EBV-specific CTL attack? 
We initially set out to investigate the occurrence and frequency of NK and T cell infection in vivo 
by separating peripheral blood and tonsillar lymphocytes, from a range of donors, to high purity 
and quantitating the EBV genome number in each population by an established Q-PCR 
method
560
. This method has advantages over those used in previous studies attempting to 
address similar questions in which immunostaining combined with EBER ISH was performed on 
fixed tissue sections
244,246,249
. In particular, applying our approach allows a substantially higher 
number of cells to be processed (10
6
-10
8
) and analysed for the presence of EBV; with a 
sensitivity of 2 EBV genomes (1 Namalwa BL cell equivalent) amongst 10
5
 EBV-negative cells. 
The overall aim of the experiments presented in this chapter was to investigate occurrences of 
EBV infection in NK and T cells in vivo, in the context of healthy viral persistence, primary 
infection and immune dysfunction. Although in vitro infection of NK and T cells with recombinant 
EBV was not a primary goal of this work, a limited amount of such data will also be presented, as 
relevant to the ex-vivo findings. 
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In the early stages of the study, whilst recruiting and screening healthy tonsil donors, we were 
fortunate to identify 3 instances of adult patients presenting with clinical and laboratory features 
consistent with a diagnosis of EBV-HLH. In addition to affording a unique opportunity to analyse 
the clinical features of a disease rarely presenting in adulthood, we were also able to apply the 
same cell-sorting and Q-PCR strategy to peripheral blood lymphocytes from these patients.  
EBV-HLH in adults  
As reviewed earlier (pages 56-65), EBV-HLH is a clinicopathological syndrome, encompassing a 
dramatically dysregulated immune response and hypercytokinaemia. The disease is 
characterised clinically by fever, splenomegaly and cytopenias accompanied by histological 
evidence of haemophagocytosis - and confers a high mortality
476
. Most descriptive reports of 
EBV-HLH have arisen from study centres in East Asia with the majority occurring in the context of 
primary EBV infection in children or adolescents. Of the rare cases of adult EBV-HLH reported, 
the majority have been in individuals of East Asian origin
495
 although isolated cases arising in 
adults of other ethnicities have been described
245,492
.  
Previous studies of EBV-HLH, incorporating analysis of both tissue biopsies and of circulating 
lymphocyte subsets, demonstrated CD3
+
 T cells (usually the CD8
+
 subset) to be the 
predominantly infected population, with isolated cases suggesting less frequent, co-infection of 
CD16
+
 cells
471
. This contrasts markedly with CAEBV where the presence of EBV in NK cells 
occurs in approximately half the cases
472
.  
Clinical features 
We investigated 3 adult patients with suspected EBV-HLH (mean age 44). All patients had EBV 
loads of 10
5
-10
6
 genomes/ml whole blood, ascertained at the referring hospital, and fulfilled 
established clinical and laboratory diagnostic criteria for the diagnosis of EBV-HLH
476
, including 
histological evidence of haemophagocytosis (Figure 10, page 114). There were no pre-existing 
clinical features indicative of a background of CAEBV.  
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Table 6 Clinical and laboratory characteristics of adult EBV-HLH patients  
 
Splenomegaly 
& 
Pancytopenia 
Ferritin 
(g/l) 
LDH 
(IU/ml) 
 
HLH 
criteria
*** 
EBV 
serology
††† Therapy
‡‡‡ Outcome 
        
HLH 
1  Yes  >16,500  5602  6/8  
IgM VCA   -  
IgG VCA   
+
  
IgG EA      - 
IgG EBNA 
+
  
IVIG/RITUX/ 
GCV/DEX/ 
CSA  
Died  
HLH 
2  Yes  22,699  1879  7/8  IgG VCA    
+
  
IgG EBNA  
+
  
MP/IVIG/ 
VP16/CSA  Died  
HLH 
3  Yes 4203  2085  6/8  
IgM VCA   - 
IgG VCA   
+
  
IgG EBNA 
+
  
DEX/VP16  CR  
        
  
                                                          
***
 Diagnostic criteria from reference476. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and 
therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131. 
 
†††
 Plus sign indicates antibody detected by enzyme immunoassay and/or immunofluorescence. Negative sign 
indicates not detected by one or both of these assays.  
 
‡‡‡
 IVIG= Pooled human immunoglobulin; GCV=Ganciclovir; CSA=Cyclosporin A; DEX=Dexamethasone; 
MP=Methylprednisolone; VP16=Etoposide; RITUX=Rituximab 
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Table 6 summarises the clinical and laboratory characteristics and described here in brief: 
Patient HLH-1: A previously fit and well 60 year old Caucasian man presented with a 3 week 
history of fevers and lethargy. Haemophagocytosis was demonstrable on a second diagnostic 
bone marrow biopsy. Despite a range of immunosuppressive therapies only a transient response 
was achieved and he died of hepatic failure 5 weeks after initial presentation. Patient HLH-2: A 
50 year old Caucasian man with a history of ulcerative colitis, described several weeks of fevers, 
anorexia and weight loss. He subsequently developed respiratory failure associated with 
radiological evidence of pulmonary infiltrates and required mechanical ventilation. A transient 
clinical response was seen following therapy according to a modified HLH-2004 protocol
476
 but 
the patient subsequently died of respiratory failure, two months after initial presentation. Patient 
HLH-3: A previously healthy 21 year old man, of Arab origin, presented with a 4 week history of 
fever, sweats, weight loss and cough – ultimately requiring intensive care support. He fulfilled the 
diagnostic criteria for EBV-HLH and a subsequent biopsy of a small lymph node confirmed 
coexisting EBV
+ 
classical HL, with EBER
+
 RS cells identified. The HLH responded well to initial 
treatment with Etoposide and Dexamethasone, following which he was successfully treated with a 
standard chemotherapy protocol for Hodgkin‟s lymphoma. 
Viral loads in peripheral blood lymphocyte populations in HLH 
Figure 11, panel A represents an example of the 3-colour fluorescence-activated cell-sorting 
strategy applied to these cases. Populations of B (CD19
+
, CD3
-
, CD16/56
-
), T (CD3
+
, CD19
-
, 
CD16/56
-
) and NK cells (CD16 or CD56
+
, CD3
-
, CD19
-
) were isolated by gating initially on total 
viable lymphocytes (forward versus side scatter plots), with subsequent gates allocated to 
exclusively isolate monofluorescent populations to high levels of purity (consistently 95-100% 
pure). DNA was then extracted from each sorted population and Q-PCR for EBV genome copy 
number performed.  For patient 1 we employed CD16 as a peripheral blood (PB) NK marker 
(gating on CD16
+
CD3
-
CD19
-
 cells), as these are usually the dominant PB NK population
312
, but 
unexpectedly found the highest viral load in a population of small lymphocytes negative for all of 
CD16, CD3 and CD19. 
117 
 
 
Figure 10 Cytopathological evidence of bone marrow erythrophagocytosis in EBV-HLH 2  
 
Photomicrograph of a bone marrow aspirate slide preparation from HLH-2 showing erythrocytes 
engulfed by a macrophage (original magnification x200). Courtesy of Dr Philip Gothard, Department 
of Infectious Diseases, University College London Hospitals, London.  
 
We hypothesised that this population may represent CD56
BRIGHT
CD16
-
 NK cells, a minority 
(~10%) NK cell subset in normal peripheral blood (introduction pages 34-37 and reference
312
). 
Consequently, we used CD56 as an alternative NK marker for the subsequent two patients. 
Figure 11, Panel B shows the high numbers of viral genomes within the NK cell populations, 
expressed as EBV copy number per million cells and compared to B and T cells from the same 
donor. In all three cases, the number of CD56
+
CD3
-
CD19
-
 (or CD16
-
CD3
-
CD19
-
 in patient 1) as a 
proportion of total peripheral blood mononuclear cells was not particularly high (2-5%). CD3
+
 
lymphocytes constituted the majority PBMC population and all patients were relatively B 
lymphopenic (CD19
+
 cells ≤2%). Note that a caveat to interpretation of the relative and absolute 
lymphocyte numbers is that in all 3 cases, patients had received treatment with corticosteroids 
prior to PBMC analysis. 
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Figure 11 High EBV genome load within circulating CD56
+
 natural killer cells in adult patients 
with EBV-HLH  
Panel A  
Fluorescence-activated sorting 
strategy (HLH patient 3 shown as 
example).  
 
Panel B  
EBV genome numbers in sorted cell 
populations for HLH patients 1, 2, 
and 3. Histograms represent the 
mean number of viral copies per 
million cell equivalents. Each data-
point was assayed at least in 
triplicate and error bars indicate 
standard deviations from the mean. 
NA = insufficient B cells for analysis 
from patient 1 as a result of in vivo 
rituximab therapy. 
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EBV gene expression  
The available cell numbers restricted analysis of viral gene expression to HLH1 and HLH2 and 
was performed on total PMBC rather than purified lymphocyte populations. RT-Q-PCR assays 
specific for viral antigen-coding transcripts (Wp, Cp, Qp, LMP1, LMP2A and BZLF1) were all 
negative, although the EBER transcripts were expressed in both cases and formally quantified by 
RT-Q-PCR in HLH-1, where levels greatly exceeded those seen in a LCL (Figure 12). 
 
 
 
Figure 12 High levels of EBER expression in PBMC from adult patients with EBV-HLH  
RT-Q-PCR data for EBV-encoded transcripts in PBMC from HLH 1 and 2.  
Panel A: EBER transcript quantitation for HLH 1 expressed relative to levels in a LCL. 
Panel B: Summary of RT-PCR assays for latent and lytic transcripts in HLH1 and 2. A plus sign 
indicates detectable transcripts, a negative sign indicates not detected. The parenthesis (+) for HLH-2 
indicates a non-quantitative (conventional end-point) PCR assay was used. 
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EBV genome load in lymphocyte subsets in health and immune 
deregulation  
The next series of experiments investigated the occurrence and frequency of in vivo infected NK 
and T cells in the absence of clinically-apparent lymphoproliferative disease. Following person-to-
person transmission of EBV, immediate contact with tissues of the oro- and nasopharynx 
represents the virus‟ first encounter with its target B cells and adversarial immune effectors. 
Within such SLT is where the CD56
BRIGHT
 NK subset dominates
312
 and, coincidentally, is the 
anatomical site of the majority of ENKTL cases
689
; all of which display a CD56
+
 phenotype
473
. 
Against this background, and given the striking EBV load in CD56
BRIGHT
 NK cells in the peripheral 
blood of adult HLH patients, we focused our attention on tonsillar, as well as peripheral blood, 
lymphocytes.  
The limited data available on infection of non-malignant T and NK infection in vivo, primarily by 
IHC and EBER ISH staining, suggests that EBV-infected NK and T cells can be seen – albeit very 
rarely – in the context of healthy persistence and symptomatic primary infection230,246,249. Due to 
technical difficulties encountered with CD56 antibodies in fixed tissues, such studies adopted 
PEN5 as an NK cell marker. However, a major limitation of PEN5 is that its expression is 
restricted to the CD56
DIM
 subset (and is down-regulated in response proliferative stimuli
316
), 
limiting its usefulness as a NK marker- particularly in SLT. As discussed earlier (page 34), as an 
optimum NK-specific marker is not currently available, the widely accepted phenotype for their 
identification in SLT has been CD56
+
CD3
- 308
. A subset of T cells is known to co-express CD56
313
 
but can be easily identified by surface expression of CD3 or CD8, both absent on NK cells. 
With this in mind we elected to employ a combination of conjugated MAbs together with a sorting 
strategy aimed at delineating NK cells, CD4
+
 and CD8
+
 T cell subsets (given the data on „cell-of-
origin‟ of CAEBV and HLH respectively471) and B cells. For the majority of the following 
experiments, 4-colour fluorescence cell-sorting was undertaken. The initial gate, based on 
forward and side scatter plots, allowed identification of lymphocytes and excluded the majority of 
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Figure 13 Isolation of highly pure lymphocyte subsets from blood and tonsil 
Four-colour fluorescence sorting strategy for isolation of pure monofluorescent lymphocyte 
populations from tonsil and blood mononuclear cells, as discussed in main text. Initial gating on small 
lymphocytes by forward/side scatter (not shown) followed by gating logic as indicated. Reanalysis of 
individual populations following sorting allowed purity/contamination analysis  
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larger cells, such as monocytes and cell-conjugates. Thereafter, monofluorescent populations 
were identified and purified: B cells defined by CD19
+
CD4
-
CD8
-
CD56
-
 ; major T cells subsets 
CD4
+
 or CD8
+
CD56
-
 CD19
-
 ; and NK cells CD56
+
CD4
-
CD8
-
CD19
-
 (figure 13, previous page). 
Note that for peripheral blood samples, antibodies to CD16 and CD56 (both conjugated to PE-
fluorochromes) were used together (alongside CD19, CD4 and CD8) in order to capture both 
major NK subsets. 
Tonsils donated by healthy donors undergoing routine tonsillectomy, patients with acute IM and 
patients receiving immunosuppressant therapy following allogeneic solid-organ transplantation 
were studied. Figure 14 shows viral load values quantitated in unsorted tonsil mononuclear cells 
(MNCs) from each patient group. Each individual symbol represents a separate tonsil donor, and 
the viral load - plotted on the y axis as a log10 scale - is presented as EBV genome number per 
million cells. Horizontal bars correspond to median values within a patient group. The highest 
values, seen in the IM group, were 3 orders of magnitude higher than in the other tonsil donors 
whilst healthy donors had the lowest median values – in the range of 102-103 genomes per million 
cells.  
Viral genome load in blood and tonsil lymphocyte subsets in healthy EBV persistence 
This series of experiments focused on healthy donors and initially confirmed that EBV is strictly 
confined to B lymphocytes in the peripheral blood, consistent with current understanding of the 
virus‟ biology56. Peripheral blood lymphocytes from a healthy donor, known to have a persistently 
high but stable viral load, were sorted to high purity and each population assessed by quantitative 
PCR (Q-PCR) for EBV copy number. Figure 15 (page 121) shows the viral load values in total 
PBMC alongside the sorted lymphocyte populations, demonstrating confinement of EBV to the 
circulating B cell population as anticipated. In keeping with their status as a minority peripheral 
lymphocyte population, the B lymphocyte viral load is several times greater than that measured in 
unsorted PBMC. The inset pie-chart displays relative proportions of cell populations present 
amongst analysed viable lymphocytes. 
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Figure 14 Distribution of EBV genome load in total tonsil mononuclear cells from different 
patient groups  
EBV genome numbers per million tonsil mononuclear cells. Each symbol represents an individual 
tonsil donor and colours indicate the different patient groups. The horizontal line indicates the median 
viral load value of each group. Note the y axis is a log10 scale.  
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Figure 15 EBV is exclusively restricted to B lymphocytes in peripheral blood from healthy 
donors  
Viral load data in total PBMC and purified lymphocyte populations, expressed as EBV genomes per 
million cell equivalents. Numerical values above each histogram indicate the mean value of Q-PCR 
performed in triplicate with standard deviations as indicated by capped vertical bars. 
 
The pie chart shows the relative proportions of NK cells, B cells and other (predominantly T lineage) 
cells within the gated lymphocyte population, as indicated by red, blue and grey segments 
respectively. 
 
The percentage figures beneath the x axis result from re-analysis of sorted populations: the top row 
indicates purity of each respective population whilst the bottom row is the percent of CD19
+
 cells 
within each sorted fraction. 
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Our attention then turned to tonsillar lymphocytes, obtained from healthy individuals undergoing 
elective tonsillectomy for chronic or recurrent tonsillitis. Although, by virtue of the indication for 
surgery, these tonsils cannot be considered entirely „normal‟, all patients were otherwise healthy 
with no history of immunodeficiency or IM. Moreover, there were no instances of clinically 
apparent infection or acute inflammation at the time of excision.  
In total, 26 separate tonsil donations were obtained and the viral load in total mononuclear cells 
ascertained by Q-PCR. The viral load distribution is shown in Figure 14 (page 120): five patients 
(19%) were EBV negative by Q-PCR, whilst the median value for the remaining 21 patients was 
approximately 300 viral copies per 10
6
 mononuclear cells. Anticipating that EBV-infection of NK 
or T cells is likely to be a rare event in this context, we elected to focus on those tonsils with a 
relatively high viral load. Lymphocytes from such donors were subject to high-purity cell sorting 
into 4 monofluorescent populations: CD19
+
, CD4
+
, CD8
+
 and CD56
+
 as described above (and see 
Figure 13, page 118). Unless numbers of purified cells were critically low, small aliquots of all 4 
sorted populations were re-analysed to confirm purity (values of 97-100% were typical) and to 
identify the phenotype of contaminating cells. 
Representative viral load data obtained from five normal tonsil (NT) sorts are shown in Figure 16. 
A consistent finding in most analysed tonsils was that the viral load in the T-MNC was equivalent 
to, or sometimes exceeded, that seen in the CD19 fraction. This contrasts with the situation in 
peripheral blood and is partly attributable to the substantially greater proportion of B cells in T-
MNC (approximately 30-70% compared to 5-10% in PBMC) and thus proportionally less 
enrichment of EBV-containing B cells after sorting. The inset pie-charts for each tonsil represent 
relative proportions of lymphocytes in the pre-sort MNC but note that tonsils were partially 
depleted of B cells immediately prior to sorting, to improve non-B cell purities (see materials and 
methods pages 85-86). This resulted in an underestimation of the in-vivo % of tonsillar B 
lymphocytes, but this approach was consistently applied to all tonsil sorts and improved purity 
yields of T and NK fractions. 
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Figure 16 EBV is predominantly restricted to B lymphocytes in tonsils from healthy donors 
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In all cases of NT analysed, EBV genomes were predominantly restricted to the CD19
+
 B 
lymphocyte population. In the majority of cases, no substantial numbers of EBV were identified in 
the CD4
+ 
or CD8
+ 
T lymphocyte populations, although low levels of virus not numerically 
explicable by contaminating B cells was often appreciable. On one occasion (NT5) there was 
stronger evidence of T cells harbouring EBV with values approaching 25% of the CD19 load. In 
this, and all cases of apparent T cell infection, a confirmatory cell-sort was repeated on at least 
one, and sometimes two, further occasion(s) using a further aliquot of T-MNC from the same 
tonsil. However, in no cases of NT analysed did CD56
+
 NK cells appear to harbour any virus. 
EBV genome load within lymphocyte subsets during infectious mononucleosis 
IM peripheral blood 
Although phenotypic analyses of EBV-infected B-cell subsets in IM has been extensively 
investigated
690-691
, much less is known about the occurrence of T or NK cell infection in the 
context of symptomatic primary infection. That a numerically and functionally robust T cell 
response - alongside elevated numbers of peripheral blood NK cells - consistently occurs in IM 
(pages 41-46) implies that ample opportunities are afforded for erroneous NK or T cell infection to 
occur via engagement with B cells. Indeed, EBV-HLH is frequently seen to occur in the immediate 
aftermath of symptomatic primary infection
240,485-486,490
.  
The next phase of investigation therefore focused on peripheral blood from patients presenting 
with IM, diagnosed locally in Birmingham on the basis of characteristic clinical features (pages 
41-42 and reference
375
) coincident with a positive heterophile antibody test (Monospot). Figure 17 
summarises the viral load data of peripheral blood lymphocyte  
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Figure 17 EBV genome load is principally restricted to B lymphocytes in the peripheral blood of 
individuals with infectious mononucleosis  
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populations sorted, as before, from five IM donors. In acute IM, the number of EBV-infected B 
cells in the blood is known to be increased by 10
3
-10
4 
fold, equating to 1-10% of all circulating B 
cells infected
383
. In three of our cases (IMB1-3), the blood sample was donated at the height of IM 
symptomatology, and within 24 hours of the diagnostic Monospot test, whereas IMB4 and IMB5 
were analysed in the immediate recovery period (approximately 10-14 days following a positive 
Monospot). Accordingly, the viral load values for the latter two donors are ten-fold lower than 
IMB1-3. As expected, in all cases the CD8
+
 T cell population was markedly expanded, alongside 
less marked increases in NK cell numbers. In some cases this was reflected in proportionally 
fewer B cells. As for normal blood, and contrasting with the situation in tonsils, the viral load in the 
purified CD19 population in IM was substantially higher than in total PBMC. 
In all 5 cases of IM blood examined, the viral load was almost entirely restricted to CD19
+
 B 
lymphocytes. As indicated previously, the NK cell population was sorted using a combination of 
CD16 and CD56 MAbs. In the case of IMB2 and 3, the viral load appreciable in these total NK 
fractions could potentially be attributable to 2% and 3% contaminating B cells, respectively, 
although the observed CD19
+
 contamination was less than this.  
IM Tonsils 
As discussed earlier (pages 26-27 and 110), although the published data is somewhat conflicting 
it is overall in keeping with infrequent infection events of T and NK cells in IM tonsils. We applied 
our cell-sorting and sensitive Q-PCR assay to try and address this issue more quantitatively. IM 
tonsil (IMT) MNC, obtained through collaboration with Dr Wolfgang Bergler (University Hospital 
Mannheim, Germany) were recovered from liquid-nitrogen storage and partially depleted of B 
cells as for NT. Figure 18 is a summary of data obtained from five such IM tonsils, presented as 
for NT. Akin to the situation with IM blood samples, the range of viral loads between IMT MNC 
could vary by 1-2 orders of magnitude. This could potentially be explained by the timing of 
tonsillectomy in relation to symptomatic presentation of IM and/or the occurrence of peak viral 
load, although this information was not available to us. 
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Figure 18 EBV genome load is not exclusively restricted to CD19
+
 B cells in the tonsils of 
patients with infectious mononucleosis  
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An initial observation of the data in Figure 18 was the striking discrepancy in some cases (IMT 1-
3), between viral load values in total MNC and CD19
+
 B cells. This difference, amounting to 3-20-
fold, is substantially greater than that seen in NT and is highly suggestive of loss, or exclusion, 
during the sorting process, of a B cell population with a high viral load. For example, B cells 
committed to plasma cell differentiation with low or absent CD19 expression could potentially be 
implicated here. Examining the non-B cell fractions, there were three main observations. Firstly, 
in most cases examined and similarly to NT, a low level viral load was evident in the CD4
+
 and/or 
CD8
+ 
T cells that could not be numerically accounted for by contaminating B cells. Secondly, one 
case (IMT4) displayed an impressively high viral load in the CD8
+ 
population, approaching the 
CD19 value. Lastly, there were three instances of apparent infection of CD56
+
 cells, 
approximating to 10-30% of the corresponding CD19
+
 load (IMT1, 3 and 4). Although definitive 
evidence of viral lytic cycle occurring in IM tonsil B cells has not been available we considered the 
possibility that cell-free virus, arising from replicative infection, may adhere to neighbouring T and 
NK cells. To ascertain evidence of such replicative infection, we undertook RT-Q-PCR to detect 
an immediate early (BZLF1) and a late (gp350) viral lytic transcript in total RNA extracted from 
purified CD19
+
 tonsillar populations. With assay sensitivity permitting detection of 1 lytic cell in 
10
3
-10
4
 latent cells, only IMT 3 manifest detectable EBV lytic transcripts (equivalent to 14% and 
1% of CD19
+
 cells expressing BZLF1
+
 and gp350
+
 respectively); the other tonsils tested were 
negative (data not shown). 
EBV genome load in blood and tonsil lymphocyte subsets from immunosuppressed 
individuals 
As discussed in the introduction (page 47-50), patients with compromised T cell effector function 
are at risk of developing EBV-driven lymphoproliferations of B cell origin. By contrast, 
considerably fewer cases of EBV
+
 NK or T cell lymphoproliferation are reported
408
; no increased 
incidence in immunocompromised persons is readily apparent.  
Most patients who develop NK and T cell lymphoproliferative diseases are considered to be 
immunocompetent; there is no antecedent history of clinically evident immune dysfunction. 
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However, the dramatically dysregulated and ineffective immune response seen in EBV-HLH, and 
the seeming inability of CAEBV patients to mount a meaningful immune response to EBV-
infected T or NK cells, intimates that host immune status may be important in pathogenesis. 
However, little data has been available on the frequency or occurrence of EBV-infected 
lymphocytes in the context of impaired T cell function. On this note, we were able to identify and 
analyse tonsillar lymphocytes (with matched peripheral blood samples in two cases) from four 
patients receiving immunosuppressive therapy with Tacrolimus (or FK-506, a calcineurin inhibitor) 
following solid-organ transplantation (SOT). Pharmacological inhibition of calcineurin results in 
suppression of signal transduction and IL-2 transcription within T lymphocytes, impairing their 
activation and proliferation
692
. Available clinical information on our patients was somewhat limited: 
IST1 and IST2 had undergone previous renal transplantation but their EBV status was not 
available at the time of surgery. IST3 and IST4 had both undergone heart/lung transplantation 
and IST4 had experienced an episode of documented „EBV viraemia‟ 2 years previously. 
Tonsillectomy was indicated for symptomatic enlargement, in one case presenting with acute 
airway compromise and another with a longer history suggestive of obstructive sleep apnoea. It is 
important to note that the intensity of immunosuppression in each case could be quite different, 
influenced by the transplanted organ type, nature of additional peri-transplant 
immunosuppression, serum levels of Tacrolimus and the time elapsed since transplantation. 
For the first immunosuppressed tonsil (IST1) we investigated, numbers of available tonsillar cells 
were limited and we therefore used 3-colour FACS (MAbs against CD19, CD3 and CD56) to 
allow sufficient numbers of purified populations to be collected. The sorting procedure, viral load 
analysis and representation of data (Figure 19) were otherwise unmodified. Notwithstanding an 
essentially normal T-MNC viral load, comparable to the median value of the NT samples (Figure 
14, page 120), we were struck by an unexpectedly high genome number in the CD56
+
CD3
-
CD19
-
 
population; 70-fold higher than in the corresponding B cells. This pattern had not been thus far 
observed in NT or IMT and we therefore sought to investigate this further. IST2 and IST3, with 
normal to moderate T-MNC viral loads showed essentially the same pattern; the viral load per 
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CD56
+
 cell patently dominated and was approximately 20 to 100-fold higher than the B cell 
counterparts. The final „immunosuppressed tonsil‟ we analysed (IST4) also manifest a high load 
in the CD56
+
 compartment, although the pattern in this case was more akin to IM tonsils 1,3 and 
4 (Figure 18, page 127); amounting to approximately one-third of the CD19 load. For IST2-4, the 
sorting procedure was repeated on at least one further occasion in each case, using separate 
aliquots of T-MNC, and the results confirmed. Note that the proportion of CD56
+ 
CD19
- 
CD4
-
CD8
-
 
cells in IST cases was not increased; amounting to approximately 0.4% of viable lymphocytes. 
For the donors of IST3 and IST4, we had the opportunity to analyse a matched peripheral blood 
sample taken at the time of tonsillectomy (designated ISB3 and ISB4 respectively). By distinct 
contrast to the matched tonsil samples, the sorted peripheral blood lymphocytes from these 
immunosuppressed patients showed EBV present almost exclusively within the B cell 
compartment. No EBV genomes were detectable in the peripheral blood NK fraction. In the case 
of ISB4, the discernible viral load in the CD8 fraction could be explained mathematically by 0.6% 
CD19 contamination (although only 0.14% contamination was evident on re-analysis) and is 
therefore best regarded as of uncertain significance. 
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Figure 19 High EBV genome copy number in tonsillar, but not peripheral blood, CD56
+
 
lymphocytes from immunosuppressed patients  
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Figure 19b Taqman PCR data for viral load ascertainment in sorted tonsil lymphocytes (IST 3). 
Representative raw data from Taqman PCR amplification plots; relative quantitation of viral genomes 
(pol) and a cellular control gene (β2-microglobulin). Each quadrant displays amplification data from 
DNA extracted from a specified purified lymphocyte population from tonsil IST3 (see figure 19). The 
x axes represent the number of amplification cycles and the coloured horizontal line is the assigned 
detection threshold. 
Cell yield for each purified population:  
CD19
+ 
(CD4
-
CD8
-
CD56
-
) = 4x10
6
 cells    
CD4
+ 
(CD19
-
CD8
-
CD56
-
) = 1x10
6
 cells   
CD8
+ 
(CD19
-
CD4
-
CD56
-
) = 5x10
5
 cells    
CD56
+ 
(CD19
-
CD4
-
CD8
-
) = 1x10
4
 cells    
(Note that no more than 1x10
6
 cells from each population were used for DNA extraction and, where 
necessary, DNA was diluted to ≤50ng/µl prior to qPCR analysis; the β2m value served as a control for 
input DNA. See Materials and Methods, page 99) 
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One key question regarding the very high genome numbers in the CD56
+
 tonsillar fraction was 
whether this represented true infection of these cells, rather than surface-bound virus. As 
described for the IM tonsils, there was no discernible lytic activity in the CD19
+
 fraction of the IST. 
One approach to address this question relating to surface virus would be to establish whether any 
viral mRNAs were transcribed in the CD56
+
 population. As the EBERs are abundantly present in 
all latently infected cells, this represented an attractive target. However, we were seriously 
challenged by limited IST material and, moreover, by very small numbers of CD56
+
 cells yielded 
from cell sorting (typically 10
3
-10
4
); insufficient for extraction of good quality RNA. I therefore took 
an existing protocol for EBER-ISH on formalin-fixed tissues and optimised it for use on small 
numbers of cells fixed in methanol/acetone, dried onto slides (page 105). EBV
+
 cell lines served 
as controls and showed intense nuclear staining, whereas only very rare EBER
+
 cells (<1/500) 
were seen in the CD56
+
 fraction purified from IST3; no appreciable EBER expression was seen in 
the overwhelming majority of cells (data not shown). Using antibodies directed to early (BZLF1) 
and late (p18, a minor capsid protein) lytic antigens immunofluorescence staining was performed 
on cells from this same CD56
+
 fraction and highlighted an isolated cell undergoing replicative 
infection (Figure 20). 
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Figure 20 Evidence of EBV full lytic cycle in rare cells within tonsillar CD56
+
 cells from an 
immunosuppressed patient 
Photomicrographs of phase-contrast, fluorescent images of purified CD56
+
 cells from donor IST3. 
DAPI staining shows all nucleated cells. An isolated cell is seen to express both early (BZLF1) and 
late (p18, a minor capsid protein) lytic antigens.  
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EBV infection of T and NK cells in vitro  
In vitro infection of primary NK cells and T/NK lines with cell-free EBV 
Experimental infection of T and NK cells in vitro was not a major focus of this thesis; an allied 
body of such work was being undertaken concurrently within our laboratory by Dr Claire 
Shannon-Lowe and Miss Emily Adland. However, given the in vivo findings described above: high 
EBV genome numbers in circulating CD56
+
 cells in HLH; similar findings in CD56
+
 tonsillar cells 
from immunosuppressed individuals; and to a lesser extent in CD56
+
 tonsillar lymphocytes in IM, 
we elected to undertake a series of complementary in vitro studies. 
The solitary report of remarkably efficient in vitro infection of human NK cells
301
 (published in 
2004 and discussed on pages 31-33) used freshly isolated primary NK cells, the majority of which 
have a CD16
HIGH
 CD56
DIM/NEG
 phenotype (Figure 4). Our interest in CD56
HIGH
 cells was 
stimulated by our in vivo findings in HLH and immunosuppression. We therefore initially set-out to 
reproduce the published data from Isobe et al but extend these studies to include IL-2 stimulated 
primary NK cells; where the majority display a CD56
BRIGHT
 phenotype in culture. NK cells were 
isolated from peripheral blood and either used immediately or cultured in IL-2-containing medium 
(page 86-87) until a CD56
BRIGHT
 phenotype dominated (typically 2 weeks). Primary B cells from 
the same donor served as a positive control. We also included NKL (an NK leukaemia line also 
infectable in the study of Isobe et al
301
) the T cell lines MOLT4 (published studies consistent with 
virus-binding but no entry
53,285
) and Jurkat (known  to express low levels of surface CD21
287
). 
Infection experiments with these individual cell populations using cell-free EBV were performed 
independently with both Akata EBV and B95-8(2089) viruses, used at an m.o.i of 100 as 
described earlier (pages 89-90). The data in Figure 21 represent a 10 day time-course 
experiment whereby RNA from an aliquot of each cell population was extracted on the indicated 
day following infection and RT-Q-PCR undertaken to quantitate EBER1, 2 and 
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Figure 21 Quantitation of EBV-encoded transcripts in primary lymphocytes and cell lines.  
Panel A shows expression of EBV transcripts over a 10 day period following infection of primary B 
cells. Histograms represent normalised transcript levels relative to a Day 10 value. 
Panel B shows expression of EBV transcripts over a 10 day period following infection of primary NK 
cells and T/NK lines. Histograms represent normalised transcript levels relative to the corresponding B 
cell value on each day. Note the different y axis scale between panels A and B 
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EBNA1 transcripts. Data for B cells is expressed relative to the Day 10 value (arbitrarily set at 1) 
whilst normalised transcript levels for the T and NK cells are shown relative to the corresponding 
B cell time-point. Panel A shows the results from primary B cell infection where, consistent with 
published results
82
, significant expression levels of EBERs are evident from Day 3 onwards whilst 
prompt initial activity from the Wp promoter is quickly superseded by Cp transcription. 
Panel B shows the results of infection of primary NK cells and T cells and demonstrates that 
infection of primary NK cells and T/NK cell lines is extremely inefficient with cell-free virus. In spite 
of a high m.o.i, no appreciable EBER transcripts are detected in freshly isolated, or in IL2-
stimulated CD56
BRIGHT 
NK cells - almost certainly indicating absence of infection. For the MOLT4 
and Jurkat T cell lines, EBER2 transcript levels are seen on day 1 and day 3 following infection. 
This equates to approximately 1-2% efficiency of the primary B cell population infected in parallel 
and suggests small numbers of transiently infected T cells. 
 
In vitro infection of tonsillar T and NK cells: cell transfer and immunological synapse 
experiments  
The data discussed above, together with complementary in vitro infection studies by Dr Claire 
Shannon-Lowe in our laboratory (including engineered expression of a recombinant CD21 
molecule in primary NK cells, that facilitated virus binding: Claire Shannon-Lowe, unpublished 
data 2008), strongly suggested that infection of NK and T cells in vitro with cell-free virus was 
extremely inefficient. Reflecting that this approach was not optimally physiological - NK and T cell 
infection in vivo is perhaps more likely to occur as a result of „transfer infection‟280 or during 
immunological encounters
299,693
 with B lymphocytes or epithelial cells - we decided to take a more 
„physiological‟ approach.  
The first series of experiments involved „bulk infection‟ of total tonsil mononuclear cells 
(ascertained to be EBV-negative or ≤102 copies/106 cells ex-vivo) with the B95-8 strain of EBV at 
different m.o.i: 10, 50 and 100. A standard infection method was used to allow initial virus binding 
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to cell surfaces (pages 89-90). Following two days culture (37C in RPMI 10% FCS 
supplemented with 175U/ml IL-2), the T-MNC were subjected to high-purity cell sorting by 
MoFlo
TM
 as for the ex-vivo analyses.  
Figure 22 shows data from 3 such experiments undertaken with an m.o.i of 10 (Panel A), 50 
(Panel B) and 100 (Panel C). Sample A and B were sorted by 3-colour fluorescence into B cells 
(CD19
+
CD3
-
CD56
-
), T cells (CD3
+
CD19
-
CD56
-
) and NK cells (CD56
+
CD3
-
CD19
-
), whilst for 
sample C, CD4 and CD8 T cell populations were further delineated. Viral loads were analysed by 
Q-PCR as before but, for this experiment, data are represented as EBV genome number per cell 
equivalent. In all three cases a similar pattern of results was seen: the dominant viral load was 
always seen in the CD19
+
 population; ranging from 10-300 fold higher than their T or NK 
counterparts. However in some cases, EBV genome number in the T and/or NK populations was 
higher than could be attributed to B cell contamination alone. For example, the 98% pure CD3
+
 
population in panel A appeared to contain approximately 10% of the B cell load. Similarly, the 
viral loads in the CD8 and CD56 fractions shown in panel C exceed that expected from the 
degree of B cell contamination.  Recognising that this could represent viral genomes or DNA 
adhering to the cell surface, aliquots of the sorted cells were stripped using chymotrypsin (as 
previously described
280
). This treatment resulted in a 66% reduction in T cell viral load, compared 
to 33% of B cell virus (data not shown). Moreover, where cell numbers permitted, the purified T 
cells were maintained in culture following sorting and the viral load was observed to fall by >80% 
within a week (data not shown). The limitations of this experimental approach then became 
apparent: the levels of EBV DNA observed in T and NK cell fractions could be potentially 
explained by cell surface virus or membrane-bound viral DNA, or even small numbers of 
contaminating high-load B cells. 
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Figure 22 EBV predominantly infects B lymphocytes following 2 days co-culture with tonsil 
mononuclear cells. 
Viral load data from purified tonsillar lymphocyte populations following in vitro infection with EBV 
at an m.o.i. of 10 (A), 50 (B) and 100 (C). Note that y axis is EBV genomes per cell. 
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We therefore adopted a different approach: maintaining the experimental model of T-MNC co-
culture, but on this occasion focusing on evidence of EBV gene expression at the single cell level, 
by virtue of GFP expression from the recombinant Akata virus. B cells were isolated from freshly 
harvested tonsil mononuclear cells (using CD19
+ 
Dynabeads
TM
 pages 85-86) and incubated at 
37C with Akata-EBV (m.o.i of 50). Aliquots of these B cells with surface-bound EBV (B/EBV) 
were either cultured separately or added back to the (B-depleted) T-MNC at ratios approximating 
to 1: 20 to 1: 2 (ie 5% to 50% B cells amongst tonsillar non-B cells). Parallel cultures with T-MNC 
infected with cell-free virus were also performed. The cultures were analysed by two-colour flow 
cytometry from day 3 onwards post-infection, as this is the earliest time of B lymphocyte 
proliferation and GFP expression following infection with EBV
53
. MAbs to CD19, CD3 and CD56 
were used to identify the phenotype of the GFP-expressing, EBV-infected cells.  
Figure 23 is a representative summary of such an infection experiment, showing data from days 
5, 7 and 10. Panel A is the positive control sample of purified tonsillar B cells (identified by CD19 
staining), infected with EBV, and demonstrates emergence of a GFP-positive population in the 
absence of T cell effectors. Panel B summarises data from co-cultured tonsillar B/EBV with 
autologous non-B cells at a ratio of 1: 10. The proportion of GFP
+
 CD19
+
 cells emerging in this 
co-culture is reduced compared to the purified B cell population in panel A. This is likely due to 
autologous T and NK effectors killing EBV-infected B cells within the culture, via recognition of 
latent and lytic viral antigens. In spite of this indirect evidence of immunological engagement of 
T/NK cells with EBV-infected B cells, we could see no clear evidence of GFP
+
CD3
+
 or 
GFP
+
CD56
+
 cells throughout the time-course to day 10. Where occasional GFP
+
 events were 
seen in the CD3-PECy5 or CD56-PE quadrants (panel B), no GFP
+
 cells were evident in the 
corresponding CD19-negative quadrant (panel A); all GFP
+
 cells were CD19
+
. This infers that any 
apparently GFP
+
 T or NK cells were simultaneously engaged with B cells, i.e. conjugate 
formation. We did not formally prove this by undertaking multi-colour analyses as the evidence for 
T and NK infection was not convincing or, at most, these were extremely rare events. 
 
144 
 
 
Figure 23 No evidence of T or NK cell infection with EBV despite autologous T/NK-mediated 
killing of EBV-infected B lymphocytes 
Two-colour flow cytometric (compensated) analysis. GFP
+ 
lymphocyte populations are identified in 
the top-right quadrant of each individual plot. Panel A comprises an analysis of purified tonsillar B 
lymphocytes 3-10 days following in vitro infection, on days indicated. Panel B represents parallel 
cultures of infected B cells co-cultured with the autologous non-B cell tonsillar fraction, to give an 
initial ratio of 1: 10 (B: non-B).  
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High viral load in CD56+ tonsillar lymphocytes following ex-vivo culture 
The in vitro data described above - extremely inefficient, or absent, T and NK cell infection under 
a range of optimised experimental conditions – could be considered in keeping with the rarity of 
EBV-driven NK and T cell proliferations in vivo and the relative infrequency of T and NK infection 
events in primary and persistent infection (figures 15-18 and references
246,249
). However, we 
remained intrigued by our in vivo findings in tonsillar lymphocytes from immunosuppressed 
patients; high EBV genome numbers in CD56
+
CD3
-
CD19
-
 tonsillar, but not peripheral blood, 
lymphocytes (Figure 19, page 131).  
Thus, in an attempt to recapitulate the in vivo observation of infected CD56
+
 tonsillar lymphocytes 
in-vitro, we initially undertook an experiment similar to that already presented in Figure 22; 
infection of freshly isolated T-MNC (from a healthy donor) using B95-8 EBV at an m.o.i of 50. 
However, in this instance we also treated the EBV-infected co-culture with 1µg/ml Cyclosporin A 
(CSA, a calcineurin inhibitor) in order to pharmacologically influence the in vitro environment, akin 
to the Tacrolimus therapy received by our immunosuppressed tonsil donors. As a control, tonsil 
MNCs from the same donor were cultured in the presence of CSA but without the addition of 
exogenous virus. As before, the cultured cells were subject to high-purity MoFlo sorting on day 2 
followed by DNA extraction and Q-PCR analysis for EBV genome load. 
The results did not demonstrate any augmentation of infection of tonsillar T or NK cells in the 
CSA-treated, EBV-infected T-MNC culture; the viral load data was almost identical to those 
shown in Figure 22, and as discussed above. However, entirely unexpectedly, the control CSA-
treated T-MNC culture showed an extremely high EBV genome load in the sorted CD56
+
 
population; without being exposed to exogenous virus (Figure 24, Panel A, CT1).  
There was no evidence of numerical expansion of the gated CD56
+ 
population; these cells 
amounted to 0.3-0.4% of the total live MNC, similar to - or less than - previous results. This is 
reflected in the minimal increase in the total MNC load after 2 days in culture; although the EBV  
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Figure 24 High viral genome load in CD56
+
 tonsillar cells following ex-vivo culture 
Panel A is data from a tonsil lymphocyte culture treated in-vitro with Cyclosporin A.  
Panel B is data from the same tonsil donor as A, sorted immediately ex-vivo, without culture 
Panel C shows data from 2 further tonsil donors, cultured without Cyclosporin.   
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copy number per CD56
+
 cell is high, the absolute EBV numbers are relatively small when judged 
against the entire T-MNC population.  
To exclude the possibility that the observed phenomenon had already occurred in vivo rather than 
following in vitro culture, an aliquot of the original T-MNC from the same donor was recovered 
from liquid nitrogen and immediately sorted. Panel B (Figure 24) shows the viral load data: 
exclusively restricted to B cells, reminiscent of the NT results presented in Figure 16 (page 123), 
and consistent with an in vitro phenomenon resulting in the high viral load in the CD56
+
 cells. 
To confirm these data, the same experiment was performed on two further healthy tonsil donors. 
For CT2 and CT3, an identical method was followed (that is, without exogenous virus) but, for 
each donor, the effect of CSA was tested by culturing half the T-MNC in the absence of CSA and 
performing two cell sorts on day 2. Both these donors had higher ex-vivo T-MNC viral loads than 
CT1, but precisely the same distribution of viral load was observed; a very high load in the CD56 
population. The data shown in Panel C, Figure 24, are from those T-MNC cultures not treated 
with CSA. This indicated that the observed phenomenon of in vitro viral entry, reactivation or 
replication in the CD56
+
 fraction was independent of CSA treatment.   
 
Characterisation and re-analysis of EBV-harbouring tonsillar CD56+ 
lymphocytes  
The results described were both striking and unexpected. The phenomenon appeared to be a 
consequence of in vitro culture but it remained unclear why, and how, tonsillar NK cells 
(apparently EBV negative in vivo - panel B, figure 24) should develop such a viral load, whereas 
efforts at in vitro infection with exogenous virus were futile. The first priority was to further 
characterise the CD56
+
 population.  
148 
 
Characterisation of CD56-expressing cultured tonsillar lymphocytes 
As discussed earlier (introduction, pages 34-35), although there exists no entirely specific NK 
marker, CD56 has been widely used and the judicious combination of non-NK specific markers, 
CD56
+
CD3
-
, has been the accepted phenotypic definition
308
. Other cell types known to express 
CD56 include cytotoxic CD8
+
 T cells (excluded on our sorting strategy) and muscle and neuronal 
cells – absent in lymphoid tissue. Malignant diseases such as multiple myeloma are well 
recognised to frequently express CD56, but normal and reactive plasma cells from blood, bone 
marrow and tonsil have been shown to be universally negative
694-695
.  
In the first instance, we used 2-colour FACS to confirm the phenotype of ex-vivo cultured tonsillar 
CD56
+
 cells. A range of B cell, plasma cell, T and NK cell markers were used together with CD56. 
We were initially struck by the emergence of a CD138-expressing population of cells after 24 
hours in culture, initially comprising ≤0.5% of T-MNC ex-vivo and increasing to 3-8% (according 
to tonsil donor) over 24-48 hours (Figure 25).  Moreover, the majority of these CD138-expressing 
cells appeared to co-express CD56. CD138 (Syndecan-1) is a plasma cell specific marker, a 
differentiation antigen that appears after the plasmablastic stage and increases in intensity in 
concert with plasma cell maturation
695
. This strongly suggested upregulation of the CD56 antigen 
on a small population of tonsillar plasma cell-like lymphocytes during in vitro culture. A majority of 
these cells also expressed low but appreciable levels of CD19. NK cells are not known to express 
CD138 and we confirmed the non-NK nature of this emergent CD138
+
CD56
+
 population by 
demonstrating mutual exclusivity of CD94 and CD138 expression in this same tonsil culture (data 
not shown). 
We were thus prompted to repeat the cell sorting and viral load experiment, applying a different 
sorting strategy and alternate combination of MAbs. 
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Figure 25 A subset of CD56
+ 
tonsillar lymphocytes co-express the plasma cell marker CD138 
following short-duration ex-vivo culture
  
Flow cytometry analysis (fluorescence-compensated) showing CD138 and CD56 expression on 
cultured tonsillar lymphocytes from a healthy donor. The top two rows are plots of CD56 or CD138 
versus isotype controls, showing the total respective populations. The lower row is a two-colour plot 
of CD56 and CD138, with cells expressing both markers identified in the top-right quadrant of each 
plot.  
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Re-analysis of EBV loads in tonsillar lymphocyte populations in vitro and in vivo 
During the final stages of these investigations, a report was published that described a minor 
CD56
+
 population that were not NK cells, but phenotypically and functionally resembled cells from 
the monocyte/DC lineage
696
. The authors noted that co-expression of CD7, expressed on virtually 
all NK cells, was the optimal phenotypic marker to distinguish NK cells from this rare 
DC/monocyte population. With this in mind, we decided to use co-expression of CD56 and CD7 
to reliably identify NK cells, whilst the combination of CD138 and CD56 would capture the newly 
identified „plasma cell-like‟ emergent population. 
Figure 26 shows the viral load data from such a sort, performed, as before, after 2 days culture 
(again, without CSA) – using MNC from the CT3 donor denoted in Figure 24 (page 142). The first 
observation is that the previously striking load in the CD56
+
 fraction is not evident when co-
expression of CD7 is used to capture „true‟ NK cells. This CD7+CD56+ NK fraction comprised 
0.8% of viable lymphocytes, in keeping with our previously described tonsil data, and consistent 
with the published literature
327
. The small viral load now seen in the NK population could be 
accounted for by 5% B cell contamination and therefore can be regarded as negative.  A 
population of CD56
+
138
+ 
cells were again clearly evident, in this case amounting to 6.7% of 
viable lymphocytes when sorted on day 2. Co-expression of CD19 on these cells was variable: a 
proportion appeared CD19 negative, whilst some expressed low levels of CD19. These 
populations were collected and analysed separately and contained equivalent viral loads, greater 
than that seen in the CD19
+
-only fraction (Figure 26). 
Together these data appeared to provide an explanation for the high EBV copy number in CD56
+
 
tonsillar cells after 2 days in culture; these were not in fact NK cells, but rather, an emergent sub-
population of „plasma-like‟ B cells co-expressing CD56. 
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Figure 26 Cultured CD56
+ 
tonsillar lymphocytes with high EBV load are not natural killer cells. 
Viral load data from total mononuclear and purified tonsillar lymphocyte populations, from a healthy 
donor, sorted after 2 days of ex-vivo culture. Each population was phenotypically defined as indicated 
by 
+
 (presence) or – (absence) of a specified markers, as discussed in the main text. The pie chart 
shows the relative proportions of NK cells (red), B cells (blue), CD56
+
CD138
+
 population (green) and 
other (predominantly T lineage) cells (grey) within the total gated lymphocyte population. 
The percentage figures beneath the x axis labels indicate the purity of each respective population on 
re-analysis. 
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This prompted reappraisal of our in-vivo findings of high genome numbers in CD56
+
 tonsillar 
lymphocytes donated by immunosuppressed patients: do these cells, isolated on the basis of 
CD56
+
CD4/8
-
CD19
-
 , truly represent NK cells? To address this, we adopted a similar sorting 
strategy – using CD7 as an NK co-marker - for re-analysis of an IST2 (Figure 19, page 131) 
immediately following recovery from liquid nitrogen (without culture). Figure 27 comprises viral 
load data from the sorted populations. By contrast to the cultured tonsil data, initially obtained 
from a healthy donor (Figures 25 and 26), there appeared to be no substantial population of 
CD138
+
CD56
+
 cells; these rare cells accounted for 0.03% of viable lymphocytes. However a 
small population (1.1%) of CD56
+
CD19
+
 cells, not previously appreciated (although contaminated 
with CD19
+
only cells), was seen to contain a viral load several times that of the CD19
+
-only 
population (Figure 27). NK cells (defined by CD56
+
CD7
+
CD19
-
CD138
-
) comprised 0.43% of T-
MNC and did not contain the substantial viral load previously seen (IST2, Figure 19, page 131); 
the small load shown could potentially be explained by 7% contamination by CD19
+
CD56
+
 cells. 
The rare CD138
+
56
+
 cells did not appear to harbour any EBV genomes but this should be 
interpreted with caution in view of the tiny cell numbers and lack of purity data for this population.  
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Figure 27 CD56
+ 
tonsillar lymphocytes from immunosuppressed patients with high EBV genome 
copy number are not natural killer cells. 
 
Viral load data from total mononuclear and purified tonsillar lymphocyte populations, from 
immunosuppressed donor IST2, sorted ex-vivo without manipulation/culture. Each population was 
phenotypically defined as indicated by 
+
 (presence) or – (absence) of a specified markers, as discussed 
in the main text. Values are expressed as EBV genomes per 10
6
 cells. Numerical values above each 
histogram indicate the mean value of Q-PCR performed in triplicate, with standard deviations as 
indicated by capped vertical bars. The pie chart shows the relative proportions of NK cells (red), B 
cells (blue), CD56
+
CD19
+
 population (black) and other (predominantly T lineage) cells (grey) within 
the total gated lymphocyte population. The percentage figures beneath the x axis labels indicate the 
purity of each respective population on re-analysis. nd = purity not determined due to insufficient cell 
numbers. 
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Discussion (I) 
EBV-HLH presenting in adult patients in the UK 
Clinical aspects 
A rare disease
374
, EBV-HLH occurs most commonly in the context of primary EBV infection
240,485-
486,490
 and, accordingly, is predominantly encountered in immunocompetent children and 
adolescents
498-500
 where it is the commonest cause of HLH
374,487-488
. By contrast, rare adult cases 
of HLH usually have an underlying cause other than EBV infection, usually attributable to 
malignancy and most commonly lymphoma
374,501
. Furthermore, most reported cases are 
described in persons of East Asian ethnicity
499
 although occurrences in patients of 
European
240,494
, Middle Eastern
492
, North American and Hispanic
245
 origin have been described. 
Our description of three cases of EBV-HLH occurring in adult patients in the UK highlights some 
uncertainties regarding disease pathogenesis. In common with more than 90% of adults 
worldwide, our three cases had serological evidence of prior EBV infection although their T-cell 
specific immunity was not tested. Whether acquired immune dysfunction is required to trigger the 
onset of EBV-HLH in EBV-immune adults is not clear. Although well-defined inherited immune 
defects
502,508
 are recognised to predispose to EBV-HLH, most patients are apparently 
„immunocompetent‟501. In the context of iatrogenic immunodeficiency, CMV appears to be a more 
frequently implicated agent, although EBV-HLH has been reported and can be associated with a 
poor outcome
511
. In our cases, HLH-1 had no history to suggest immune dysfunction, HLH-2 was 
receiving therapy with 5-aminosalicylic acid (mesalazine) for inflammatory bowel disease 
(previously treated with Azathioprine) and HLH-3 was subsequently diagnosed with EBV
+
 
Hodgkin‟s Lymphoma (mixed cellularity subtype). This has recently been recognised to be 
associated with HLH
697
, although EBV infection of NK cells in the context of HL has not been 
previously described. Thus, an influence of relative immunosuppression in some cases may be 
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contributory, but this issue requires formal investigation including analyses of EBV-specific T 
cells. 
We have also been aware of three further cases of EBV-HLH in adults from the UK Midlands 
region between 2007 and 2009, two of which were associated with EBV-positive HL in the context 
of HIV infection. In these cases, the clinical features of HLH were quite distinct from the HL and 
likely due to a coincident T or NK infection (as in patient HLH3), although we were unable to 
investigate these additional patients using the methodology described here. The remaining case 
was more „typical‟, immediately following symptomatic primary EBV infection in a young adult.  
The high mortality in EBV-HLH is attributable, at least in part, to delays in diagnosis - the initial 
clinical presentation can be almost indistinguishable from a wide range of infective and 
inflammatory conditions
487
, a difficulty often compounded by the apparent absence of 
haemophagocytosis on initial biopsy. Although undoubtedly a rare disease, we believe that the 
incidence in adults in western countries is underestimated. The criteria established by Henter et 
al
476
, alongside a high clinical suspicion, remain key to diagnosis. Delineating the phenotype of 
the virus-harbouring cell to inform the application of targeted therapies
698
 is an attractive concept, 
but requires larger collaborative studies of adults and children with EBV-HLH. 
EBV-infected NK cells in HLH 
Published data has shown that CD3
+ 
T cells, most often the CD8
+
 subset, both in tissue 
biopsies
240,245,464-465,467,469,493
 and circulating lymphocytes
471,494
, are the dominant infected 
population in EBV-HLH. Focusing on studies examining peripheral blood lymphocytes, Kasahara 
et al relied upon semi-quantitative EBER in-situ hybridisation
471
 and, consistent with the majority 
of reports, identified CD8
+
 T cells as the dominant target cell. The same study identified a smaller 
number of EBER positive CD16
+
 cells seen but the cells were not co-stained with CD3 to 
delineate between cytotoxic T cells and NK cells. Whilst our study of HLH patients was ongoing, a 
report was published describing 2 adult cases of EBV-HLH which stated that one case involved 
infection of NK cells – but details of data supporting this finding were not provided699. 
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Interestingly, a relatively large study of non-Asian children with EBV-HLH used Q-PCR on purified 
peripheral blood lymphocytes and found the dominant viral load in CD19
+
 cells, followed by CD3
+
 
T cells. However, the median total PBMC load exceeded the median CD19 load, suggesting an 
unidentified population. It is notable that NK cells were excluded on their isolation protocol
494
.  
The advantages of our approach of investigating EBV-HLH cases are the use of three-colour flow 
cytometry to clearly define peripheral lymphocyte populations (Figure 11A, page 115), in 
conjunction with a sensitive Q-PCR assay. Applying the conventional definition of a NK cell, 
CD56
+
CD3
-308
, two of three cases we investigated had a high viral genome load in circulating NK 
cells (Figure 11B, page 115). For HLH1, although we cannot be absolutely certain of the identity 
of the CD3
-
CD16
-
CD19
-
 small lymphocyte population – we believe this most likely represents the 
CD56
BRIGHT 
NK subset. That our data is the first to clearly show peripheral blood CD56
+ 
cells as 
the dominant EBV target may be a „real‟ finding - for example relating to host immuno-genetic 
factors or acquired immune-deregulation - or may have simply become apparent because this cell 
population was not specifically addressed in previous studies. 
As a result of our subsequent findings of CD56
+
 cells of B lymphoid origin in tonsils both in vitro 
and in vivo (discussed later) we reflected on whether the infected cells in our HLH patients were 
indeed NK cells. Unfortunately there was no remaining primary material to address this directly; 
for example by looking for B-cell specific mRNA or Ig VDJ rearrangements. However, the 
circumstantial evidence weighs against a B cell origin in our HLH patients. Firstly, in contrast to 
the tonsil data, we did not find significant levels of virus in peripheral blood CD56
+
 cells ex-vivo in 
IM or immunosuppression. Secondly, again in contrast to tonsillar cells, when we cultured PBMC 
from a healthy donor and performed the same cell sort on day 2 we did not find any virus in the 
CD56
+
 compartment; the viral load data were akin to that seen in ex-vivo PBMC (one experiment, 
data not shown). Thus it seems likely that the CD56
+
CD3
-
 cells in the HLH patients are of NK 
origin, but future analyses should attempt to confirm this with cellular RNA or DNA studies and by 
applying CD7 as a co-marker alongside CD56 to accurately identify NK cells. 
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Available data on viral gene expression in the context of EBV-HLH remains ill-defined
122
.  In two 
of our cases, sufficient cell numbers were available for RNA extraction, albeit from total PBMC 
rather than separated lymphocyte subsets. This could potentially result in interpretative difficulties 
if any EBV-infected B cells present were transcriptionally active
122
. Nonetheless we interpret our 
data as meaningful because PBMCs were devoid of B cells in HLH-1, and for HLH-2 the viral load 
in the NK cell fraction was a log higher than in the B cells. Our results showed an apparently 
tightly restricted pattern of viral gene expression with high levels of EBERs exclusively expressed 
– greatly exceeding transcript levels seen in an LCL - but an absence of protein-encoding 
transcripts (Figure 12A and B, page 116).  The significance of this observation is unclear but may 
be of relevance to a recent study suggesting a role for EBERs, present in serum from patients 
with HLH, in disease pathogenesis
198
.  
EBV genome load in blood and tonsillar lymphocyte subsets in health 
and immune dysfunction   
Studies in primary infection and healthy persistence, predominantly based on 
immunohistochemistry combined with EBER ISH for identification of EBV-infected cells, have in 
some instances demonstrated rare T
229
 and NK
230,246,249
 cell infection in tonsillar tissue, whilst 
other studies have not
230,247-248
. The limitations of these studies, as discussed (pages 27 and 34, 
introduction), include imperfect sensitivity and specificity of cell lineage markers, usually applied 
singly rather than in combination and thus further limiting specificity. For NK cell identification, the 
NK antigen PEN5 has been used
246,249
, but this marker is not usually expressed on the 
CD56
BRIGHT
 population that dominates in tonsillar tissue
259
. Moreover, the sensitivity of this semi-
quantitative approach is limited by virtue of the manual approach of cell counting via a 
microscope.  
Our approach of high-throughput, high-purity cell sorting of (typically) ≥108 viable tonsil 
lymphocytes followed by a Q-PCR method able to detect as few as 2 EBV genomes in a 
background of 10
5
 cells offered clear advantages, although it lacks evaluation at the single-cell 
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level. The lack of a sensitive and specific NK marker was addressed by using a combination of 
MAbs consistent with the customary phenotypic definition (CD56
+
CD3
-
CD19
-
). Using four-colour 
cell sorting to isolate specific monofluorescent populations allowed us to achieve consistently 
high purities of total tonsillar NK cells and the major T cell subsets. 
Normal tonsils 
Our analyses of tonsils donated in the context of healthy persistence (Figure 16, page 123), albeit 
on a background of recurrent tonsillitis, allowed three main observations to be made. The first 
related to the discrepancy between T-MNC and CD19 viral loads, which is discussed below in the 
context of IM. The second observation was the occasional, albeit low level, finding of EBV 
genomes in the CD4 and CD8 T cell populations. Although, where seen, this was not explicable 
by CD19 contamination, definitive conclusions cannot be drawn. In particular, questions remain 
about whether this could be surface rather than intracellular virus and, importantly, how this data 
would appear at the single-cell level. The presence of surface virus however seems less likely 
when the CD56
+
 population is considered, serving as an internal control; consistently negative for 
EBV genomes in NT. On this note, an immunohistochemical study
249
 of routine tonsillectomy 
sections found frequent instances of conjugate formation between EBER
+
 cells (of plasmacytoid 
morphology) with both CD4 and CD8 T cells. By virtue of forward scatter and side scatter criteria, 
our cell sorting strategy should, in principle, have excluded cell conjugate formation. Nonetheless 
this observation could be relevant to our findings, considering the transfer of cell membrane and 
associated receptors that can occur during immunological encounters
299,693
. Lastly, in our normal 
tonsils we found no evidence of EBV in the CD56
+
 population.  
Infectious mononucleosis 
In the context of symptomatic primary infection, a previous study adopting a similar experimental 
approach included healthy children with acute symptomatic EBV infection. In these cases the viral 
load was confined to the CD19 cells with no evidence of CD4 or CD8 infection, although NK cells 
were not examined in this study
700
. Moreover, it was unclear whether those studied represented 
bona fide IM cases.  
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In our analyses, the diagnosis of IM was unequivocal – on the basis of characteristic symptoms 
and a positive Monospot test – blood was donated by 3 such cases at the height of the illness 
and 2 cases in the early convalescent phase (Figure 17, page 125). In these individuals the virus 
was almost exclusively restricted to CD19
+
 B cells; small numbers of EBV genomes in the NK 
fractions could potentially be explained by 2-3% contamination by „high-load‟ B cells, although by 
CD19 staining this was not manifestly the case. Thus, it remains unclear whether this represents 
a rare infection event in circulating NK cells or simply contamination by an undefined B cell 
population.  
Turning to IM tonsils (Figure 18, page 127), we were initially struck by the finding of marked 
discrepancies in viral load between total MNC (harvested for DNA extraction immediately 
following recovery from liquid nitrogen) and the sorted CD19 population. In three cases this 
amounted to a 3-20 fold higher value in T-MNC and was much more marked in IMT than seen in 
NT. In one case a comparator EBV load was also measured in the T-MNC population after 
density centrifugation (Lymphoprep
TM
) but prior to sorting. The load in this viable MNC population 
was approximately one-third lower than in the original ex-vivo MNC (data not shown) and 
suggests that dying/dead cells contributed proportionally more to the viral load value. With this in 
mind, another explanation may be the inadvertent exclusion of CD19
DIM
 B cell populations 
(potentially containing higher EBV copy numbers) with this sorting strategy; which gated on the 
CD19
HIGH
 cells in the interests of achieving high purities. An alternative but related explanation 
could be the demise of lytically-infected B cells during the sorting process.  
In most analysed IM tonsils, we found a „low level‟ viral load in the CD4+ and/or CD8+ T cells that 
could not be numerically accounted for by contaminating B cells (discussed under NT – above). 
However, in one case (IMT4, Figure 18, page 127) the CD8
+
 fraction contained a substantial viral 
load, approaching the CD19
+
 value. We do not have data at the single-cell level; in principle this 
could equate to 1 in 10 CD8
+
 cells infected with an EBV genome or the presence of considerably 
fewer cells participating in replicative infection. CD8
+
 T cells are greatly outnumbered by their 
CD4
+
 counterparts in normal and IM tonsils so there were insufficient purified CD8
+
 cells to 
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analyse viral gene expression in this population. However RT-Q-PCR analysis of RNA from 
CD19
+
 cells in IMT4 (Figure 18, page 127) showed transcriptional evidence of full lytic cycle in the 
tonsillar B cell compartment and thereby susceptible to attack by lytic-epitope specific CD8
+
 T 
cells
382
. Thus, in the case of IMT4, infection of the CD8
+
 cells could be rationally explained 
immunological encounters with lytic cells. The subsequent fate of this infected CD8
+
 population, 
however, remains challenging to determine in an in vivo context. 
Lastly, we were interested to see apparent infection of CD56
+
 cells (in 3 of 5 IM tonsils 
examined), equivalent to 10-30% of the corresponding CD19
+
 load (IMT1, 3 and 4, Figure 18, 
page 127). Although these loads could not be accounted for by the level of CD19 contamination, 
uncertainties relating to the cause of the discrepant MNC/CD19 load caution that the CD56 data 
should be interpreted carefully; for tonsils IMT1 and IMT3, 1-2% contamination of an 
uncharacterised cell present in the T-MNC could potentially account for the CD56 viral loads. 
Immunosuppressed patients 
Both inherited and acquired, numerical and functional, defects of T cell immunity have long been 
recognised to substantially increase a person‟s risk of developing EBV-driven B cell 
lymphoproliferation
405-406,701-702
. A previous study has shown that EBV-harbouring memory cells, 
rather than lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients
160
. 
For NK and T cell lymphoproliferations, usually seen to arise in the context of apparently intact T 
cell immunity, no data is available on the occurrence of EBV-infected T and NK cells. One recent 
report focused on HIV-infected children established on antiretroviral therapy, taking a similar 
approach of cell sorting and EBV genome quantitation in CD19
+
, CD4
+
 and CD8
+
 peripheral blood 
fractions
700
. In a majority of patients assessed, there was convincing evidence of EBV in the 
highly purified CD4
+
 and CD8
+
 subsets, although the median T cell viral loads were 5-15 fold 
lower than of the comparator CD19
+ 
subset (NK cells were not assessed). Interestingly, given that 
participants‟ median CD4 counts were 500/µl, their level of immunosuppression would be 
considered relatively „mild‟. In fact, these viral load data are reminiscent of the viral load 
distributions we have described in our cases of NT and IMT. 
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We had the opportunity to analyse tonsillar lymphocytes donated by four paediatric patients who 
had previously undergone allogeneic solid-organ transplantation and were consequently receiving 
T cell suppressive therapy with Tacrolimus, a calcineurin inhibitor. Using the same sorting 
strategy as for NT and IMT, we were struck by the unexpected finding of high genome numbers in 
the non-B, non-T, CD56
+
 fraction (Figure 19, page 131). Although this is a numerically minor (0.3-
1%) population amongst tonsillar lymphocytes, on a „per cell‟ basis this population harboured the 
dominant viral load. By contrast, in 2 cases where matched peripheral blood samples were 
available, the same phenomenon was not apparent; these data were indistinguishable from 
normal peripheral blood.  
An important question was whether this phenomenon was due to adherent surface virus or viral 
DNA, rather than true infection. We attempted to answer this question by staining purified CD56
+
 
cells (from IST3, Figure 20, page 133) for EBER expression at the single-cell level and found that 
only a tiny minority of cells were EBER
+
 (data not shown). We considered whether this could 
relate to the occurrence of lytic cycle, explaining the high viral load and shown to result in EBER 
downregulation
193
. In the same CD56
+
 population, we identified only a single cell with evidence of 
lytic replication including detection of a late viral capsid protein. However this finding should be 
interpreted in the context of recent studies in our laboratory, where Q-PCR measurements of viral 
load in induced AKBM cells
703
 have been undertaken. At both the single cell level and in sorted 
lytic populations, the estimated viral load is in excess of 10,000 copies per lytic cell (Dr A.I Bell 
personal communication, 2010). Thus, very small numbers of lytic cells amidst an EBV-negative 
(or latently infected) population could potentially explain our findings. However, we note an 
immunohistochemical study of 15 tonsillectomy samples from immunosuppressed patients that 
did not reveal any BZLF1 expression, or any substantial numbers of EBV-transformed cells
704
. 
Nevertheless, although this issue was not yet entirely resolved and with these provoking data in 
mind, we moved on to complementary studies investigating in vitro EBV infection of T and NK 
cells. 
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EBV infection of T and NK cells in vitro  
We began by aiming to reproduce the findings of the only published study that has accomplished 
efficient in vitro infection of NK (leukaemia) lines and primary NK cells
301
. We extended these 
experiments to include IL2-stimulated CD56
BRIGHT
 primary NK cells and applied sensitive RT-Q-
PCR assays for EBER expression to look for evidence of infection. No clear evidence of NK cell 
infection was seen (Figure 21B, page 135), whilst B cells from the same donor were readily 
infectable, displayed the co-ordinated transcriptional program of latent gene expression and 
expressed the anticipated levels of EBERs (Figure 21A, page 135). Low levels of EBERs were 
evident after 24-72 hours in the MOLT4 and Jurkat T Cell lines but this was not sustained; 
presumably the virus was lost or the cells died by apoptosis. 
As discussed in the introduction of this thesis (page 31), NK cells do not express CD21 and the 
mechanism of viral entry is entirely unclear. It is reasonable to speculate that in vivo infection 
could occur via immunological synapse formation with latent or lytic target cells. Indeed, 
conjugate formation between PEN5
+ 
and EBER
+
 tonsillar cells are readily seen by 
immunohistochemistry in healthy viral persistence
249
. 
We therefore adopted a more physiological approach and undertook a series of tonsillar co-
culture experiments to provoke T/NK immunological encounters with newly-infected, EBV-
transformed autologous B cells. The first set of experiments, involving „bulk infection‟ of tonsillar 
MNC followed by cell sorting on day 2, suggested a minority of T and NK cells may be infected 
(Figure 22). However, EBV Q-PCR was unable to delineate between adherent virus/viral DNA 
and genuine infection. Thus we changed our experimental approach to incorporate a more 
convincing indicator of infection at the single-cell level. However, despite seeing evidence of B 
cell infection, proliferation and subsequent containment of outgrowth by tonsillar T/NK effectors, 
we were unable to demonstrate unequivocal T or NK infection (Figure 23, page 140). This assay 
assumes that GFP will be expressed, as in B cells, if the recombinant Akata virus enters NK or T 
cells; as was reported in the study of Isobe et al
301
.  
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Prompted by our in vivo data from IST (Figure 19, page 131), we next tested whether 
pharmacological impairment (via calcineurin inhibition) of T/NK function would provoke 
susceptibility to in vitro infection. This effect was not achieved, but serendipitously led to the 
unforeseen result of high viral loads in cultured CD56
+
 tonsillar lymphocytes, independent of 
CSA. 
Noting a recent paper that demonstrated a differential effect of calcineurin inhibition on NK cell 
subsets, where CD56
BRIGHT
 cells appeared to display resistance to this drug compared to their 
CD56
 DIM 
counterparts
334
, we considered whether such treatment may result in a reliance on 
CD56
BRIGHT 
NK cells for containment of  B cells transformed by EBV
363
 or cells in lytic cycle
298
. 
However the magnitude of the genome load per cell, occurring within 48 hours of culture impelled 
us to better characterise the CD56
+
 cells.  
Characterisation and analysis of EBV-harbouring tonsillar CD56+ 
lymphocytes 
As discussed earlier (NK cell phenotype, page 34) CD56 is expressed across NK subtypes and, 
together with an absence of CD3 (or CD4 and CD8), can accurately identify NK cells in vivo and 
in vitro, particularly in tonsillar tissue
308
. However, CD56 is not NK-specific; expression on other 
lymphoid cells, including cytotoxic T cells
314
 and malignant plasma cells
705
 is seen. Previously, 
comprehensive analyses of bone marrow, blood and tonsillar tissue have demonstrated an 
absence of expression on normal and reactive plasma cells
694-695
. 
Notwithstanding this, our analyses of tonsillar lymphocytes ex-vivo have shown that within 24 
hours of culture, a population of cells expressing the plasma cell differentiation antigen CD138 
emerges that co-express CD56 (Figure 25, page 145). Such cells also manifest low surface levels 
of CD19 but not CD94, implicating their origin as B cell and not NK cell. This finding of aberrant 
CD56 expression on a population of tonsillar, plasma-like B cells provided a potential explanation 
for our viral load findings in cultured lymphocytes. Indeed, previous work has shown that in vivo 
differentiation of healthy tonsillar B cells into plasma cells (as defined by a CD38
HIGH
CD20
LOW
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phenotype) initiated viral replication
212
. In response to data from a paper published during the 
later stages of this work
696
, we adapted our sorting strategy to identify NK cells with greater 
specificity (i.e. co-expression of CD7 and CD56) and also to delineate the newly identified 
CD56
+
CD138
+
 population. The viral load in the „true‟ NK population was negligible (figure 26, 
page 147) in distinct contrast to initial results from the same tonsil; amounting to <1% of the 
originally observed genome load (CT3, Figure 24, page 142). This confirmed our suspicion that 
the cultured CD56
+
 cells with a high genome load were not NK cells. However, although the viral 
load in the cultured CD138
+
CD56
+
 fraction was higher than that in the „standard‟ B cell population 
(irrespective of CD19 expression), this was still lower than anticipated when considering the 
magnitude of the viral load in the initial CD56
+
 population. This raised the question of whether the 
original CD56
+
 cells with a high genome load had been excluded on the new sorting strategy. As 
we were restricted to collecting 4 populations of cells, defined by combinations of 4 different 
fluorochromes, clearly there would be „lost‟ populations. Such relevant populations may include: 
CD19
LOW
CD56
+
138
-
 or CD19
+
56
+
138
+
. Nevertheless, the fundamental conclusion from these 
data is that a lymphocyte of B/plasma-cell phenotype, co-expressing CD56, is the likely identity of 
the EBV-harbouring cell.  
As to the original findings in tonsillar CD56
+
 cells from immunosuppressed patients (Figure 19, 
page 131), reanalysis showed that the viral load in the NK cell population, now defined by 
CD56
+
CD7
+
, was negligible. In this instance, a CD56
+
CD138
+
 population was much less 
prominent than in the cultured T-MNC, but a discernible CD19
+
CD56
+
 population was also 
collected and contained at least 4x the viral load of the CD19
+
-only population (figure 27, page 
149). Notably, a population of plasma cells (as defined by CD19
LOW
CD138
+
) had a viral load 
equivalent to a CD19
+
 B cell, although a lack of data at the single-cell level limits interpretation 
here. Consistent with the in vitro findings, these data suggest the existence of a hitherto 
undefined CD56
+
 population of B cell origin. Such cells appear to contain higher numbers of EBV 
genomes than a conventionally-defined B cell and, although the data in Figure 20 (page 133) 
lends support to the notion that this could be due to viral replication, this remains to be definitively 
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proven. In retrospect, examining the flow cytometric plots of previously analysed tonsillar 
lymphocytes ex vivo often reveals a small but definite population of cells co-expressing CD19 and 
CD56 (Figure 13A, page 118) – as was the case for IST2.   
As mentioned, CD56 is thought to be absent on normal plasma cells but almost always 
expressed in the setting of malignant myeloma
695
. Interestingly, myeloma cells circulating into the 
peripheral blood usually lack CD56, whereas myeloma cells in bone marrow or pleural/ascitic 
effusions clearly express CD56
695,706
. However, analogies with myeloma are less relevant to the 
clinical setting in which we made our initial observation of high genome load CD56
+
 cells. Such T 
cell-impaired patients are at risk of PTLD, not infrequently seen in tonsillar tissue
707
 and often 
displaying evidence of plasmacytic differentiation
408
.  
During preparation of this thesis, a study was published that combined surface 
immunofluorescence and EBER ISH („immuno-FISH‟) to investigate the phenotype of EBV+ cells 
in the peripheral blood from a range of patients, including those with HIV-infection and following 
HSCT
708
. Consistent with our findings in peripheral blood, these analyses could find no EBV 
genomes in an identically-defined NK population (CD56/16
+
 CD3
-
). Using detection of intracellular 
κ and λ Ig light chains combined with an absence of CD20 expression to define plasma cells, the 
authors reported frequent EBV infection of these cells in the peripheral blood. Notably, the 
genome load per cell was actually lower than their B cell counterparts. Interestingly, a population 
of undefined EBV-harbouring cells was identified in a majority of patients; negative for T-cell, B-
cell, and monocyte markers. This is reminiscent of an immunohistochemical study of EBV
+
 tonsil 
sections in healthy persistence where 11% of EBER
+
 cells were of unconfirmed phenotype. 
Although their morphology and occasional expression of CD20
LO
 suggested they were of 
plasmacytoid in nature, this was not confirmed; no CD138
+
EBER
+
 cells were seen
249
. A similar 
phenomenon has been reported in IM, where a substantial proportion of cells could not be clearly 
assigned a B or T lineage, using CD20, CD79a, CD3 and CD45RO as markers
247
.  
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These data are pertinent to our findings, where two main issues remain to be resolved. The first 
relates to the frequency, phenotype and significance of tonsillar-derived CD56
+
 B lymphoid cells 
both in vivo, where co-expression of CD19 identifies them as of B-lymphoid origin and in vitro, 
where a population of CD138
+
CD56
+
 cells emerges rapidly during ex-vivo culture. Such an 
investigation would include the application of a wider panel of B cell and plasma cell markers, 
comprehensive analysis by multicolour flow cytometry and immunohistochemical staining of 
immunosuppressed tonsil sections. This interesting work is beyond the scope of this thesis. The 
second area to be addressed relates to the nature of EBV infection in these CD56
+
 cells: the 
genome load per cell; whether this is lytic or latent infection; and what pattern of EBV gene 
expression is manifest. 
Amongst these unanswered questions, we can summarise our investigations of in vivo and in 
vitro infection of NK and T cells by drawing the following conclusions: EBV infection of peripheral 
blood NK and T cells appear to be extremely rare events in healthy persistence, primary infection 
and immunosuppression. In tonsillar T cells, our data is consistent with infrequent infection events 
in health and immune-deregulation (with the exception of 1/5 IM cases where a high CD8 load 
was seen). Convincing evidence for infection of tonsillar NK cells was absent amongst our patient 
groups, and particular caution should now be attached to the conventional NK phenotypic 
definition of CD56
+
CD3
-
; a previously unrecognised population of CD56
+
 tonsillar B lymphoid 
cells, associated with high EBV loads, has opened up a new avenue of investigation.  
Taken together with the inability to infect NK and T cells in vitro with any degree of efficiency, our 
data lead us to speculate that the development of T/NK lymphoproliferative disease is likely to be 
„an accident‟ of a rare in vivo infection event. However, the relative contribution of viral gene 
expression and cellular genetic changes (whether pre-existing, coincidental or EBV-induced) 
remain to be clarified. The lack of a good experimental model of NK and T cell infection, coupled 
with the rarity of such events in vivo in the absence of disease, severely hampers scientific 
progress in this area. Thus, it is likely to be more informative (at least in the short-term) to 
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examine cells and tissues from patients with established T/NK disease in order to better 
understand both disease pathogenesis and basic biology of these rare cellular-viral interactions. 
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Results (II): EBV gene expression in NK and T cell malignancies 
and studies with LMP1 
Introduction 
Published data on EBV gene expression in tumours of NK and T cell origin is limited to a small 
number of studies
73,564-565,610,614
 (and pages 59-60, 67-68 and 74-75). Moreover, studies 
examining the impact of EBV-encoded gene products on cellular phenotype have not been 
forthcoming; their role in pathogenesis remains unclear. We began this chapter of work by 
characterising the pattern of gene expression in CAEBV and ENKTL and in particular wished to 
focus on the role of LMP1 in pathogenesis of NK cell disease. This EBV-encoded, bona fide, 
oncoprotein
86
 is known to induce pleiotropic effects in B cells and epithelial cells in which it is 
thought to contribute substantially to the malignant phenotype of corresponding tumours
439
. By 
contrast, studies investigating LMP1 function in T/NK cells are scarce; limited to isolated in vitro 
studies in an EBV-negative T lymphoma cell background
120-121
. No data exist on its contribution to 
NK cell phenotype or lymphoma pathogenesis.  
Although considerable time was invested in this area of study, we were severely hampered by 
technical difficulties relating to gene transfection/transduction in primary NK cells and NK cell 
lines. Ultimately, a useful experimental model to examine the effects of LMP1 in NK cells was 
established but, due to time constraints and prioritisation of other areas of study (see Results part 
III), no definitive phenotypic data was obtained. Nonetheless, this work facilitated important 
technical progress regarding the expression of viral genes in primary human NK cells and 
resulted in a cell model that can be directly taken forward for analyses of global gene expression 
changes and functional studies. 
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SNK 6 SNT 8 SNK 10 SNT 16 
Patient age at 
diagnosis (years) 
62 48 17 13 
Primary tumour ENKTL ENKTL CAEBV CAEBV 
CD56 positive positive positive negative 
sCD3 negative positive negative positive 
TCR complex - δ - α 
TCR gene germline rearranged germline rearranged 
EBV TR clonal clonal clonal clonal 
Cytogenetic 
abnormalities 
complex, incl. 
6q abnormality 
complex incl. 
6q abnormality 
complex complex 
Table 7 Characteristics of SNT and SNK cell lines established from ENKTL and CAEBV  
Adapted from references
562,709
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Expression and regulation of EBV-encoded genes in T/NK 
lymphoproliferations  
Published data, based on both primary material
73,564-565,610
 and cell lines established from patients 
with ENKTL and CAEBV
562
, are consistent with a restricted „Latency II‟ pattern of viral gene 
expression. However, interpretation of these data are somewhat limited by the lack of quantitative 
analyses at the mRNA level. We therefore began by characterising a number of IL-2-dependent 
T/NK cell lines, originally established from Japanese patients and kindly provided by Dr Norio 
Shimizu, Tokyo, Japan. A summary of the clinical and phenotypic characteristics is shown in 
Table 7, with data derived from the original cell line descriptions
562,709
.  
Figure 28A shows Western blot data of cell lysates from these four cell lines, compared to a LCL 
control and an EBV-negative NK leukaemia line (NKL
303
) and figure 28B represents RT-Q-PCR 
results. As anticipated, and consistent with a restricted pattern of latent gene expression, EBNA2 
is absent from all T/NK lines. Expression of EBNA1 protein is seen to be substantially lower in all 
four T/NK lines compared to a LCL, corroborated by proportionally lower levels of Qp-initiated 
transcripts. The difference in EBNA1 protein size is attributable to the variable Gly-Ala repeat 
domain
21
.  
LMP1 protein levels of the two ENKTL tumour lines (SNK6 and SNT8) greatly exceed that of a 
LCL, whilst the two CAEBV-derived lines exhibit considerably lower levels. Applying primers 
within conserved sequences spanning the exon 2–exon 3 junction region (identified by sequence 
analysis of a panel of virus isolates from different geographical regions
133
), initial Q-PCR assays 
for LMP1 mRNA were entirely negative. This was resolved by using an alternative probe
133
 
(based on the Chinese
25
 rather than B95-8
21
 sequence) for assaying the T and NK lines, whilst 
the standard probe was maintained for the LCL. We confirmed the presence of a corresponding 
polymorphism in the SNT and SNK lines by sequencing of LMP1 exon 2 and 3. No evidence of 
further sequence changes relevant to the PCR primers/probes were seen (data not shown). 
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Figure 28  ENKTL and CAEBV cell lines display a Latency II pattern of viral gene expression 
Panel A is a Western blot probed with antibodies to EBNA1, EBNA2, LMP1, and LMP2A compared 
with a LCL and an EBV-negative NK line (NKL). Calregulin served as a loading control. 
Panel B shows RT-Q-PCR results for Qp-initiated EBNA1 and spliced LMP1 and LMP2A transcripts. 
All data is normalised to GAPDH transcript levels. Data for Qp is expressed relative to the BL line 
Rael, whereas LMP1 and LMP2A are relative to an a LCL, assigned a value of 1 
Interestingly, the magnitude of difference in LMP1 protein levels between cell lines are not 
precisely mirrored at the mRNA level. SNK6 LMP1 transcript levels are only marginally higher 
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than the comparator LCL despite a much greater difference seen at the protein level. More 
strikingly, SNT8 LMP1 mRNA levels are lower than the LCL, whilst the protein appears more 
highly expressed.  
With regard to LMP2A, using a monoclonal antibody to the N-terminus of the protein, no 
expression was evident in any of the 4 T/NK lines, concurring with a virtual absence (≤10-3 of a 
LCL) of spliced LMP2A transcripts. This issue is explored further in the next chapter (Results part 
III).  
Being interested in the high expression of LMP1 in the two ENKTL lines, we examined expression 
of this membrane protein at the single cell level. Immunofluorescence staining for LMP1 
expression in SNK6 and SNT8 is shown in Figure 29 and, similarly to a LCL shows 
heterogeneous expression between cells, with focal, polarised membrane staining evident within 
individual cells. For SNK6, the majority of cells are seen to express LMP1, albeit at variable 
intensity, whilst levels in SNT8 are generally lower or just at the threshold of immunofluorescence 
detection. Notably, higher levels of LMP1 are expressed in the larger cells within the SNT8 
culture. These data are pertinent as the published studies of primary ENKTL tumours describe 
LMP1 expression as limited to a subset of tumour cells
73
 although the proportion of LMP1
+
 cells 
can vary substantially from tumour-to-tumour
614
. For the CAEBV lines SNK10 and SNT16, less 
intense expression was seen in a majority (>50%) of cells (data not shown), similarly to the 
smaller cells in the SNT 8 culture.   
We therefore turned our attention to primary ENKTL tissue sections, donated by patients 
diagnosed in the UK, and applied immunohistochemical stains for LMP1 using the CS1-4 
antibody
681
. In 7 cases examined, by contrast with the cell line data but consistent with previous 
studies
73
, LMP1 was restricted to minority of EBER
+
 T/NK tumour cells (Figure 30). 
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Figure 29 LMP1 is heterogeneously expressed in the majority of cells in ENKTL lines 
Phase contrast immunofluorescence microscopy of SNK6 and SNT8 ENKTL tumour cells stained 
with MAbs CS1-4. DAPI is the blue nuclear stain and red fluorescence indicates LMP1 protein.  
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Figure 30  In primary ENKTL tissue, LMP1 expression is restricted to a sub-population of 
EBER
+
 malignant cells 
EBER in-situ hybridisation on a 4µm formalin-fixed, paraffin-embedded ENKTL tissue section 
(optical magnification  x200). Courtesy of Dr Simon O’Connor, Department of Histopathology, 
Nottingham University Hospitals.  
Immunohistochemical stain of a 4µm formalin-fixed, paraffin-embedded ENKTL tissue section using 
CS1-4 antibodies. The image was captured with a Nikon CoolpixE995 digital camera, via a Nikon 
Eclipse E400 microscope (optical magnification  x400). 
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Together these data raised a number of questions concerning the role of LMP1 expression in 
initiation and/or potentiation of T/NK lymphomagenesis as well as factors governing its 
expression in vivo and in vitro. On this latter point, we were interested in work by Kis et al that 
examined cytokine-mediated regulation of LMP1 expression in vitro in the absence of EBNA2
114-
115
. In the context of IL-2 dependent ENKTL cell lines, those authors showed that removal of IL-2 
resulted in a fall in levels of LMP1 protein, and cytokines such as IL10
114
, IL15 and IFN
115
 could 
restore LMP1 protein expression in the absence of IL-2. Focusing our investigations on the role of 
LMP1 in the pathogenesis of ENKTL, we wished initially to reproduce and extend these findings 
to include a quantitative analysis at the transcriptional level. Figure 31 represents data from a 
time-course analysis following IL-2 depletion from the standard culture media of SNK6 (page 88). 
Immediately following the harvest of an aliquot of cells to represent day 0, the cells were 
repeatedly washed in RPMI/10% FCS, including 30 minutes incubation at 37C, to ensure reliable 
depletion of IL2. Thereafter the cells were cultured in their original media (with 10% HS) but 
without IL2. Cell proliferation was clearly impaired and by day 6 the majority of cells appeared 
unhealthy by light microscopy. At this stage, the culture was divided into three: replenishment of 
IL-2, addition of IL-15 or no change. On the days indicated, cells were harvested and centrifuged 
on a density gradient (Lymphoprep
TM
) in order that only viable cells were assessed for protein 
and mRNA analysis.  
Panel A shows RT-Q-PCR data: the initial (day 0) LMP1 mRNA value was adjusted to 1 and 
subsequent values represented relative to this. A substantial fall in LMP1 transcripts is evident by 
24 hours and does not recovery spontaneously in the absence of IL2. By day 6 LMP1 transcripts 
are less than 10% of the original value but are considerably restored, although not completely, by 
48 hours of exposure to either IL2 or IL15. Panel B is a Western blot showing corresponding 
expression at the protein level. Consistent with previous data
115
 a fall in LMP1 protein is seen and 
is mirrored by mRNA levels, although the fall in protein level appears to lag behind the transcript 
changes.  
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However, in terms of the observed cell phenotype – impaired proliferation and eventually cell 
death - we were unable to delineate the effect of IL2-withdrawal per se and loss of LMP1 
expression. In order to resolve the relative contributions of LMP1 and IL2 to cell survival and 
proliferation, an experimental system was required whereby LMP1 expression could be regulated 
independently of IL-2. 
Optimisation of in vitro gene delivery to primary NK cells and lines 
With the above data in mind and with the aim of determining the contribution of LMP1 to the 
growth and survival of ENKTL tumour cells in vitro, we began by testing different ways of 
delivering LMP1-expression systems to the SNK and SNT cell lines. It quickly became clear that, 
using electroporation methods, the majority of these cell lines were very difficult to transfect either 
due to substantial cell death and poor viability post-transfection (SNT8) or extremely inefficient 
plasmid transfection (SNK10 and SNT16). Only the SNK6 line was sufficiently robust and 
„transfectable‟ to allow conduct of these experiments. 
Using our laboratory‟s standard method of electroporation (page 107-8) it was possible to deliver 
small expression plasmids into 10-20% of the SNK6 population, albeit with high rates (typically 
≥60%) of associated cell death at 24 hours (data not shown). This could be further optimised 
using the Amaxa (Lonza) electroporation system. However, we wished to establish a stable, 
inducible system of LMP1 expression and so initially adopted the pRTS-CD2 vector used 
previously within our laboratory
55
, a derivative of the pRTS-1 expression plasmid
710
. This plasmid 
carries a truncated rat CD2 gene, the EBV origin of replication (oriP) and the EBNA1 gene (for 
episomal maintenance), in addition to a bi-directional doxycycline (dox)-regulated promoter 
controlling expression of GFP and truncated NGF receptor in one direction and LMP1 in the other 
direction
711
.  
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Figure 31 IL2 deprivation of ENKTL cell lines results in a fall in LMP1 mRNA and protein 
levels, that are restored by IL2 or IL15 treatment. 
 
Panel A shows RT-Q-PCR data of LMP1 mRNA levels over a time-course of 8 days; RNA was 
extracted from harvested cells on days indicated. LMP1 transcripts were normalised to GAPDH and 
compared to the Day 0 level (ascribed a value of 1). Error bars indicate standard deviations from a 
mean value of PCR performed in triplicate. 
 
Panel B is the corresponding protein expression data for identical time-points, assayed by Western blot 
with CS1-4 antibody. Calregulin serves as a loading control. 
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Figure 32, Panel A shows the most efficient transfection data from a large series of 
electroporation experiments. The small eGFP plasmid was efficiently transfected into SNK6 using 
the Amaxa nucleofection system, albeit associated with high cell mortality, but the substantially 
larger pRTS-CD2 plasmid was more challenging. An extensive series of optimisation experiments 
achieved a maximum transfection efficiency of approximately 8% (applying a combination of 
220V, 950µF with 5µg pRTS-CD2-LMP1 plasmid). The next challenge was to purify the 
transfected population and an initial approach of using rCD2 as the selection antigen was greatly 
suboptimal due to very low surface levels of rCD2 apparent on transfected SNK6 cells. We 
therefore took the alternative approach of inducing GFP expression (by addition of doxycycline) 
followed by FACS. By undertaking multiple transfections in parallel (for example 10 cuvettes of 
10
7 
cells), we were able to collect a small but pure population (≥95%) of GFP-expressing cells for 
subsequent expansion in culture (without doxycycline) and experimental use. However, following 
a 10-14 day culture period after cell-sorting, the pRTS-CD2-LMP1 plasmid (and the pRTS-CD2 
control vector) was consistently lost from the SNK6 cells; the cultured cells were <5% GFP-
positive when reassessed by FACS (data not shown). 
Faced with this setback, we abandoned the pRTS-CD2 system and turned to lentiviral constructs 
in an attempt to achieve efficient, stable and inducible LMP1 expression. Pilot experiments to test 
the feasibility and efficiency of this approach used a GFP-expressing lentiviral construct, originally 
generated by Dr Graham Taylor in our laboratory. Figure 32, panel B demonstrates evidence of 
efficient lentiviral infection of SNK6, as assessed by FACS at 48 hours. 
These encouraging experiments coincided with collaborative discussions with Professor WC 
Chan, Omaha, Nebraska who had recently published data on genome-wide transcriptional 
changes of resting and IL2 stimulated NK cells
712
 and subsequently compared this to cellular 
changes in NK malignancies
713
. These extensive transcriptional datasets provided a unique  
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Figure 32 Efficiency of transfection/transduction of NK cell lines and primary cells: 
Flow cytometric histograms of transfected/transduced SNK6 tumour cells with GFP-expressing 
vectors. The black bar indicates percent of GFP-expressing cells (green plot) compared to the mock 
transfected/transduced population (black plot). 
Panel A shows data at 48 hours following electroporation using a small eGFP plasmid (left plot) and a 
larger, stable, inducible expression plasmid. 
Panel B shows data at 72 hours following infection of SNK6 with a GFP-expressing lentivirus.  
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Figure 33 Phenotypic analysis and lentiviral transduction of IL-2-stimulated peripheral blood 
human NK cells 
Panel A Single-colour flow cytometric histograms of primary NK cells stained with PE-conjugated 
CD56 (top plots) and CD16 (bottom plots) MAbs (x axis = log10 fluorescence).Black-shaded 
histograms represent the antigen-expressing population compared to the relevant isotype control 
(unshaded plots).  
Panel B shows GFP expression data at 72 hours following infection of cultured primary NK cells with 
a GFP-expressing lentivirus. Green plots represent transduced population, compared to un-transduced 
NK cells (black plots).  
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opportunity to assess the role of LMP1 in NK lymphomagenesis, by comparison with a 
transcriptional profile of LMP1
+
 NK cells. We planned to achieve this via lentiviral expression of 
LMP1, in IL-2 activated primary NK cells. This approach would enable us to delineate the effects 
of IL2 and LMP1 at the transcriptional level, assess LMP1‟s contribution to the tumour 
transcriptome and also provide an opportunity for follow-on functional studies of the biological 
effects of LMP1 in a normal NK cell background.  
The schematic shown earlier in Figure 8 (page 87) summarises the protocol for NK cell isolation 
from peripheral blood (page 86).  The principle of this protocol was straightforward: application of 
a cocktail of antibodies to allow elimination of all non-NK mononuclear cells from PBMC, resulting 
in a pure population of untouched NK cells. As described, the majority of peripheral blood NK 
cells comprise the cytotoxic CD56
DIM
 CD16
BRIGHT
 subset whilst the remaining 10% are 
CD56
BRIGHT
CD16
DIM/NEG
 and express the high-affinity heterotrimeric (α) IL-2 receptor328-329. 
Thus, following in vitro stimulation with IL-2 the latter population preferentially proliferate and 
eventually dominate the culture. Figure 33A comprises flow cytometric analyses of CD56 (top 
panels) and CD16 (bottom panels) expression on peripheral blood NK cells. The plots show 
relative levels of antigen expression immediately after isolation, followed by assessment at day 
10 and day 21 by which time the CD56
BRIGHT
 population had typically dominated the culture. 
We next tested the efficiency of lentiviral transduction of these proliferating, IL2-sensitive NK cells 
using the constitutive GFP-expressing lentiviral vector. Figure 33B represents a typical flow 
cytometry analysis at 72 hours, where 30% transduction efficiency was routinely achieved. These 
encouraging data, together with the opportunity to maximise our understanding of LMP1‟s role in 
NK lymphomagenesis via collaboration with Prof WC Chan, directed us to focus efforts on 
achieving a stable, inducible system of LMP1 expression in primary human NK cells. 
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Figure 34 Principle of the FH1TIR5UTG vector (adapted from Herold et al
714
)  
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A stable, inducible system of LMP1 expression in primary NK cells 
Our aim was to incorporate inducible expression of LMP1 alongside a constitutively expressed 
fluorescent marker to allow identification and sorting of lentivirus-infected cells. We were 
interested to learn of such a lentiviral system, recently designed to express shRNAs in an animal 
model
714
 and are grateful to Dr Marco Herold for providing the requisite vectors for expression of 
mRNA, prior to publication. Figure 34 schematically describes the principle of the FH1TIR5UTG 
vector system adapted from Herold et al
714
. Briefly: a codon-optimised tet-repressor (tetR) and 
eGFP were positioned downstream of an ubiquitin promoter and separated by a T2A peptide
715
 to 
allow reliable and independent expression of both protein products. The gene of interest is placed 
under control of the H1 promoter with tetO (H1t) sequences present at the 3′ end of the TATA 
box. Constitutive expression of the tetR protein blocks transcription and upon addition of the 
inducer doxycycline, the tetR is released, thereby permitting expression of the gene of interest.  
Figure 35 demonstrates the cloning strategy we used to engineer LMP1 expression in this 
lentiviral system, under the control of the TREX-promoter. PCR primers, to amplify LMP1 from 
SNK6
562
 DNA, were designed to contain a BamHI site at the 5‟ end of the forward primer and an 
EcoRI site followed by a PACI site at the 5‟ end of the reverse primer. The LMP1 PCR product 
was first TA-cloned into a Topo vector (Invitrogen) and then released by digestion with EcoRI and 
BamHI restriction enzymes. This was ligated into an intermediate vector (FTGW, figure 35A), 
replacing eGFP and inserting downstream of the in situ TREX-p. Together with the TREX-p, 
LMP1 was cut from this intermediate vector and cloned into the final vector FHIT-IR5-UTG (figure 
35B) which contained the tetracycline repressor protein gene and eGFP under the control of an 
ubiquitin promoter. This final vector was packaged into a lentivirus and used to transduce cultured 
primary NK cells, as described in materials and methods (pages 108-9).  
184 
 
 
 
Figure 35 Cloning strategy for inducible LMP1 expression in a lentiviral vector 
Simplified schematic map of the LMP1 lentiviral vectors, FTGW-LMP1(intermediate vector, top 
panel) and FTREX(LMP1)UTG (final vector, bottom panel). LMP1 expression was controlled by 
virtue of a tetracycline-regulated promoter (TREX-P) whilst eGFP and the tetracycline repressor 
protein (hTetR) were constitutively expressed from the ubiquitin promoter (ubiquitin-P).  
FTREX(LMP1)UTG 
10973bp 
FTGW-LMP1 
9395bp 
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Figure 36 comprises a series of flow cytometric analysis for GFP-expression which confirmed the 
ability of the LMP1-lentirus to infect NK cells and hijack the host cellular transcriptional 
machinery. Transduction efficiencies of 20-40% were consistently achieved in proliferating 
primary NK cells. As for the cell sorting (discussed next) it was found advantageous to gate on 
cells using both FL1 and FL2 fluorescence channels without compensation, in order to distinguish 
genuine GFP expression from auto-fluorescence (Figure 36, lower panels). Concomitant with a 
fall in the proportion of GFP
+
 cells in the culture, the intensity of GFP-expression increased and 
both parameters ultimately stabilised.  
Inducible expression of LMP1 in primary NK cells  
We next wished to examine the stringency of repression and the dynamics of doxycycline-
induced LMP1 expression within this lentiviral system.  Aliquots of cultured, lentiviral-transduced 
primary NK cells in which approximately 15% of the cells were GFP
+
 by FACS analysis, were 
treated with incremental concentrations of doxycycline as indicated in Figure 37A. The Western 
blot shown includes SNK6 (the ENKTL cell line from which the LMP1 gene was cloned) and a 
dilution of SNK6 in BJAB (an EBV negative cell line) - to result in approximately 15% EBV 
positive NK cells - as comparators. In the absence of doxycycline LMP1 expression is stringently, 
though not absolutely, repressed. Low concentrations of doxycycline are seen to induce LMP1 
expression in a dose-dependent manner. LMP1 expression levels essentially reached a plateau 
at concentrations greater than 10ng/ml (data not shown). 
Figure 37B demonstrates characteristic membrane staining using MAbs to LMP1 in an 
immunofluorescence assay. The focal, polarised morphology of the protein expression in these 
LMP1-expressing primary NK cells is akin to the SNK6 cell line data shown in Figure 29 
(page169).  
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Figure 36 Stable transduction of primary NK cells with a LMP1-expressing lentivirus  
Flow cytometric plots representing a time-course following infection of cultured primary NK cells 
with a GFP
+
 (LMP1
+
) lentivirus, compared to an untransduced control. The top panels show data 
presented in histogram form whilst lower panels show GFP
+
 cells detected by fluorescence channels 1 
and 2 (uncompensated data)  as applied for gating of subsequent cell sorting.  
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Figure 37 Inducible expression of LMP1 in primary NK cells via a lentiviral vector. 
Panel A is a Western blot probed with antibodies to LMP1. Expression of LMP1 protein in LMP1-
lentiviral-infected primary NK cells, un-induced and induced (at indicated doxycycline 
concentrations) is compared to the SNK6 cell line and a 15% dilution of SNK6 protein in BJAB 
(EBV-negative BL). Calregulin serves as a loading control. 
Panel B shows LMP1 expression in primary NK cells at the single-cell level, by phase-contrast 
immnuofluorescence microscopy. DAPI is the blue nuclear stain and the red fluorochrome represents 
LMP1 expression in the NK cell cytoplasm/membrane.  
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Purification of lentiviral-transduced NK cells and LMP1 transcript quantitation  
As shown in Figure 36, a small but distinct population of GFP
+
 NK cells are readily identified by 
flow cytometry. In order to obtain a purified population of LMP1
+
 primary NK cells for RNA 
extraction and subsequent analyses of transcriptional changes, we used the MoFlo cell sorter to 
separate GFP
+
 from GFP
-
 cells, 48 hours following LMP1-induction with 10ng/ml doxycycline. 
Figure 38A shows a typical fluorescence plot for such a cell-sort, where the lentiviral-transduced 
cells are gated on the basis of GFP as detected by FL1 and FL2 fluorescence channels. GFP-
negative cells were collected as a control. Figure 38B represents a RT-Q-PCR analysis of LMP1 
transcripts in RNA extracted from one such cell sort, compared to the SNK 6 ENKTL line and a 
LCL. In this instance the GFP
+
 NK cells were 97% pure, whilst the GFP- population was 99.5% 
pure on reanalysis. Expression of LMP1 mRNA in the transduced primary NK cells is comparable 
to that of the SNK6 line, whilst transcripts can also be detected in the GFP- population at a level 
in excess of that explicable by the negligible GFP
+
 contamination. The reason for this is unclear 
but may represent LMP1 transcription from a population of transduced cells with insufficient GFP 
expression for fluorescent detection.  
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Figure 38 Purification of lentiviral-transduced NK cells and LMP1 mRNA quantitation   
Panel A: Gating strategy (MoFlo cell-sorter) for isolation of purified GFP-expressing lentiviral-
infected NK cells. GFP positive cells were isolated as indicated via fluorescence detection in channels 
1 and 2 (uncompensated data).  
Panel B: RT-Q-PCR data of LMP1 transcript expression in purified GFP
+
/- NK cells from the cell-sort 
shown in panel A. Cells were treated with 10ng/ml of doxycycline 48 hours previously to induce 
LMP1 expression; RNA was extracted immediately following cell-sorting. Transcript levels were 
normalised to GAPDH and compared to those seen in the SNK6 line and a LCL (ascribed a value of 1) 
assayed in parallel.  
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Discussion (II): EBV gene expression in NK and T cell malignancies 
and studies with LMP1 
Latent EBV gene expression in NK and T cell lymphoproliferative disease has been generally 
regarded as a Latency II pattern, although this description has been largely based on a small 
number of semi-quantitative studies
73,564-565,610
. Comprehensive, quantitative analyses have been 
hindered by the rarity of these malignancies and the related challenge of obtaining good quality 
viable tissue for study; particularly as ENKTL tissue is frequently necrotic
474
. Based on available 
data it appears that a majority of ENKTL tumour cells within a lesion are of latency I type whilst, at 
a given point in time, only a subpopulation of cells additionally express LMP1
73
 - the number of 
which can vary substantially between tumours
614
. Expression of LMP2 has been largely 
unresolved and is investigated further in results Part III.  In the context of CAEBV, initial non-
quantitative analyses of PBMC detected Qp, LMP1 and LMP2A transcripts in some donors, 
although LMP1 was seen in less than half the samples analysed and, when expressed, often at 
apparently low levels
564
. A follow-up, quantitative study
563
 of CAEBV PBMC, has confirmed 
heterogeneity of LMP1 expression between donors; undetectable in one-third of cases, whilst 
often low in others. However, single-cell analyses for LMP1 were not performed. 
Our quantitative analyses of T/NK cell lines, derived from Japanese patients with ENKTL and 
CAEBV, support the existence of a latency II pattern of viral gene expression (Figure 28, page 
169) but, by contrast to the situation apparent in primary tissue, the majority of tumour cells 
express LMP1 (Figure 29, page 170). These observations are pertinent both for the use of these 
cell lines as representative in vitro tumour models and for understanding the regulation of LMP1 
expression in vitro and in vivo.  
It is conceivable that LMP1 expression independently provides a survival advantage amongst 
T/NK tumour cells, promoting outgrowth of this subpopulation in vitro and thus the establishment 
of a cell line representative of the parent. However, because corresponding data is not available 
on LMP1 expression at the single-cell level for the specific tumours from which these cell lines 
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were established
562
, it remains difficult to be certain how representative the observed LMP1 
expression is. Our own analysis of LMP1 expression in primary tissue at the mRNA level (Figure 
39 and discussed further in Results Part III) illustrates substantial heterogeneity between tumours 
– consistent with previous immunohistochemical studies614. Interestingly, a recently established 
ENKTL cell line (derived from a Caucasian patient with disseminated ENKTL) kindly donated by a 
French group
716
, has dramatically lower LMP1 mRNA levels than SNK6 and SNT8 (data not 
shown). The significance of this is unclear but cautions against the interpretation that all ENKTL 
lines express higher LMP1 than CAEBV lines. 
 
 
Figure 39 Inter-tumour heterogeneity of LMP1 mRNA expression in ENKTL biopsies 
Quantitative RT-PCR results of LMP1 transcripts. LMP1 Ct values are adjusted for GAPDH Ct 
values. Ct0 is the assay threshold of detection. The left y-axis represents (Ct0-Ct), while the right-hand 
y-axis shows the equivalent fold difference in transcript levels. RNA was originally extracted from 
frozen ENKTL biopsy sections (1-5) used in a previous study
713
 and high-quality, random-primed 
cDNA was kindly donated by Professor WC Chan, Omaha, Nebraska. SNK6 cell line and cultured 
primary NK cells served as positive and negative controls respectively.  
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A further level of complexity is that considerable heterogeneity of LMP1 is seen within tumour 
lines; at the threshold of immunofluorescence detection in some cells whilst highly expressed in 
adjacent cells. In fact similar observations have been made in LCLs, where LMP1 levels vary 
among individual cells such that the difference between the highest and lowest 5% of cells may 
be as great as 100-1000fold
717-718
. Using an RT-Q-PCR assay that detects „total‟ LMP1 mRNA 
(i.e. does not discriminate between ED-L1 or TR-L1 promoter usage), we noted a marked 
discordance between levels of protein and trancript in SNK6 and SNT8. This was seen both in 
standard culture conditions (Figure 28, page 167) and following IL-2 withdrawal (Figure 31, page 
173), where protein expression is substantially higher than may be expected for the transcript 
level (as compared to a LCL within the same assays). This observation was unexpected as LMP1 
is a relatively short-lived protein with a half-life of 2
719
 to 5
720
 hours in B cells, but the situation in T 
and NK cells could be quite different; a less labile protein may not be so susceptible to temporal 
changes in rates of new protein synthesis. Interestingly, a recent study reported a phenomenon of 
temporal fluctuations in LMP1 levels within individual cells, observed by isolating LMP1
HIGH
 and 
LMP1
LOW
 subpopulations from a LCL
721
. To explain the rapid fluctuation, the authors propose a 
model in which LMP1 drives its own synthesis through an autocatalytic route until a threshold is 
reached at which the protein induces autophagy and, thereby, its own degradation. On a similar 
note, fluctuating LMP1 levels are seen to demonstrably impact on the level of specific T cell 
recognition - mediated through LMP1‟s dose-dependent activation of HLA class I expression711. 
It is also likely that regulatory factors governing LMP1 expression in vitro and in vivo differ in the 
two environments; either the existence of potent in vitro signals augmenting expression and/or, 
loss of repressive factors present in vivo. On this point, the influence of specific cytokines on 
LMP1 expression in ENKTL cells in vitro had been described
115
 and we confirmed these findings, 
showing that the effect is transcriptionally mediated (Figure 31, page 173). Relevant to this 
observation is that IL-2 is a potent activator of the JAK/STAT pathway in NK cells
712
 and that both 
known LMP1 promoters (page 11-12 and figure 3, page 13) respond to activation of the 
JAK/STAT pathway, with evidence of functional STAT-binding motifs at both sites
108,110
. Although 
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it is reasonable to assume that the EBNA2-independent, L1-TR promoter (pages 11-12 and figure 
3, page 13) is the principal driver of LMP1 transcription in T/NK cells, this remains to be formally 
shown. pL1-TR is transcriptionally active in the other latency II tumours, NPC
68,81,108
 and HL
108
 
but, as non-quantitative assays have been applied, there remains some doubt as to which 
promoter dominates in these tumours
124,108
. STAT3 was specifically implicated in activation of L1-
TR, via the kinase v-Src
108
. Interestingly, STAT3 has been recently implicated in survival and 
proliferation of ENKTL cells in vitro, alongside evidence of constitutive STAT3 activation in 
ENKTL tissue biopsies
716
. 
Appreciation of the influences of such regulatory factors allowed important methodological 
lessons to be learnt during our investigations. Experimental culture conditions, including IL2 
concentration and type/batch of serum, were seen to substantially influence LMP1 protein 
expression. Faced with these confounding factors careful control of culture conditions within 
experiments was required, but to meaningfully address the function of LMP1 we needed to 
establish a system of inducible LMP1 expression impervious to the influence of cytokines. 
We encountered considerable difficulties in efficiently transfecting and maintaining plasmids 
within T/NK lines, but ultimately established a lentiviral system that can demonstrably deliver 
individual EBV genes into a normal NK background. Furthermore, effective transcriptional 
repression in the absence of doxycycline and dose-dependent inducibility (Figure 37A, page 183) 
of LMP1 will allow both genotypic and phenotypic analyses of its role in the initiation and/or 
potentiation of T/NK lymphomagenesis. The CD56
BRIGHT 
NK population is most amenable to in 
vitro studies given its proliferative response to IL-2 and indeed the available data suggests this 
may be the apposite NK population to study in the context of ENKTL
473,716
. Immunofluorescent 
analysis of LMP1
+
 primary NK cells (Figure 37B, page 183) showed that the membrane 
localisation and apparent focal aggregation of the protein to be similar to the pattern observed in 
SNK6 cells (Figure 29, page 169). Indeed, in B cells, the anatomy of LMP1 localisation in the cell 
membrane is thought to be critical for its effective function
722-723
 . Interestingly, a study that 
transfected a LMP1 plasmid into EBV-negative T cell lymphoma lines (including CEM117) showed 
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that expression of the viral protein was exclusively restricted to the nucleus and, accordingly, 
appeared to lack associated signalling functions seen in B cells
724
. Time considerations did not 
permit a formal assessment of the functions of LMP1 expressed in primary NK cells, but the 
pattern of expression at the single-cell level infers that the viral protein will maintain signalling 
capabilities described in B cells. 
If time had permitted, planned experiments included a global transcriptional mRNA array, using 
an Affymetrix U133 platform. RNA from IL2-stimulated primary NK cells from the same donor, 
transduced with a similar lentivirus (made by ligation of the FTGW vector without insertion of 
LMP1) (Figure 35, page 180), have been generated in parallel as a control for this array. 
Comparison of this transcriptional profile with existing data on resting, IL2-stimulated and 
malignant NK cells may allow some insight into the respective roles of IL2, LMP1 and other EBV-
encoded transcripts. Figure 40 is a schematic outlining this proposal, hypothesising that 
expression of a distinct group of genes, common to LMP1
+
 NK cells and ENKTL tumour tissue, 
may exist: either within a subpopulation of malignant cells or more widely expressed at the 
transcript level in primary tumours. Differentially expressed genes could be subsequently 
validated both by RT-Q-PCR and protein analyses in the same LMP1-expressing NK cells and in 
primary ENKTL/CAEBV tissue/cells. On this note, during the course of these investigations we 
have established collaboration with the ongoing International T cell project (CI Professor Massimo 
Federico, Modena, Italy). This prospective study encompasses collection of clinical data and 
diagnostic biopsy material of all mature T and NK cell neoplasms – of which 50-100 ENKTL 
biopsies are anticipated. This affords a unique opportunity to examine viral and cellular gene 
expression in a large, pathologically and clinically well-defined, cohort (from patients of various 
ethnicities) and correlate with response to treatment and clinical outcome. Genes of interest 
identified in the LMP1-array and validation studies can be addressed in this group. These studies 
would be complemented by characterising the apoptotic and proliferative phenotype of LMP1
+
 NK 
cells, where the effect of cytokines including IL-2 can also be evaluated. 
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Figure 40 Schematic outlining experimental plan for global gene expression analysis of LMP1-
expressing primary NK cells. 
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Results (III): Mystery of the missing target§§§ 
Introduction  
As discussed in the introduction (pages 68-70 and 76-79), a majority of patients with ENKTL and 
CAEBV will fail to respond to, or relapse following, conventional chemo- and/or 
radiotherapy
473,561,623,628
. Novel therapeutic approaches are therefore urgently required for the 
spectrum of EBV-associated NK- and T-cell malignancies. In the context of PTLD, expression of 
the full complement of EBV proteins has permitted successful therapeutic targeting of this 
disease with EBV-specific cytotoxic T cells (CTLs) with the resultant clinical outcome data serving 
as a proof-of-principle for such an approach
416,421
. For EBV
+
 malignancies with a more restricted 
pattern of gene expression, in the absence of the highly immunogenic EBNA3 family of proteins, 
such an approach has been more challenging
434
. However, more recent experience with EBV
+
 HL 
has shown that infusion of polyclonal autologous CTLs containing augmented LMP2-specificities, 
achieved via an in vitro protocol of LMP2-overexpression in antigen-presenting cells
396
, can result 
in meaningful disease responses including attainment of CR
395
. These encouraging data open up 
the possibility of adopting a similar approach in T/NK lymphoproliferations and indeed preliminary 
data have suggested responses in this disease group
395
. However, a fundamental prerequisite to 
any CTL-based therapy is that an appropriate cognate antigen is present within the tumour cell; in 
T/NK lymphoproliferations the expression of LMP2 has been far from clear.  
In the context of CAEBV, non-quantitative PCR studies of PBMC and cell lines demonstrated 
expression of LMP2 mRNA, but did not distinguish between the LMP2 species
564-565
 and no 
analyses of protein expression have been available.  
                                                          
§§§
 Chapter title originally used for an Inside Blood commentary by Richard Frederick Ambinder, Johns 
Hopkins School of Medicine (reference 725. Ambinder RF. Mystery of the missing target. Blood. 
2010;116(19):3691-3692.) in relation to the Plenary Paper (reference 726. Fox CP, Haigh TA, Taylor GS, et al. 
A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK and T cell 
lymphoproliferative disease encodes a target for cellular immunotherapy. Blood. 2010. ) containing data 
presented within this chapter of the thesis. 
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For ENKTL, no convincing evidence of LMP2 protein expression has been presented, whilst non-
quantitative PCR studies suggest low or absent levels of both LMP2A and 2B in primary 
tissue
73,610
. Against this background, we decided to investigate the expression of LMP2 in T/NK 
malignancies and its utility as a CTL-target. 
Antigen expression and presentation in ENKTL and CAEBV cell lines 
Before investigating LMP2 as a putative immunologic target in ENKTL and CAEBV, we first asked 
whether the target malignant cells have retained the capability to process and present antigen, 
noting that defects in the MHC class I/transporter associated with antigen processing (TAP) 
pathway have been described in EBV
+
 BL
458
. Expression of surface HLA class I and II complexes 
was confirmed in all 4 EBV-positive NK/T tumour cell lines analysed by flow cytometry. Figure 
41A shows SNT 16 and SNK 6 as representative examples demonstrating moderate to high 
expression of surface HLA class I, while HLA class II expression was equivalent to levels in an 
LCL. Western blot analysis of cell lysates (Figure 41B) shows total MHC class I and TAP levels to 
be broadly equivalent across cell lines, and comparable with an LCL. 
 
The original descriptions of the SNK and SNT cell lines, demonstrating presence of LMP1 and 
absence of EBNA 2 protein
562,709
, suggested a Latency II pattern of viral gene expression but did 
not address LMP2 expression. We initially probed a Western blot with the 14B7 MAb
131
 and 
detected LMP2A protein in the LCL control but not in any of the ENKTL or CAEBV cell lines 
(Figure 42A). However, because the available monoclonal antibodies for detection of LMP2 
protein all recognise defined epitopes within the LMP2A-unique N terminus
130
, the LMP2B protein 
cannot be detected with this technique. A schematic of the exon structure and conventional 
splicing pattern of LMP2A and LMP2B mRNAs, traversing the terminal repeat (TR) region, is 
shown in Figure 42B. Consistent with the immunoblotting data, LMP2A transcripts were virtually 
undetectable in all cases by RT-Q-PCR Figure 42C.  
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Figure 41 Antigen processing and presentation capability of EBV
+
 T and NK tumour lines. 
Panel A: Flow cytometric analysis of cell surface HLA class I and II. Representative data from 2 lines 
(SNT 16 and SNK 6, black shading) compared with a LCL (dark grey shading) and isotype controls 
(light grey) are shown.  
Panel B: Western blot of whole cell lysates probed with antibodies to transporter associated with 
antigen processing (TAP) 1 and 2 and total cellular class I heavy chains (HC 10) in NK- and T-cell 
lines, shown relative to levels in a LCL. Calregulin serves as the loading control.  
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We then used a combination of primers to amplify across the exon 1B-exon 2 junction by RT-Q-
PCR and found that LMP2B transcripts were also expressed at extremely low levels in all 4 NK- 
and T-cell lines (Figure 42C).  
 
Figure 42 Expression of LMP2 in the context of ‘Latency II’ T and NK tumour lines 
A. Western blot of whole cell lysates of EBV-positive NK and T cell tumour lines probed with 14B7 
MAb to LMP2A alongside a LCL and an EBV-negative NK line (NKL). 
B. Schematic indicating the exon structure of the LMP2 gene and splicing patterns of conventional 
LMP2A and LMP2B transcripts, across the terminal repeat region of the genome. Each transcript 
contains a unique 5’ first exon (‘1A’ for LMP2A, shaded grey and ‘1B’ for LMP2B, shaded white).  
C. RT-Q-PCR for LMP2A and LMP2B mRNA. Grey and white shaded bars represent levels of 
LMP2A and LM2B transcripts respectively, relative to a LCL. Each data point was assayed in 
triplicate and error bars indicate standard deviations from the mean value.  
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To exclude the possibility that the apparent lack of LMP2 mRNA expression was due to sequence 
variation within the LMP2 gene, we performed genomic sequencing of LMP2 exons 1 and 2 in all 
4 cell lines. Figure 43 shows the exon sequences corresponding to the PCR primers (yellow 
shading) and probe (red shading), aligned against the prototype B95-8
21
 and Chinese GD1
25
 
strains and highlights the base substitutions (both coding and silent). This confirmed that the 
LMP2 gene was intact in these cells and aside from previously described
156
 single-base 
polymorphisms detected in SNT16 compared with the prototype B95-8 EBV, corresponding to the 
common reverse LMP2 primer
133
, there were no other sequence variations to explain the low 
transcript levels detected by PCR. The RTQ-PCR data for SNT16 shown in Figure 42C was 
obtained using an alternate reverse primer, accordingly designed to account for the 
polymorphisms shown.  
Thus, the finding of extremely low (100-1000 fold lower than a LCL in most cases) LMP2A and 
LMP2B mRNA levels in the T/NK lines appeared to be a genuine result. However, it was difficult 
to reconcile these findings with emerging clinical evidence suggested of LMP2-CTL-therapy-
mediated responses in ENKTL and CAEBV in vivo (Dr C. Bollard, Houston, personal 
communication January 2009 and reference
651
). Noting recent evidence suggesting that MHC 
class I epitopes are predominantly generated from rapid degradation of newly-translated 
(defective) ribosomal products
727
, we questioned whether these low LMP2 transcript levels were 
sufficient for CTL recognition in vitro. Consequently, we set-out to investigate CTL recognition of 
LMP2 in these T/NK lines. 
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Figure 43 DNA sequence alignment of LMP2A exon 1 and 2 coding sequences relevant to RT-Q-
PCR primers/probe 
 
Segments of LMP2A coding sequences of all four SNT and SNK cell lines relevant to the RT-Q-PCR 
primers/probe and aligned against the prototype B95-8 and Chinese GD1 strain sequences. Each dot 
represents a base unchanged from the prototype sequence whilst base substitutions are specified; lower 
case synonymous, upper case replacement. The highlighted regions in yellow and red correspond to 
the sequence targets of the 5′ and 3′ PCR primers and Taqman probe respectively. The bases 
highlighted in green are polymorphisms identified in the SNT 16 sequence corresponding to the 
reverse LMP2 PCR primer.  
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LMP2-specific T cell recognition of EBV+ T/NK tumour lines 
Polyclonal LMP2 T-cell effectors recognise and kill ENKTL and CAEBV cell lines 
We first asked whether the polyclonal CTL preparations generated from CAEBV and ENKTL 
patients
395,651
 for clinical use (containing expanded LMP2-specificities), could recognise and kill 
our NK- and T-cell lines in spite of the very low transcript levels. These initial studies were 
performed by Dr Catherine Bollard, Houston, Texas, following collaborative discussions initiated 
by Dr C Fox. Polyclonal CTLs were produced as per Dr Bollard‟s clinical trial protocol 
(ClinicalTrials.gov identifier: NCT00062868) by stimulation of PBMCs from ENKTL patients with 
autologous antigen-presenting cells transduced with a recombinant adenovirus expressing an 
LMP1/LMP2A fusion protein
395-396,728
.The epitope specificities of the CTLs were analysed by 
peptide-loaded pentamer staining
395-396
 and their ability to kill HLA-compatible ENKTL and 
CAEBV tumour lines tested in standard 5-hour 
51
Chromium release assays. Figure 44 comprises 
data from two such analyses: CTLs from patient 1 contained 6.9% and 2.3% CD8
+
 cells specific 
for HLA-A*0201-CLGGLLTMV and HLA-A24-TYGPVFMSL, respectively (Figure 44A top plots), 
while CTLs from patient 2 contained 4.75% and 4.79% CD8
+ 
cells specific for HLA-A*0201-
CLGGLLTMV and HLA-A*0201-FLYALALLL, respectively (Figure 44A bottom plots). In 
cytotoxicity assays, CTLs from both patients killed SNT 16 and SNK 6 at significant levels 
compared with an autologous LCL (Figure 44B). 
Recognition and killing of ENKTL and CAEBV lines by LMP2-specific CD8+ T-cell 
clones 
The observation that these polyclonal CTLs contained considerable numbers of LMP2-specific T 
cells suggested that these cells were the dominant effectors in the cytotoxicity assays, but the 
presence of T cells with other specificities could not be excluded. Thus, faced with paradoxically 
low, or absent, levels of LMP2A and LMP2B transcripts in the T and NK  
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Figure 44 Specific killing of EBV
+
 NK and T cells by polyclonal CTL lines, containing LMP2-
specificities, from ENKTL patients. 
Panel A. Dual-colour flow cytometry of CTL lines derived from two ENKTL patients prepared by ex 
vivo stimulation with LMP2/LMP1-transfected antigen-presenting cells. CTLs were stained with a 
PerCP (Peridinin-chlorophyll protein) conjugated anti-CD8 antibody and with the PE-conjugated 
HLA-peptide pentamers: HLA-A*0201-CLGGLLTMV, HLA-A*0201-FLYALALLL, HLA-A24-
TYGPVFMSL as described in reference
395-396
 ). Numbers within the right upper quadrant of each plot 
indicate the percentage of viable peptide/pentamer-specific CD8
+
 cells. 
Panel B. The CTL lines shown in panel A were tested in standard 51Chromium-release assays for 
their ability to kill EBV
+
 NK and T cell tumor lines. Results are expressed as the mean percentage 
of specific chromium release from the target cells at effector: target ratios titrated from 5:1 to 40:1, 
tested in triplicate. Autologous and HLA-mismatched LCLs were positive and negative controls 
respectively, for each assay. 
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lines, we further examined the specificity of this recognition in our laboratory. Two previously 
characterised CD8
+
 effector clones with different LMP2-peptide specificities (FLYALALLLL, 
TYGPVFMCL)
390,729
 restricted through HLA-A2 (FLY) and -A24 (TYG) respectively, were initially 
tested in standard 18-hour IFN–release assays. Figure 45A shows specific recognition of SNT 
16 by both CD8
+ 
clones, albeit at lower levels compared with HLA-matched LCL targets within the 
same assay. For these 2 effector clones, the immune recognition translated into specific killing, 
as demonstrated using a standard 5-hour 
51
Cr-release assay (Figure 45B). Augmentation of the 
recognition by preloading target cells with excess exogenous cognate peptide indicated that the 
maximum killing of the SNT 16 targets was similar to that of HLA-matched targets, suggesting 
that the weaker recognition of the endogenously LMP2 antigen might reflect differences in levels 
of LMP2 expression or efficiency of FLY- and TYG-peptide processing. Recognition of SNT16 by 
CD8
+
 clones with specificities against LLWTLVVL
390
 and, to a lesser extent CLGGLLTMV
390
, was 
also observed (data not shown). Experimental blocking of surface HLA class I by pre-incubation 
with the W6-32 MAb, substantially reduced recognition of SNT16 by the TYG clone - as 
determined by a >90% reduction in IFN-release (Figure 46). 
In view of these data with the CAEBV-derived SNT16 line, we sought to extend our investigations 
of LMP2-recognition to encompass other EBV
+
 NK and T cell lines. Methodologically, there were 
2 obstacles to overcome: first, to broaden the HLA repertoire of potential LMP2 epitope 
presentation and, second, to resolve the problem of how to measure cytokine production by the 
effector clones in the face of substantial levels of spontaneous cytokine release (including IFN-, 
TNFα and GMCSF) from the other 3 tumour cell targets. To address the first issue, expression of 
a recombinant HLA-A11 molecule in SNK6 and an LCL control was achieved by infection with a 
retroviral construct, allowing us to test for recognition by a HLA-A*1101-restricted CD8
+ 
LMP2 
clone with specificity for SSCSSCPLSK
390
. Expression of an irrelevant HLA allele, HLA-DR1, in 
the target cells using the same retroviral construct served as a negative control. To delineate 
between spontaneously produced IFN- from the SNK 6 target with that from the effector T cells, 
we pre-stained the effectors with CFSE, enabling quantitation of IFN- production in CFSE
+ 
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Figure 45 Recognition and killing of SNT 16 by LMP2-specific CD8
+
 T cell clones through HLA 
A2 and A24. 
 
Panel A. CD8
+
 clones specific for endogenously processed LMP2-derived peptides FLYALALLLL 
and TYGPVFMCL were co-cultured for 18 hours with 10
5
 target cells (gray and black bars indicate 
5000 and 10,000 CD8
+
effectors per well, respectively). HLA-matched and -mismatched LCLs were 
positive and negative controls respectively. Other controls included SNT 16 and CD8
+
 effectors 
cultured alone to assess spontaneous IFN-γ release. Error bars indicate one standard deviation from the 
mean. Results are representative of those seen in 3 separate experiments. Relative to the maximal 
values seen using the same target cells pre-loaded with 5μM cognate peptide, recognition of the 
unmanipulated cells were as follows: FLY (SNT16=14%, LCL=26%), TYG (SNT16=5%, 
LCL=15%). 
Panel B. Lysis of SNT 16 and LCL targets by the LMP2-specific FLY and TYG CD8
+
 clones shown 
in A. Five hour 
51
Chromium-release assays were conducted with SNT 16, HLA class I–matched and 
mismatched LCL targets. Spontaneous release of 
51
Cr was <30% of maximum release. Results are 
expressed as the percentage of specific chromium release from the target cells at the indicated effector-
to-target ratios. Grey lines indicate results following pre-incubation for one hour with 5μM of cognate 
peptide. Results are representative of those seen in 3 different experiments. Error bars indicate one 
standard deviation from the mean. 
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Figure 46 LMP2-specific recognition of SNT16 is restricted through HLA class I 
CD8
+
 clones specific for TYGPVFMCL (5000 per well) were co-cultured for 18 hours with 10
5
 target 
cells (SNT16 and HLA-matched LCL). Targets were pre-incubated with mAbs specific for HLA class 
I (clone W6-32
683
) or controls (YE2/36-HLK antibodies
685
) for 1 hr before introducing effector T cells 
to the assay. IFN- release (ng/ml) is represented as a percentage of the control (class II MAb) result. 
 
T cells by intracellular cytokine staining. These additional, labour-intensive experiments and 
retroviral cloning were performed by Miss Tracey Haigh, to complement a parallel project within 
the immunology group and allowed Dr C Fox to focus on the subsequent molecular 
characterisation work. A representative example of data, derived from Tracey Haigh‟s 
experiments is illustrated in Figure 47A and clearly demonstrates A11-restricted recognition of 
SNK6-A11 by the SSC clone. Notably, recognition of SNK6-A11 cells exceeded the recognition of 
an A11-matched LCL. Finally, to further substantiate the LMP2 specificity of SNK6-A11 
recognition, a recombinant TCR, recently developed in our laboratory (S.P. Lee et al, manuscript 
in preparation) and specific for HLA-A*1101/SSCSSCPLSK was employed. The A11-SSC TCR, 
expressed in a non-SSC specific CD8
+
 clone derived from a healthy donor, was tested against 
SNK6-A11 in a CFSE/IFN-–release assay as before. The results (Figure 47B) confirmed the 
specificity and magnitude of LMP2-recognition of the ENKTL-derived cell line. Taken together, the 
data in figures 45 and 47 clearly demonstrate LMP2-specific T-cell recognition and killing of 
IFN-release: % of unblocked control 
TYGPVFMCL/A24 
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tumour cell lines derived from both CAEBV and ENKTL patients, through a number of epitopes in 
the context of 3 different HLA restrictions. The magnitude of T-cell recognition was comparable 
with an LCL in some instances, and was always greatly in excess of what might be expected from 
the apparent expression of LMP2A and LMP2B transcripts in the tumour lines (Fig 41C, Pg 195). 
 
Figure 47 LMP2-specific T cell recognition of SNK 6 exceeds that of a LCL 
Dual-colour flow cytometry: the x axis represents fluorescence from CFSE-stained CD8
+
 effectors and 
the y axis denotes IFN-γ production as determined by intracellular staining. CFSE-negative cells 
(i.e. LCL or SNK6 targets) have been gated out of this analysis. HLA class I mismatched LCLs and 
SNK6 transduced with a control retrovirus (+control RV) are negative controls. The upper plots within 
panel A and B indicate T cells expressing IFN-γ in response to endogenously-processed peptide, 
whilst the lower plots of each panel show IFN-γ expression by T cells following pre-incubation of 
targets with exogenous cognate peptide. Numbers in the right quadrants indicate the percent of cells 
positive (upper quadrant) or negative (lower quadrant) for IFN-γ production. Panel A shows SSC-
specific CD8
+
 clones tested against HLA-matched LCLs and SNK6-A11. Panel B shows effector T 
cells expressing a recombinant SSC/A11 TCR tested against A11
+
 LCL and SNK6-A11. 
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LMP2 epitope sequences in SNT16  
Previous work analysing LMP2 sequences of virus derived from both healthy donors and EBV-
associated tumours, across a range of ethnicities, had identified that LMP2 epitope-encoding 
sequences were largely conserved amongst isolates
390
. However, to be certain that no significant 
sequence changes were present in the SNT16 line that would preclude the observed T cell 
recognition, we sequenced the full–length LMP2 gene from DNA extracted from these cells. 
Figure 48 is an amino acid alignment of SNT16 LMP2A compared against the B95-8 and Chinese 
GD1 strains. The majority of defined CD8
+
 epitopes are located in the transmembrane domains of 
the protein
391
 (including the five epitopes shown). Aside from a single amino-acid substitution 
corresponding to a non-anchoring amino-acid in TYG and CLG there were no epitope sequence 
changes in SNT 16, reinforcing its legitimacy as a target for specific CD8
+
 effectors. 
We therefore resolved to further investigate expression of LMP2 in these cells to reconcile the 
immunologic data with the paradoxically low LMP2A and LMP2B transcripts. 
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Figure 48 Epitope sequence conservation of LMP2 epitopes in SNT 16: legitimate CD8
+
 T cell 
targets 
 Predicted amino acid sequence of the full-length LMP2A protein, derived from the coding exon 
sequences of SNT16, compared against the prototype B95-8 and Chinese GD-1 sequences.  The 
LMP2B protein starts at amino-acid position 121. Each dot represents an amino-acid unchanged from 
the prototype sequence, whilst sequence changes resulting in amino-acid replacement are shown. The 
key for highlighted regions is as follows:  
Grey:  LMP2A N-terminus      
Yellow: Epitopes for CD8
+
 LMP2-specific T cells     
Green:  Amino-acids common to two epitopes    
Red:  Amino acid polymorphism  
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Identification of an alternative LMP2 transcript 
The schematic shown in Figure 41C, (page 195) indicates the known exon structure and splicing 
pattern of conventional LMP2A and LMP2B mRNAs as seen in LCLs. To address whether 
alternatively spliced or variant LMP2 transcripts may be expressed in our NK- and T-cell lines, we 
initially used conventional end-point PCR to simply ask whether mRNA transcripts comprising 
exons 1-3 (straddling the variably sized terminal repeat region) and/or exons 2-6, (located 3′ to 
the terminal repeat region) were expressed in the tumour lines. While an exon 1-3 product was 
clearly present in the LCL control, such spliced LMP2 transcripts were undetectable in all 4 NK- 
and T-cell lines (Figure 49A top gel). By contrast, using a forward primer located in exon 2 and a 
reverse primer within exon 6 resulted in visible PCR products of the expected size in all 4 cases 
(Figure 49A bottom gel). Interestingly, similarly to LMP1 (Figure 28) the 2 ENKTL lines (SNK 6 
and SNT 8) apparently expressed these LMP2 transcripts at levels comparable with an LCL, 
while the 2 CAEBV lines expressed much lower levels of LMP2 exons 2-6 (Figure 49B). 
In light of this finding, we designed two new RT-Q-PCR assays that amplified LMP2 sequences 
within exon 2 and exon 6 and quantitated their relative expression compared with that seen in a 
LCL. We focused on exon 2 as it represents the first transcribed exon 3′ to the TR region and 
exon 6 as this encodes peptides recognised in the T-cell assays described earlier. We designed 
these assays against sequences within the respective exons to avoid exon-exon junctions in case 
of unidentified splice variants. We found that LMP2 transcripts containing exon 2 and exon 6 were 
highly expressed in SNK 6 and SNT 8, exceeding LCL levels, whereas lower levels 
corresponding to 5%-20% of LCL levels, were detected in SNK 10 and SNT 16 (Figure 5B). 
These results indicated expression of an alternative LMP2 transcript initiated upstream of exon 2 
and pointed to an explanation for the initially paradoxical T-cell recognition data. To eliminate the 
unlikely possibility that these transcripts arose in the conventional LMP2B first exon („1B‟) - 
thereafter „running through‟ the TR region, un-spliced, to exon 2 – we designed a further 
quantitative RTPCR assay. Using a forward primer within exon 1B and a reverse primer in the 3′  
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Figure 49 Expression of a LMP2 transcript containing exons 2 to 6 in EBV positive NK and T 
cell tumour lines 
A: Schematic of LMP2 gene structure and location of RT-PCR primers. B: Products of conventional 
RTPCR (35 cycles) separated and visualised on a 1% Agarose gel. The upper panel shows products of 
RTPCR amplification using a forward primer in exon 1 and reverse primer within exon 3 (F1 and R3 – 
see supplementary table 1), whilst the lower panel shows results using a forward primer in exon 2 and 
a reverse primer within exon 6 (F2 and R6). C: Quantitative RT-PCR assays– using primers and 
probes designed within exons 2 and 6 respectively. Data is expressed using cycle threshold (Ct) 
values, where ‘Ct0’ = assay threshold of detection. LMP2 transcript Ct values are normalised to 
GAPDH Ct values. The left-hand y axis represents ∆(Ct-Ct0), whilst the right hand axis shows the 
equivalent, relative levels of transcript.  
A 
B 
C 
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non-coding region prior to the TR, we excluded the existence of significant levels of such an 
mRNA (data not shown). 
Identification of 5′ sequences of the novel LMP2 transcript in ENKTL and CAEBV lines 
To further investigate the origin of LMP2 transcripts in the NK and T tumour cells, we subjected 
SNK6 RNA to 5′ rapid amplification of cDNA ends (RACE). 5' RACE, or “anchored” PCR, is a 
technique that facilitates the isolation and characterisation of an unknown 5' origin of an mRNA 
template, starting downstream from a defined internal sequence within the transcript
688
. A 
schematic of the procedure is shown in Figure 9 (page 104). 
We initially used a reverse primer within exon 6 (see table 5) for synthesis of first-strand cDNA, 
followed by nested gene-specific primers within LMP2 exons 5 and 4. The final nested PCR 
product was gel-extracted and cloned into TA vectors for sequencing of individual cDNAs (page 
103). The sequences of two novel LMP2 cDNAs (identified in 4 separate cDNA clones obtained 
from SNK6) are shown in Figure 50, initiating upstream of the start codon of exon 2. For cDNA 
clone SNKR2B1d, the 5′ end was identified within the non-coding region upstream of exon 2, but 
not quite within the TR, whilst the longer SNKR2B1j sequence initiated within the last repeat of 
the TR region; the 5′ end is located 84 bases upstream of exon 2. Interestingly, the SNKR2B1j 
cDNA appeared to be „missing‟ a segment compared to the genomic sequence but realigned at 
the start codon of exon 2. The significance of this observation was not further investigated at this 
stage. Importantly, when the same RACE experiment was performed on LCL RNA (analysed in 
parallel), we identified 5′ cDNA ends containing exon 1A or exon 1B upstream of the TR, 
indicating the expected pattern of mRNA splicing (Figure 51).  
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Figure 50 Identification of 5’ ends of LMP2 transcripts by 5′ RACE of SNK 6 cDNA 
5’ RACE products from SNK 6 LMP2 cDNA. cDNA strands amplified from 2 of 7 isolated clones 
(SNKR2B1j and SNKR2B1d) are shown aligned to the B95-8 genome sequence. Grey shading 
indicates LMP2 coding sequence. Runs of G bases (shaded red) represent complementary sequence to 
the annealed poly-DC primer and correspond to the 5′ end of the isolated cDNA. The abridged anchor 
primer (AAP) sequence is highlighted yellow. 
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Figure 51 LCL 5′ RACE sequence: confirmation of LMP2 transcript initiation upstream of the 
TR from a conventional LMP2 first exon  
5’ RACE products from LMP2 cDNA of a LCL control. A representative cDNA clone is shown 
(X50R2B1A) aligned against B95-8 RNA sequence. The run of G bases (shaded red) represent 
complementary sequence to the annealed poly-DC primer and correspond to the 5′ end of the isolated 
cDNA. The abridged anchor primer (AAP) sequence is highlighted yellow. 
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Quantitation of novel LMP2 transcripts in T/NK lymphoproliferative disease 
These results suggested that a previously uncharacterised LMP2 transcript may initiate from a 
hitherto unidentified promoter within the TR of the EBV genome and that this transcript (termed 
LMP2-TR), rather than the conventional LMP2A/2B mRNAs, is preferentially expressed in these 
NK- and T-cell lines. Figure 52A is a schematic showing the location of the 5′ ends of the novel 
cDNAs in the context of the LMP2 gene structure. To confirm that the LMP2-TR mRNA is the 
dominant LMP2 transcript in these cells, we designed a further quantitative RT-PCR assay using 
a forward primer in the intervening sequence between the TR region (see table 5, page 102, for 
primer sequences and co-ordinates) and exon 2; note this assay does not detect conventionally 
spliced LMP2A or LMP2B transcripts, both of which splice directly into the first ATG of exon 2. As 
this assay would also detect residual DNA, all RNA samples were treated with DNASE I and, 
moreover, parallel RNA samples without reverse transcriptase (no RT controls) were included to 
exclude the possibility of contaminating DNA being detected. The quantitative data from this new 
assay are presented alongside levels of conventionally spliced LMP2A and LMP2B transcripts in 
Figure 52B. The novel LMP2-TR mRNA was by far the dominant LMP2 transcript in all 4 ENKTL 
and CAEBV cell lines.  
We next analysed cDNA derived from an additional series of ENKTL and CAEBV cell lines (YT, 
NKYS, HANK1, KA13, SNK1, SNT13
713
). For these cell lines and the subsequent PCR analyses 
of primary tissue (see below) the exon 6 forward primer was substituted for a primer spanning the 
exon 5-6 junction, as the RNA from these samples had not been not treated with DNAse I, and 
included a no RT control as before. In this extended panel of cell lines we found a similar pattern 
of LMP2 transcript expression, in which LMP2-TR dominated in all cases (Figure 53). Consistent 
with previous results, where seen in occasional T/NK cell lines, expression of conventional 
LMP2A and/or LMP2B transcripts was substantially lower (≥100-1000 fold). Notably, the LMP2-
TR mRNA was also transcribed in EBV-transformed B cells, albeit at 30 to 60-fold lower levels 
than in SNK 6 and SNT 8 (Figure 52B). 
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Figure 52 Identification of 5 ends by RACE and quantitation of novel LMP2-TR transcripts in 
NK and T-cell tumour lines. 
(A) LMP2 schematic: numbers indicate the exact 5 ends of 4 of 7 cDNAs identified by RACE (EBV 
genome coordinates: NC007605). Three other 5 cDNA ends identified in SNK 6 (coordinates 19, 80, 
and 83) correspond to the intervening intron and beginning of exon 2.  
(B) Quantitative RT-PCR results of conventional LMP2A (grey), LMP2B (white) and the novel 
LMP2-TR (black) transcripts. LMP2 Ct values are adjusted for GAPDH Ct values. Ct0 is the assay 
threshold of detection. The left y-axis represents (Ct0-Ct), while the right-hand y-axis shows the 
equivalent fold difference in transcript levels.  
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Figure 53 LMP2-TR is the dominant LMP2 transcript in an extended panel of ENKTL and 
CAEBV cell lines 
Quantitative RT-PCR results of conventional LMP2A (grey), LMP2B (white), novel LMP2-TR 
(black) and ‘total’ LMP2 transcripts (green) as judged by the exon5/6 assay. Note that for these PCR 
assays, input cDNA was 2μl in a reaction volume of 20μl, compared to 5μl in 25μl for the cell line 
PCR studies for Figures 47 and 50.)  
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Recognising that observed patterns of gene expression in cell lines in vitro may not necessarily 
be representative of the situation in primary tissue, we turned to biopsies from patients with 
ENKTL. By means of immunohistochemical staining with the 15F9
131
 LMP2A MAb, we found no 
evidence of LMP2A protein expression on formalin fixed biopsy sections from a total of 7 ENKTL 
patients (3 such examples shown in Figure 54A), while an EBV
+ 
polymorphic PTLD biopsy 
included as a positive control demonstrated characteristic membrane/cytoplasmic staining in a 
subpopulation of cells (Figure 54A). Because the LMP2 MAbs engage with the N-terminus of 
LMP2A, detection of LMP2B (and LMP2-TR) is only possible by RT-PCR. We therefore examined 
a second set of biopsies from which good quality RNA, extracted from frozen material, was 
available
713
. While conventional LMP2A and LMP2B transcripts were absent or virtually 
undetectable, LMP2 transcripts were readily detected in 7/7 ENKTL biopsies using RT-Q-PCR 
assays that amplified LMP2 exons 5-6 and TR-initiated transcripts. No signals were seen in 
(EBV-negative) normal NK cells, or in a single case of EBV
+
 aggressive NK leukaemia (Figure 
54B). For the latter ANKL case, we confirmed the EBV positivity of this tumour by demonstrating 
high levels of EBER expression by RT-Q-PCR (data not shown).  
Although the exact transcription initiation site for the novel LMP2-TR transcript in ENKTL and 
CAEBV cells was not precisely mapped, the results of the RT-PCR and RACE experiments infer 
that the promoter lies within the TR region. This situation is somewhat analogous to LMP1 
expression in Latency II NPC cells where transcription is initiated from a promoter within the 
terminal repeats
109
 and raised the possibility that, similarly to the bidirectional LMP1/LMP2B 
promoter active in LCLs
126
, another bidirectional promoter in the terminal repeats might give rise 
to both LMP1 and LMP2 transcripts. On this point, we considered the transcriptional regulation of 
LMP1 mediated by IL2 and other cytokines in the SNK 6 cell line (as presented in Results part II, 
Figure 31, page 173) and asked whether LMP2-TR levels were similarly influenced. Using the 
same RNA samples as analysed in the assay of Figure 31, whereby SNK6 cells were deprived of 
IL-2 stimulation over several days followed by re-stimulation with IL2 or IL15, we also quantitated 
LMP2 transcripts by RT-Q-PCR. 
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Figure 54 LMP2-TR, but not LMP2A or LMP2B, are expressed in primary ENKTL tissue 
A Immunohistochemistry of FFPE tissue sections with antibody clone15F9, specific for LMP2A. 
Images were captured with a Nikon Coolpix E995 digital camera, via a Nikon Eclipse E400 
microscope (optical magnification x400). A case of EBV
+
 B cell PTLD is a positive control. Sections 
from 3 representative cases of ENKTL (i-iii of seven) shown.  
B. Quantitative RT-PCR data using cDNA derived from 7 primary ENKTL frozen tissue biopsies and 
1 EBV
+ 
aggressive NK leukaemia (ANKL) sample. Note that for these PCR assays, input cDNA was 
2μl in a reaction volume of 20μl, compared to 5μl in 25μl for the cell line PCR studies for Figures 
47and 50. 
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Figure 55 shows RT-Q-PCR data from LMP2 exon 6 and LMP2-TR assays performed on these 
samples and compared against LMP1 mRNA levels. For each assay, normalised transcript 
values are expressed relative to day 0 which was assigned a value of 1. Mirroring the pattern 
seen with LMP1 transcripts, the LMP2-TR and exon 6 transcript levels fall rapidly in the absence 
of IL-2 and do not recover spontaneously in its absence. Similarly to LMP1, LMP2-TR transcript 
levels are re-established with IL-2 re-treatment and, to a lesser extent, with IL-15 treatment. With 
these dynamic expression data in mind, we quantitated LMP1 transcripts in a number of T/NK cell 
lines and the same primary ENKTL tissue samples as analysed in Figure 54B. Figure 56 
compares the Δct values (adjusted for GAPDH levels) of LMP1 with LMP2-TR and shows that in 
a majority of both cell lines (panel A) and primary tissue (panel B), a clear correlation of the two 
transcripts is apparent. The notable exceptions were primary biopsy cases ENKTL 6 and ENKTL 
7, with low and high levels of LMP2-TR respectively, where no LMP1 transcripts were detectable.  
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Figure 55 Expression of LMP2-TR is dependent on exogenous cytokines and mirrors expression 
of LMP1 in the SNK6 cell line 
RT-Q-PCR data of LMP1 and LMP2 mRNA levels in the SNK6 cell line. Transcript levels were 
normalised to GAPDH and represented relative to a nominal day 0 value of 1.   
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Figure 56 LMP2-TR expression closely correlates with LMP1 expression in a panel of ENKTL 
and CAEBV cell lines and primary ENKTL tissue 
RT-Q-PCR data of LMP1 and LMP2-TR mRNA levels in ENKTL and CAEBV cell lines (panel A) 
and primary ENKTL biopsies (panel B). LMP transcript Ct values were normalised to cellular 
GAPDH Ct values. The left hand y axis represents ∆(Ct-Ct0
)
, whilst the right-hand axis shows the 
equivalent fold difference in transcript levels. Ct0
 
represents the assay threshold of detection. (Note 
that for these PCR assays, input cDNA was 2μl in a reaction volume of 20μl, compared to 5μl in 25μl 
for the cell line PCR studies for Figures 47 and 50.) 
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Discussion (III) 
Conventional LMP2 expression and T cell recognition of T/NK tumour 
lines 
Results from ongoing clinical studies targeting EBV-encoded proteins in „Latency II‟ malignancies 
have shown promising results
395,651
. However, in contrast to HL
131
 and NPC
132
, where the most 
immunogenic of the available target proteins, LMP2, is demonstrably expressed, the situation in 
NK and T lymphoproliferations remained to be clarified. A single study previously reported the 
presence of conventional LMP2A and LMP2B mRNAs by non-quantitative PCR in some ENKTL 
biopsies, although in the majority of their cases the expression of these transcripts appeared low 
or absent
73
. 
Our results showed that ENKTL and CAEBV cell lines had the machinery for antigen-processing 
and presentation but, interestingly, evidence of LMP2A protein expression was not apparent. 
Moreover, conventionally spliced LMP2A and LMP2B transcripts were virtually undetectable 
using sensitive reverse transcriptase (RT)-Q-PCR assays
37,133
. Although substantial variations in 
LMP2 sequences are uncommon
390-391
, exon 2 polymorphisms (relative to B95-8) have been 
described in NPC
156
 and we therefore applied an alternative RT-Q-PCR reverse primer to 
address these sequence changes. Additionally, we undertook sequencing of the exon 1 and exon 
2 segments in the 4 NK and T cell lines to encompass the regions corresponding to the PCR 
primers and probe. In three cases, no relevant polymorphisms were seen, whilst the single-base 
changes SNT16 were accounted for by the alternate reverse primer
156
. 
The apparent absence of LMP2 expression in these cells raised serious concerns about targeting 
of this viral antigen in vivo with cellular immunotherapies. However, our unexpected in vitro 
observation was difficult to reconcile with preliminary data from trials of adoptive transfer of 
LMP2-containing CTL preparations in ENKTL patients where frequent evidence of clinical 
response, including sustained complete responses in some cases, was emerging
651
. Given the 
224 
 
anticipated prognosis of patients with relapsed/refractory ENKTL, whereby very few patients are 
salvaged even with intensive chemotherapy
473
, these clinical outcome data were compelling.  
We thus pursued our interest in LMP2 as an immunotherapeutic target by initially asking whether 
the same therapeutic polyclonal CTL products, generated by in vitro LMP2-stimulation
396
 of 
PBMC from ENKTL and CAEBV patients, could recognise and kill class I-matched T/NK lines. 
Specific tumour cell lysis by such CTL products containing LMP2-specificities was indeed 
observed. We could not be certain however, that such killing was LMP2-specific given the nature 
of the in vitro stimulation protocol; the contribution of minor LMP1 specificities, for example, could 
not be excluded. Moreover, some of these polyclonal lines contained appreciable numbers of 
CD4 effectors which could have contributed to the observed killing. On this note, HLA class I 
mismatched CTLs from two donors were seen to kill SNT16,  whilst a class II mis-matched LCL in 
the same assay was not killed (Data not shown; Dr C Bollard, personal communication June 
2010); raising the possibility of CD4-mediated killing of SNT16. 
Encouraged by these suggestive data, we confirmed the LMP2-specificity by showing clonal 
CD8
+
 LMP2-specific T cell recognition and killing of SNT16 and SNK6 via a number of distinct 
transmembrane epitopes, across three HLA restriction elements, in a range of T cell assays. The 
class I specificity of the interactions was assured by HLA class I blocking experiments and, 
critically, by employing a recombinant A11/SSC TCR.  
These persuasive immunologic data, particularly in the case of SNK6 where the magnitude of T 
cell recognition was comparable to or exceeded that of an LCL, strongly implied that LMP2 was 
indeed expressed in the T and NK tumour lines, but a paradox was presented by the mRNA and 
protein data. In common with the vast majority (>90%) of known LMP2 class I epitopes, those 
tested in our work correspond to transmembrane regions of the LMP2 protein
391
 -  common to 
both LMP2A and LMP2B - and thus could not help distinguish between the two forms. Although 
the majority of LMP2 epitopes appear to be conserved among different isolates we confirmed the 
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sequence conservation of SNT 16 LMP2 (figure 48, page 205), underscoring its validity as a 
target for the clones tested. 
Investigating expression of an alternate LMP2 transcript  
Given the convincing immunologic evidence, we were impelled to more critically examine the 
expression of LMP2 in the T and NK tumour cells. It became apparent that a LMP2 transcript, 
originating upstream of exon 2, was indeed highly expressed in the ENKTL cell lines (SNK6 and 
SNT8) and at lower levels in the CAEBV lines (SNK10 and SNT16). Notably, the level of 
expression in SNK6 and SNT16 appeared to correlate with the magnitude of T cell recognition in 
the assays described. These novel LMP2 transcripts appeared to initiate within the TR region of 
the viral genome, although the alternate LMP2 promoter was not precisely mapped.  
The longest cDNA isolated from the 5′ RACE procedure initiated >80 bases upstream of exon 2, 
but curiously appeared to be missing a segment of intervening, non-coding sequence (figure 50, 
page 209). This was not investigated at this time but could be potentially explained by alternative 
splicing into the first ATG of exon 2. Targeted quantitation of LMP2 transcripts arising from within 
the TR confirmed that LMP2-TR was clearly the dominant form expressed in a total of 10 ENKTL 
and CAEBV lines examined, where levels of conventional LMP2A and 2B were very low or 
absent.  
Crucially, this pattern of expression was mirrored in ENKTL primary tissue biopsies; an absence 
of LMP2A protein and LMP2A/2B mRNA, whilst TR-initiated LMP2 was appreciable in all cases 
examined. We found substantial variations in the LMP2-TR transcript levels and, although we did 
not have access to matching tissue sections to appraise the extent of tumour infiltrate in each 
case, the implication is that significant heterogeneity of expression exists between biopsies. Of 
note, in some cases (ENKTL 5 and ENKTL 7, Figure 54, page 215) LMP2-TR expression 
exceeded that of the SNK6 line, where the cell population is demonstrably 100% EBV
+
. We did 
not have the opportunity to examine primary cells from CAEBV cases, but note with interest a 
recent quantitative study that examined viral gene expression in PBMC from Japanese CAEBV 
226 
 
patients
563
. In contrast to the majority of published reports, the authors used a LMP2 PCR assay 
that targeted sequences in exon 6 and would therefore have detected all forms of LMP2 
including, albeit inadvertently, the novel LMP2-TR transcript. However, due to differences in 
methodology and representation of their data, direct comparison with our results is difficult. 
The LMP2-TR mRNA is predicted to encode a LMP2B-like protein - the N-terminus of LMP2A will 
certainly be absent from the translated product - and thus cannot be detected by currently 
available antibodies
130-131
. Consequently, at the present time, we are unable to determine the 
pattern of LMP2-TR expression at the single cell level. It would be particularly interesting to 
determine whether expression is uniform throughout the tumour cell population or, similarly to 
LMP1 protein expression in ENKTL, is restricted to a sub-population of malignant T/NK cells. On 
this point we considered the L1-TR promoter identified in NPC
109
 that, if bidirectional, could  give 
rise to both LMP1 and LMP2-TR transcripts – akin to the LMP1/LMP2B promoter in LCLs126. 
Consistent with this possibility, we observed an intimate association of LMP1 and LMP2-TR 
mRNA levels in cytokine-manipulated SNK6 cells and, moreover, a clear relationship between 
LMP2-TR and LMP1 mRNA levels in primary ENKTL tissue was apparent. Although these 
observations require careful investigation and further characterisation, they suggest the existence 
of a co-regulated LMP1/LMP2 promoter within the TR region. The two observed exceptions to 
this were ENKTL cases 6 and 7, where LMP1 mRNA appeared absent despite substantial levels 
of LMP2-TR. We did not have matched biopsy material to address LMP1 expression at the 
protein level in these cases, but our inability to detect transcripts may relate to sequence 
variation; LMP1 is recognised to be highly polymorphic gene
730-731
. Primer sequences for the 
LMP1 PCR assay were originally chosen in conserved regions spanning the exon 2–exon 3 
junction, identified by sequence analysis of a panel of virus isolates from different geographical 
regions
133
. These primers were used in conjunction with two alternative probes specific for either 
the B95-8 or CAO LMP1 alleles, but in neither case were LMP1 transcripts amplified in ENKTL 6 
and 7 (Figure 56, page 218). However, other unknown sequence changes cannot be excluded as 
an explanation for these data. 
227 
 
We cannot be certain the putative LMP2-TR promoter is present in each of the 538bp TR 
sequences, although this may be anticipated from their repetitive nature
27
. The alternate LMP1 
promoter (L1-TR) identified in a study of NPC
109
 was not found beyond the first TR, but the nature 
of the RACE technique – whereby the smaller of the isolated transcripts are likely to be 
preferentially amplified – cautions against this interpretation and is also relevant to our findings. If 
multiple copies of the LMP2-TR promoter, corresponding to the variable number of TRs, do 
indeed exist then it would be interesting to examine the impact of TR number on transcript 
expression. Within individual donors, different B-cell clones can differ by as many as 15 to 20 TR 
sequence reiterations
732
. For reasons that are not yet clear, a recent study of epithelial cells 
unexpectedly determined an inverse relationship between LMP1 levels and TR number; 
increased activity of the L1-TR promoter was seen at lower TR reiterations. On this point it is 
interesting to recall the original descriptions of the SNK and SNT lines
562
 whereby SNT8 and 
SNK6 (the ENKTL lines with high LMP1 levels) appear to have a fewer TRs (by Southern blot 
analysis) than the CAEBV lines SNK10 and SNT16 which express lower levels of LMP1 (and 
LMP2-TR). These observations add a further level of complexity to regulation of both LMP1 and 
LMP2-TR expression and require further study.  
Although the L1-TR promoter is demonstrably transcriptionally active in NPC
68,81,108
 and HL
108
, 
quantitative data is lacking
124,108
 and it thus remains somewhat uncertain which LMP1 promoter 
dominates in these cell types. Indeed the same question can be applied to LCLs, where the 
relative contribution of the L1-TR promoter to LMP1 mRNA expression is unclear. Although some 
caution should be applied when directly comparing RTQ-PCR data from different assays (due to 
variations in, for example, PCR efficiency), our analyses of LMP2 expression in LCLs suggest 
that the putative LMP2-TR promoter generates a small but significant contribution to the „total‟ 
LMP2 levels within a LCL (Figure 52, page 212). It remains to be clarified why the virus has 
evolved to have two different promoters to drive expression of LMP2B-like and LMP1 proteins. 
Expression of conventional LMP2A and 2B cannot occur without circularisation of the viral 
DNA
125
, but our data suggests that LMP2-TR could be transcribed from the linear viral genome 
228 
 
immediately following infection. Studies in B cells have shown that viral episomes are detectable 
in the nucleus after 16-24 hours following in vitro infection
41,53
, raising the question as to what 
benefit the virus would derive from a more rapid production of latent membrane transcripts 
immediately following cell entry. 
We are not aware of previous reports describing naturally high levels of LMP2B in the absence of 
LMP2A. Although the function of LMP2B in B cell and epithelial malignancies is ill-understood 
(page 16), evidence of a negative regulatory effect upon LMP2A signalling
151
 has been 
presented. The high level of LMP2-TR transcripts (and LMP2B protein as detected by LMP2-
specific effector T cells) in the absence of detectable LMP2A, in both primary ENKTL tissue and 
derived cell lines, suggests that the LMP2B protein is likely to have another hitherto unidentified 
function that might be involved in lymphomagenesis. Studies in epithelial cells have suggested 
that, rather than simply modulating the activity of LMP2A, LMP2B may directly contribute to the 
attenuation of cellular IFN responses
155
. The function of LMP2A has been well characterised in B 
cells where a major function - mimicry of BCR signalling - appears to confer a survival 
advantage
137
. However for cells that lack a BCR - such as T and NK cells - such functions may be 
dispensable. Moreover, as the experimental data examining LMP2B function are derived from 
studies of B cells (and epithelial cells), these findings cannot necessarily be extrapolated to the 
T/NK setting where LMP2A is absent.  
Our preliminary observations indicating co-regulation of LMP1 and LMP2-TR expression in T/NK 
cells (Figures 55 and 56, pages 217-8) could indicate functional complementarity of the two 
proteins or participation in a feedback mechanism to regulate the putative bidirectional promoter. 
Further work is clearly required to ascertain the function of the translation product of LMP2-TR 
(predicted to be LMP2B or LMP2B-like) in NK and T cells and to delineate its phenotypic impact 
from that of LMP1. Notwithstanding this, the consistent expression of LMP2-TR as the dominant 
LMP2 mRNA in a range of cell lines and primary tissue, in some cases exceeding cell line levels, 
implicates this truncated protein in the initiation and/or potentiation of T/NK lymphomagenesis.  
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As an immunotherapeutic target, our data support the current clinical approaches of LMP2-
directed targeting of T/NK lymphoproliferations and, potentially, provide a basis for „screening‟ 
patients (via PCR analyses on biopsy material) prior to embarking on such therapies. However, 
the lack of a suitable antibody to allow routine detection of LMP2B in tissue sections currently 
limits the applicability of such an approach.  
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Final conclusions 
Factors contributing to the pathogenesis of T and NK 
lymphoproliferations 
By comparison to EBV-associated lymphomas of B cell origin such as BL and HL, a substantially 
smaller body of literature has reported on investigations into the pathogenesis of EBV-associated 
T and NK lymphoproliferations. This may be partly accounted for by their relatively recent 
characterisation and incorporation into international lymphoma classification systems
474,569
, 
compounded by their comparative rarity
250-252,374,473,561,615-618
, particularly outside East Asia
473
. 
However the importance of these diseases, both biologically and clinically, can be appreciated by 
three essential observations. First, the strength of the association with EBV; virtually 100% of 
ENKTL and ANKL cases contain clonal EBV
460-462,242-243,245,463-471
, irrespective of geographic 
origin, such that the absence of virus would cast doubt on the accuracy of diagnosis of these 
entities
474
. Indeed, such an association is more consistent than the much-studied EBV
+ 
HL and 
(„non-endemic‟) BL. Second is the broad clinical spectrum of disease, manifest across a wide 
range of age groups: EBV-HLH, often associated with primary infection, that can present within 
the first few years of life
374
; CAEBV that presents most commonly in children at a mean age of 
approximately 11 years
561
; and ANKL and ENKTL that most commonly present in the 5
th
 and 6
th
 
decades of life. Third is the poor prognosis associated with all these disease entities; a feature 
common to this range of lymphoproliferations is an inherent resistance to conventional cytotoxic 
agents. Interestingly, this latter point contrasts strikingly with HL and BL which are amongst the 
most chemosensitive of all malignancies.  
Of further interest is why infection of similar or identical cell types is associated with such a 
diverse spectrum of clinical illnesses, occurring both in previously EBV-naive and ostensibly EBV-
immune individuals. For example, NK cell infection may give rise to CAEBV, ENKTL or HLH. 
Although a relationship between the phenotype of the infected cell and the nature of the clinical 
presentation (at least for the systemic childhood lymphoproliferations) has been suggested
471-472
, 
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such delineation may not be absolute. Our investigation of EBV-HLH in adult patients{Fox, 2010 
#2146} suggests that more detailed phenotypic analyses of EBV-infected cells are required 
before definitive conclusions can be drawn. The importance of these analyses relates to 
understanding the biology of the normal cell counterpart of the disease in question as well as 
diagnostic and classification considerations.  Initial misapprehensions regarding the T cell origin 
of ENKTL, due in part to diagnostic technicalities, have turned out to be only partly incorrect. It is 
now understood that although the majority of tumours are of NK origin, a significant minority are 
derived from cytotoxic T cells. Work in this area is still active: a very recent study has, by gene 
expression profiling, further defined a functionally distinct subset of γδ T cells as giving rise to a 
minority of cases classified as ENKTL
733
. 
Irrespective of the cell phenotype, cellular genetic abnormalities in CAEBV and ENKTL are a 
consistent finding. Chromosomal aberrations, identified by both conventional and high-resolution 
methodology, are frequent and often complex in these diseases
556,713
. Although not well 
characterised, recent studies have highlighted the potential contribution of some of these 
abnormalities to disease pathogenesis
713,733-734
. Furthermore, such observations on cellular 
abnormalities raise fundamental questions relating to early events in pathogenesis: is the cell 
genetically unscathed at the time of viral entry, or are pre-existing abnormalities a requisite for 
viral entry and/or establishment of latency?  
Other non-viral contributors to pathogenesis have not been clear but the distinct geographical 
distributions of these diseases, clustered in East Asia and Central/South America, may suggest a 
host genetic or environmental predisposition. Studies examining associations of viral strain with 
EBV
+
 malignancies in different geographical regions have mostly concluded that the tumour-
associated virus strains are simply representative of that seen in the corresponding healthy 
control population
33
, although ENKTL and CAEBV have not been comprehensively examined in 
this regard. 
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For the majority of patients with EBV-associated T and NK lymphoproliferations, the illness is not 
anteceded by clinical evidence of immune-compromise; these patients are considered to be 
immunocompetent by conventional criteria. However, the quality and quantity of EBV-specific 
immune responses in affected patients has not been examined and it thus remains unclear 
whether subtle defects in viral-specific cellular or humoral responses may contribute to 
pathogenesis. Further considerations relate to the complexity and influence of immune cells in the 
tumour microenvironment
735
.  
The contribution of Epstein-Barr virus to the pathogenesis of T and NK 
lymphoproliferations 
The unanticipated association of EBV with rare but characteristic T- and NK cell 
lymphoproliferations was substantiated by studies throughout the 1980s and 1990s that 
consistently identified monoclonal viral genomes in lymphoma tissue
460-462
 and circulating NK 
cells, CD8
+
 and CD4
+
 lymphocytes 
242-243,245,463-471
 from these patients. Although clinically 
heterogeneous, the principal unifying feature of such illnesses appeared to be the clonal 
expansion of EBV-infected T and/or NK cells associated with a restricted pattern of viral gene 
expression
73,563,610,614
.  
Whilst EBV-associated B cell malignancies can be viewed as rare accidents of the virus‟ natural 
lifestyle within the B cell system of the host, its association with T and NK disease raises many 
new questions about the viral entry route into these cell types and the viral contribution to 
lymphomagenesis. 
In addition to the challenges posed by the rarity of the illnesses, a major hindrance to addressing 
these questions has been the lack of a suitable in vitro model of infection of T and NK cells. An 
isolated report
301
 of efficient NK infection has, to-date, not been reproduced by other laboratories 
and whilst virus-binding (and infrequent entry) to T cells can be achieved
289,292
, the establishment 
of a latently–infected cell has proved experimentally very challenging. 
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Consequently we began our studies by addressing a relatively straightforward, but as yet 
unanswered, question: What is the frequency T and NK cell infection in vivo and under what 
circumstances may this occur? By sensitively quantitating EBV genomes in highly purified 
peripheral blood and tonsil lymphocyte populations from a range of donors, we were able to draw 
some conclusions. Firstly, instances of tonsillar (but apparently not peripheral blood) CD4
+
 and 
CD8
+
 T cell infection are occasionally appreciable in the context of primary infection and healthy 
persistence although the fate of these cells in this context remains unclear. Secondly, the 
interesting and unexpected finding of high viral genome numbers in tonsillar CD56
+
 cells ex-vivo 
from immunosuppressed persons and (from healthy donors) following in vitro culture was 
resolved, at least in part, by delineating these cells as of B cell and not NK origin. These findings 
have highlighted new questions about the phenotype of B cell subsets in vivo and in vitro and 
their relationship to EBV. Moreover, these observations served to underscore our findings - in a 
range of donors - that infection of normal NK cells in health and immune deregulation is a very 
rare event.  
The evident limitations of our experimental approach were the lack of data at the single-cell level 
(i.e. numbers of genomes per infected cell), interpretative difficulties posed by small numbers of 
contaminating populations and the inability of the PCR assay to distinguish between surface and 
intracellular virions/viral DNA. The recent description of a combined „immuno-FISH‟ technique708 
to identify the phenotype of EBV-harbouring cells (by virtue of EBER expression) has merit in this 
respect. Moreover, recent technological advances in flow cytometry permit high-throughput, high 
resolution images of individual cells directly in flow, alongside high fluorescence sensitivity
736-737
. 
In principle this would allow assessment of the intensity and location of fluorescent probes (to 
EBV DNA or RNA) on or within cells, in rare sub-populations within heterogeneous samples. 
Our ex-vivo findings need to be reconciled with the consistent finding of clonal forms of EBV in 
patients with T/NK disease; providing evidence that an infection event occurs early in 
pathogenesis. Taken together with our data, in contrast to the situation in B cells, a valid 
hypothesis may be that in the rare instances when EBV erroneously infects a T or NK cell in vivo, 
234 
 
a relatively high chance of developing disease ensues. It is possible that the frequently observed 
cellular chromosomal aberrations result from EBV-mediated genomic injury (for example via 
expression of EBNA1
738
 or LMP1
739
) or, alternatively, they pre-date and predispose to viral 
infection. However, it cannot be assumed that such a target cell is a normal and fully 
differentiated T or NK cell at the time of initial infection. Considering this latter point alongside the 
marked inefficiency of in vitro infection of these lineages, it remains possible that T, NK or 
common precursors are at enhanced susceptibility of infection. Relevant to this point are findings 
of CAEBV PBMC, where co-existing infection of CD4
+
 and/or CD8
+
 and/or CD16
+
 cells
564
 with 
monoclonal EBV has been described. Interpretative caution should be applied however, as the 
clonality analyses in this study were performed on total PBMC, rather than individual T and NK 
populations. Attempts at in vitro infection of NK and/or T cells at distinct stages along their 
differentiation pathway from a common lymphoid progenitor may be a worthwhile next step. An 
alternative approach could take advantage of recent developments in humanised mouse 
models
740
, to provide an in vivo environment in which T or NK cell infection may be more readily 
manipulable. The current lack of meaningful in vitro models of infecting these cell types remains a 
major barrier for biological progress in this area. 
The absence of an experimental model of infection of T and NK cells presents challenges in 
determining both the pattern of viral gene expression and the function of expressed transcripts 
and proteins in these cell types. However from the available molecular pathological evidence 
obtained from studies of primary ENKTL and CAEBV tissues, a limited number of gene products 
can be implicated in pathogenesis. We therefore sought to establish a method of expressing 
individual viral genes in primary NK cells, such that their expression would be both stable and 
inducible, to allow delineation of their impact upon genotype and phenotype of this cell lineage. 
LMP1 was, initially at least, the most obvious candidate to investigate given its presence in 
ENKTL tumour cells and its well characterised oncogenic role in B cells. Unfortunately there was 
insufficient time to characterise the effects of LMP1 expression in CD56
BRIGHT
 primary NK cells. 
Nevertheless, the cell model we established, with levels of mRNA and topography of protein 
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expression at the single-cell level similar to ENKTL tumour lines, provides opportunities to directly 
examine the effects of LMP1 in a normal NK cell background. However, to implicate LMP1 in 
tumour pathogenesis we need to reconcile the findings in biopsy material from T/NK diseases 
where the LMP1 protein is frequently absent from some tumour cells within an ENKTL biopsy and 
is apparently not expressed in some cases of CAEBV PBMC. Three potential explanations follow: 
LMP1 expression is cyclical within individual cells in order to achieve an optimum equilibrium of 
its phenotypic effects, perhaps to balance proliferative and anti-apoptotic functions; or that LMP1 
is truly restricted to a sub-population of cells and invokes expression of soluble factors that 
promote growth/survival of LMP1-negative cells in a paracrine manner; or that other EBV-
encoded gene products are widely expressed within a tumour and are more essential for 
pathogenesis whilst LMP1 serves a minor, complementary role. 
In the interest of tumour cell survival, any benefit that is derived from the expression of viral 
antigens is offset by their liability as targets for host effector immune cells. Unlike PTLD, occurring 
in the T cell compromised host, T/NK lymphoproliferations do not express the immunogenic 
EBNA3 family of proteins and of the notionally available Latency II proteins, LMP2 is the most 
immunogenic. However, expression of LMP2 had not been well characterised across the 
spectrum of T/NK diseases, although early clinical results indicated convincing responses to 
polyclonal LMP2-specific CTLs in the context of poor-prognosis ENKTL and CAEBV. Against this 
background, our investigations of LMP2 unexpectedly led to the finding of a hitherto unidentified 
LMP2 transcript; initiated from within the TR region of the viral genome, encoding downstream 
epitope-encoding exons serving as targets for LMP2-specific CD8
+
 CTLs. The results of this 
chapter of work can be viewed as having four principal implications: first, that LMP2 is indeed a 
valid immunotherapeutic target in T/NK disease as LMP2-TR appears to be widely expressed and 
contains cognate epitopes for CTL recognition; second that the heterogeneous and often high 
levels of expression of LMP2-TR in cell lines and primary tissue implicate this truncated protein in 
initiation or potentiation of T/NK lymphomagenesis; third, that any future analyses of LMP2 
expression in EBV-infected cells (of all lineages) should take account of LMP2-TR when 
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assessing expression at the mRNA and protein level; and fourth, that the identification of a novel 
LMP2B-like protein from a putatively bidirectional TR promoter has connotations for the range of 
EBV-associated tumours and raises new questions about the complementarity of LMP1 and 
LMP2B in EBV-infected cells. 
Subsequent investigations may be best focused on the function of these latent viral proteins by 
individual and co-expression in a normal cell background (via inducible lentiviral expression 
systems) and complemented by gene silencing (via inducible lentiviral shRNA systems
714
) in 
T/NK tumour cell lines in vitro. The recent description of a SCID-mouse xenograft model of 
ENKTL may offer opportunities for related in-vivo studies of gene expression and function
741
. As 
discussed, perhaps the most significant hindrance to biological progress is the lack of an efficient 
model of T/NK infection; this remains a priority area to study. Critically, the findings from such 
investigations should be directly related to, and in some cases may inform, studies of pathological 
and clinical data derived from international collaborative studies. This approach offers an 
opportunity to maximise the acquisition of clinically and biologically meaningful data, which may 
ultimately lead to improved diagnostic and therapeutic tools for these poor prognosis diseases. 
Looking forwards, the study of these fascinating lymphoproliferations of T and NK origin, strongly 
associated with EBV, not only provides an opportunity for progress in our understanding of 
pathogenesis of these rare diseases but may also allow broader virological, immunological and 
pathological lessons, relevant to the relationship of EBV and its human host, to be learned. 
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